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In this work, statistical learning approaches are exploited to discover biomarkers for
Alzheimer’s disease (AD). The contributions has been made in the fields of both biomarker
and software driven studies. Surprising discoveries were made in the field of blood-based
biomarker search. With the inclusion of existing biological knowledge and a proposed
novel feature selection method, several blood-based protein models were discovered to
have promising ability to separate AD patients from healthy individuals. A new statistical
pattern was discovered which can be potential new guideline for diagnosis methodology.
In the field of brain-based biomarker, the positive contribution of covariates such as age,
gender and APOE genotype to a AD classifier was verified, as well as the discovery of
panel of highly informative biomarkers comprising 26 RNA transcripts. The classifier
trained by the panetl of genes shows excellent capacity in discriminating patients from
control. Apart from biomarker driven studies, the development of statistical packages
or application were also involved. R package metaUnion was designed and developed to
provide advanced meta-analytic approach applicable for microarray data. This package
overcomes the defects appearing in previous meta-analytic packages – 1) the neglec-
tion of missing data, 2) the inflexibility of feature dimension 3) the lack of functions to
support post-analysis summary. R package metaUnion has been applied in a published
study as part of the integrated genomic approaches and resulted in significant findings.
To provide benchmark references about significance of features for dementia researchers,
a web-based platform AlzExpress was built to provide researchers with granular level of
differential expression test and meta-analysis results. A combination of fashionable big
data technologies and robust data mining algorithms make AlzExpress a flexible, scalable
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SNR . . . . . . . . . . Signal-to-Radio
SP . . . . . . . . . . . . Specificity
SPECT . . . . . . . Single Photon Emission Computed Tomography
SVD . . . . . . . . . . Singular Value Decomposition
SVM . . . . . . . . . . Support Vector Machine
SVMFS . . . . . . . Support Vector Machine Forward Selection
SVMTFS . . . . . Support Vector Machine Top Forward Selection
TC . . . . . . . . . . . . Temporal Cortex
TN . . . . . . . . . . . . Training
TS . . . . . . . . . . . . Testing
WM . . . . . . . . . . . White Matter
WRFP . . . . . . . . Whole-Range Feature Pool





This chapter generally discusses the encyclopedic knowledge about Alzheimer’s disease
(AD). An overview of Alzheimer’s disease (AD) is introduced with introudction of symp-
toms, prevalence, pathology, prognosis, diagnosis and most importantly biomarkers to
date.
1.2 Alzheimer’s disease (AD) introduction
Alzheimer’s disease (AD) is a common type (60 ˜80%) (https://www.alzheimers.
org.uk/about-us/news-and-media/facts-media) of dementia, with common early
symptoms such as short term memory loss which progressively advancing to confusion,
irritability, aggression, mood swings, trouble with language, and long-term memory loss.
50 million people worldwide are living with dementia worldwide in 2018. This number is
estimated to be more than triple to 152 million by 2050 [1]. There are 7.7 million new
cases of dementia each year, implying that there is a new case of dementia somewhere
in the world every four seconds. The total estimated worldwide cost of dementia was
US$604 billion in 2010. About 70% of the costs occur in Western Europe and North
America (http://www.alz.co.uk/). There are 850,000 people with dementia in the
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UK, with numbers set to rise to over 1 million by 2025. This will soar to 2 million by 2051.
225,000 will develop dementia this year, that’s one every three minutes. (https://www.
alzheimers.org.uk/about-us/news-and-media/facts-media). 773,502 (94%) of
these people with dementia were aged 65 years or over. Non-genetic risk factors include
age, midlife high blood pressure, high BMI, diabetes, cerebrovascular disease, smoking,
light-to-moderate alcohol consumption and antihypertensive therapy [2].
1.2.1 Symptoms, stages and types
Memory loss that disrupts daily life may be a symptom of AD or other dementia. To be
more specific, Alzheimer’s association (https://www.alz.org) suggests the following
signs and symptoms as possible indicator of onset of AD:
 Memory loss that disrupts daily life
 Challenges in planning or solving problems
 Difficulty completing familiar tasks at home, at work or at leisure
 Confusion with time or place
 Trouble understanding visual images and spatial relationships
 New problems with words in speaking or writing
 Misplacing things and losing the ability to retrace steps
 Decreased or poor judgment
 Withdrawal from work or social activities
 Changes in mood and personality
1.2.1.1 Different stages of AD
Based on the intensity of the typical Alzheimer’s symptoms, it can be classified into
several subtypes and stages.
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Mild AD (early stage) This includes the beginning of cognitive impairment that
causes difficulties in remembering daily routine such as tasks at work, paying bills , and
others. Because these symptoms are not very serious, the patients at this stage manage
to remain functional with a certain amount of difficulty. They take longer to perform
the same task which they used to do quicker before, and this becomes a pattern.
Moderate AD (middle stage) Because of a significant amount of neuronal damage,
the symptoms of moderate Alzheimer’s are more intense. The confusion becomes worse
and due to the amount of memory loss, they become increasingly dependent on others.
These individuals, even though physically agile, are not able to perform routine tasks as
the delusions take over the sensory processing of their thoughts.
Severe AD (late stage) As the plaques and tangles spread, the brain cells start dying.
This results in shrinkage of brain tissue. The patients with this condition are typically
bedridden and are hardly able to communicate.
These subtypes are more like stages of the disease, and it often progresses from a
milder to a more severe form. The sooner the patient is diagnosed with the condition,
the better are the chances of treating and preventing its progression.
1.2.1.2 Mild cognitive impairment (MCI)
Mild cognitive impairment (MCI) is a condition where someone has minor or subtle
problems with cognition - their mental capabilities such as memory or thinking. In MCI
these difficulties are worse than would normally be expected for a healthy person of their
age. However, the symptoms are not intense enough to interfere remarkably with daily
life, and so are not defined as dementia.
It is estimated that between 5 and 20% of people aged over 65 have MCI (https:
//www.alzheimers.org.uk/). It is not regarded as a type of dementia, but a person
identified with MCI is more likely to continue to develop dementia in the future.
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Symptoms The term MCI describes a set of symptoms, rather than a specific disease.
A person with MCI has mild problems with one or more of the following:
 Memory - for example, forgetting recent events or reiterating the same question
 Reasoning, planning or problem-solving - for example, struggling with thinking
things through
 Attention - for example, being very easily distracted language - for example, taking
much longer than usual to find the right word for something
 Visual depth perception - for example, struggling to interpret an object in three
dimensions, judge distances or navigate stairs
These symptoms may have been noticed by the individual, or by those who know
them. For a person with MCI, these changes may cause them to experience minor
problems or need a little help with more demanding daily tasks (for example paying
bills, managing medication, driving). However, MCI does not cause major problems with
everyday living. If there is a significant impact on everyday activities, this may suggest
dementia.
Most healthy people experience a gradual decline in mental abilities as part of ageing.
In someone with MCI, however, the decline in mental abilities is greater than in normal
ageing. For example, it’s common in normal ageing to have to pause to remember
directions or to forget words occasionally, but it’s not normal to become lost in familiar
places or to forget the names of close family members.
If the person with MCI has seen a doctor and taken tests of mental abilities, their
problems will also be shown by a low test score or by falling test scores over time. This
decline in mental abilities is often caused by an underlying illness.
Why is MCI important for AD study Neuropathological and neuroimaging evidence
suggests that biological changes associated with dementia, and Alzheimer’s disease (AD)
in particular, occur long before, perhaps decades before, the onset of symptoms [3,
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4]. Given this, it is therefore probable that there are indicators of incipient dementia
occurring before the onset of the full dementia syndrome [5]. The syndrome of MCI
appeared to have become widely accepted [6] as a general concept that is of subjective
memory impairment in the context of cognitive impairment relative to age-matched
controls and yet no loss of function and no dementia.
The firmly established concept of MCI have huge medical potentials, because it
is very likely that a disease-modifying therapy will have only limited use in those with
established disease because of extensive neuronal loss. Therefore one possible therapeutic
approach would be to test new drugs and to use proven disease-modifying compounds
in those at risk of developing dementia. Abundant evidence of high conversion from
MCI to AD support the notion that MCI is the harbinger of dementia [4,5,7–13], which
means people with this syndrome can be suitable cases for evaluation and treatment.
Consequently, breakthrough of MCI pathology will definitely have massive positive impact
on AD diagnosis and drug discovery, so MCI is very important for AD study.
1.2.1.3 Early onset AD (EOAD) and late onset AD (LOAD)
Despite AD mostly occurs in the elderly, a small proportion of AD occurred before the
age of 65, which is called early onset AD (EOAD), and is considered to have a more
aggressive course and shorter relative survival time [14]. About 5% of patients develop
symptoms before age 65, where most of these patients have the sporadic form of the
disease, but 10-15% have a genetic form that is generally inherited as an autosomal
dominant fashion [15]. For the majority of AD cases, they are late onset AD (LOAD)
that occurred after the age of 65.
1.2.1.4 Familial AD (FAD))
Familial Alzheimer’s disease (FAD) is a form of Alzheimer’s disease that doctors know
for certain is linked to genes. In families that are affected, members of at least two
generations have had the disease. FAD makes up less than 1% of all cases of Alzheimer’s.
Most people who have early onset Alzheimer’s have FAD.
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1.2.2 AD pathophysiology
The debate of AD pathophysiology can date back to the time in 1907 when Alzheimer
observed the neuropathological traits of the disease i.e. amyloidal plaques and hyper-
phosphorylated neurofibrillary tangles (NFTs). Several hypotheses have been proposed
on the basis of the diversed causative factors so as to explain this multifactorial dis-
order [16] such as the Aβ hypothesis, cholinergic hypothesis, inflammation hypothesis
and tau hypothesis [17]. Recently it has been implied that the most acknowledged Aβ
hypotheses, commonly used for the last two decades, is not responsibe for the complex
pathophysiology of this incapacitating disease [18]. Recent studies have also remarked
the role of Aβ oligomers in synaptic impairment, indicating that these are basically the
only one out of several other signals that disintegrate brain functions [18–21]. And
formations of amyloid plaques that develop in the later age appear to be rather late
event [20].
According to the amyloid cascade hypothesis, the APP is aberrantly processed by β−
and γ−secretases but normally cleaved by α−secretase leading to an imbalance between
production and clearance of Aβ peptide [22]. Consequently, Aβ peptides spontaneously
aggregate into soluble oligomers and coalesce to assemble fibrils insoluble beta-sheet
conformation and are eventually deposited in diffuse senile plaques [18]. Some recent
studies has indicated that Aβ42 oligomers are formed by cooperative activities of both
neurons and its associated astrocytes [20]. It was found that Aβ42 oligomers induce ox-
idative damage, promote tau hyperphosphorylation, results in toxic effects on synapses
and mitochondria [7, 17]. But the role of Aβ42 senile plaques cannot be ignored as
Aβ42 plaques that are supposed to be appear during late stage attract microglia [23].
Microglial activation attribute to the production and discharge of proinflammatory cy-
tokines, including IL-1β, TNF-α, and IFN-γ. In turn, these cytokines stimulate the
nearby astrocyte–neuron to produce further amounts of Aβ42 oligomers, thus activating
more Aβ42 production and dispersal [20]. Oligodendroglia (OLGs) also has association
with neurons–astrocyte complex; Aβ oligomers also result in its decomposition [24].
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Aβ oligomers aggregates are regarded to contribute to the neuronal and vascular de-
generation in AD brains [25]. It causes oxidative stress, a situation to which OLGs are
particularly susceptible because their reduced glutathione (GSH) content is low and they
have a high concentration of iron, thus presenting an impaired ability to scavenge oxy-
gen radicals [21]. It has also been reported that Aβ oligomers possesses an increased
potential for damaging cholesterol rich membranes, such as those discovered in OLGs
and myelin [25, 26].
Previous studies focusing on the receptors pharmacology of Aβ have implied that
Aβ42 monomers activate the neuroprotective signaling of insulin-like growth factor-1
receptor (IGF-1R), whereas Aβ42 oligomers target a host of neurons’ and astrocytes’
membrane receptors, such as the scavenger receptor for advanced glycation end prod-
ucts (RAGE), Frizzled receptor, insulin receptor, NMDAglutamate receptor, p75 neu-
rotrophin receptor (p75NTR), α7 nicotinic ACh receptor (α7nAChR), ApoE receptors,
formyl peptide receptor-like 1 (FPRL1/2), cellular prion protein (PrPc) acting as an Ab
oligomer receptor, and the calcium-sensing receptor (CaSR) [27, 28]. Removal of Aβ
oligomers from the brain happens by several pathways including proteolytic degradation
by the proteases neprilysin and insulin degrading enzyme (IDE), uptake by astrocytes and
microglia, passive flow into the cerebrospinal fluid and sequestration into the vascular
compartment by soluble form of the low-density lipoprotein receptor related protein 1
(LRP1) [29,30]. The effect of NO on IDE-mediated degradation of Aβ has been investi-
gated an The essential effect of the astrocyte–neuron interconnections is the astrocytes
abilities to promote or lessen neurotransmitters release into the synapses they envelop
with the Ca2+ they respectively let out or take up during their Ca2+ waves [24]. When
neurons Aβ42 production exceeds the safe limit, toxic Aβ42 oligomers start spilling out
of the neurons and onto their enveloping astrocytes both cell types being empowered
with Aβ42 oligomer-binding receptors besides accumulating or dispersing in the extra-
cellular surrounding [20]. Due to the intimate physical and functional interdigitations
in the neurons client group, the Aβ42 oligomers releases by the neuron can directly
connected with the a- 7nAChRs of its partner astrocytes [31]. The signals from these
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receptors induce the astrocytes to exocytose the glutamate they have been taking up
from the neuronal synapses [31]. The discharged glutamate activates the extrasynaptic
NMDARs of the astrocytes’ partner neurons [31,32]. The resulting signals trigger Ca2+
surges evoking a cascade of events, including dysfunctional mitochondria pumping out
ROS, which inflict an oxidative damage, caspase 3 activation, tau hyperphosphoryla-
tion, excess production of NO, ROS and VEG-F thereby destroying dendritic spines and
neuronal synapses and severing communications within the astrocyte’s neurons and be-
yond [31]. Armato and others have shown that CaSRs (present on the cell membranes
of astrocytes and neurons on which Ab42 oligomers binds) selective allosteric antagonist
(calcilytic) NPS 2143 specifically stops the excess release of endogenous Aβ42 from the
Aβ25–35-exposed human astrocytes and neurons [28, 31].
d it has been shown that increased NO levels, which have been reported in AD, can
weaken enzymatic function, potentially leading to increment Aβ oligomers deposition in
the brain and development of AD [32].
It has recently been reported that there is a ’contagion’ like diffusion of Aβ42
oligomers and hyperphosphorylated tau oligomers via exocytosis (synapses) or exosomes
to closely associated target cells (astrocytes and oligodendrocytes), which in turn be-
come producer cells of Aβ and tau oligomers [33]. Experimental evidence have implied
that intracerebral (i.c.) administration of small amounts of brain extract containing mis-
folded Aβ from patients with AD or from Aβ-APP transgenic (tg) mice induces cerebral
β-amyloidosis and related pathologies in APP tg mice in a time- and concentration-
dependent manner [33].
The essential effect of the astrocyte–neuron interconnections is the astrocytes abili-
ties to promote or lessen neurotransmitters release into the synapses they envelop with
the Ca2+ they respectively let out or take up during their Ca2+ waves [24]. When
neurons Aβ42 production exceeds the safe limit, toxic Aβ42 oligomers start spilling out
of the neurons and onto their enveloping astrocytes both cell types being empowered
with Aβ42 oligomer-binding receptors besides accumulating or dispersing in the extra-
cellular surrounding [20]. Due to the intimate physical and functional interdigitations
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in the neurons client group, the Aβ42 oligomers releases by the neuron can directly
connected with the a- 7nAChRs of its partner astrocytes [31]. The signals from these
receptors induce the astrocytes to exocytose the glutamate they have been taking up
from the neuronal synapses [31]. The discharged glutamate activates the extrasynaptic
NMDARs of the astrocytes’ partner neurons [31,32]. The resulting signals trigger Ca2+
surges evoking a cascade of events, including dysfunctional mitochondria pumping out
ROS, which inflict an oxidative damage, caspase 3 activation, tau hyperphosphoryla-
tion, excess production of NO, ROS and VEG-F thereby destroying dendritic spines and
neuronal synapses and severing communications within the astrocyte’s neurons and be-
yond [31]. Armato and others have shown that CaSRs (present on the cell membranes
of astrocytes and neurons on which Ab42 oligomers binds) selective allosteric antagonist
(calcilytic) NPS 2143 specifically stops the excess release of endogenous Aβ42 from the
Aβ25–35-exposed human astrocytes and neurons [28, 31].
1.3 AD Biomarker
A biomarker is defined as a biological feature found in blood, other body fluids, or
tissues that is a sign of a normal or abnormal process, or of a condition or disease. A
biomarker may be used to see how well the body responds to a treatment for a disease
or condition. For any diseases including AD, the discovery of biomarkers will contribute
to better understanding of the pathological process or cause of the onset of diseases,
and could potentially leads to a successful treatment of the disease. The biomarkers can
be of any different categories, from biochemical molecules, magnetic resonance imaging,
to electrical signal. The diagnosis and treatment of many diseases such as cancer have
benefit from the emergence of biomarkers in recent decades.
1.3.1 Cerebrospinal fluid biomarkers
For many decades, the definitive diagnosis of AD has depended on the postmortem de-
tection of senile plaques (SPs) and neurofibrillary tangles (NFTs). The neuropathology
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of AD is now better understood in relation to amyloid and tau pathology – consequently
Aβ and tau assays having been explored and examined during the last two decades
to offer first ’core feasible’ cerebrospinal fluid (CSF) biomarkers [34]. The biochemical
composition of Cerebrospinal fluid (CSF) is also able to provide information on the brain
chemistry. In the early 90s, the first publication documented elevated CSF amounts of
t-tau in patients with AD dementia [35]. After that, augmented CSF concentrations of
p-tau and reduced levels of Aβ1–42 have been described. Replications of these findings
were discovered by large numbers of studies. Compared to cognitively normal elderly
subject, a level decrease of CSF Aβ1–42 to about 50%, an increase in CSF t-tau to ap-
proximately 300% and a less evident growth in CSF p-tau to about 200% were reported
recursively [36]. Combing Aβ1–42 with tau provides excellent discriminative value for AD
patients against age-matched healthy controls, with a sensitivity of 85% and a specificity
of 86% (refer to equation 2.25 about sensitivity and specificity). Nonetheless, a deterio-
ration of specificity is observed when these ratios are used to discriminate AD from other
dementias [37]. Several other combinations of tau, Aβ1–38, Aβ1–40 and Aβ1–42 were
also trialed in many studies to execute the discriminations between AD, non-Alzheimer
dementias (NAD) and healthy controls, among which the ratio Aβ1–42/Aβ1–38/p-tau
robustly distinguished AD against NAD, reaching the requirements for an applicable
screening and differential diagnostic AD biomarker [38, 39]. Except those core biomark-
ers with high certainty of pathological involvement, other molecules were also found to
be of help for diagnosis. Notably, one study has reported the increase of concentration of
eight amino acids in AD versus MCI [40], another larger examination has also managed
to detect eight molecules with statistical significance [41].
1.3.2 Blood-based biomarkers
Blood is a biofluid which is much more easily reached and manageable than CSF, there-
fore, searching for consistent blood-based biomarkers is required. Yet, definite data
regarding the association of plasma Aβ1–40 and Aβ1–42 concentrations with incipient
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AD is presently lacking [34]. Some studies revealed that increased Aβ1–40 or Aβ1–42
levels be an indicator of development of AD [42, 43], while other analyses showed no
associations [44, 45] or opposite [46] results. A low Aβ1–42/Aβ1–40 ratio is reported
to foresee the onset of future AD [42, 47, 48], conversely, an increased [43, 49] or no
obvious difference [44] between incipient AD subjects and healthy controls are also re-
ported. It is described in a recent meta-analysis study that low Aβ1–42/Aβ1–40 ratio
could forecast the progression of AD, yet no evidences of such link have been presented
for single peptides [50]. In regard to tau, some studies have emphasized the discrepancy
in the modulation of CSF tau levels comparing with blood. In case of hypoxic brain
damage following cardiac arrest, tau is dramatically cleared after promptly released into
blood [51], on the contrary, CSF tau levels remain high for several weeks after an acute
neurological insult [52]. Moreover, remarkable increase in the tau level is observed in
CSF of AD patients but less in commensurate plasma samples. In fact, the correlation
between the tau levels in CSF and plasma compartment does not exist [53]. Recently
a cross-sectional study has shown that the plasma concentration of tau appears to in-
crease in AD samples compared to MCI and healthy controls. MCI-AD samples (i.e.
MCI converters to AD) presents similar levels of tau as those detected in MCI-stable
(i.e. MCI non-converters to AD) and healthy controls [54].
Last decade witnessed the development of mass spectrometry-based technologies
that has elected proteomics as the chief platform to inspect the plasma/serum pro-
teome for the discovery of next-generation biomarkers showing diagnostic, prognostic,
or therapeutic efficacy [55]. The capability of synchronously quantifying large number of
plasma analytes enables the discovery of more biomarker patterns which help distinguish
AD patients from healthy controls [56, 57]. Although the existence of an inflammatory
process in AD has been confidently suggested, based on the pathways those biomarkers
are connected with, such panel of proteins are still difficult to reproduce in indepen-
dent studies [58]. No findings of transcripts/proteins/metabolites in blood have been
successfully replicated to be definitively approved as AD biomarkers [34]. In spite of
the unsatisfactory repeatability of protein biomarkers, some encouraging findings with
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promising diagnostic accuracy across cohorts still support the prospect of blood-based
protein biomarkers as the future of AD diagnosis [57, 59, 60].
1.3.3 Neuroimaging biomarkers
Reduction of hippocampus volume, detected from structural MRI, is among the principal
biomarkers of AD in the International Working Group (IWG) [61] and NIA-AA (the Na-
tional Institute on Aging (NIA) at National Institutes of Health (NIH) and the Alzheimer’s
Association(AA)) criteria [62] (refer to Section 1.4.2). A reduced hippocampus vol-
ume has been found across multiple studies in AD and MCI subjects (for meta-analysis
see [63]). However, it is not specific to AD and is found in other conditions, including
fronto-temporal dementia [64], vascular dementia [65], Lewy-body dementia [66] and
depression [67]. Another structural marker is whole brain volume as longitudinal marker
of disease progression and treatment effects, and it has already been used as secondary
endpoint in some clinical trials [68]. But it obtained less attention with the emergence of
regionally more specific protocols, which are derived from local measures of grey matter
concentration or cortical thickness. The foundation of the application of MRI is closely
related to the assumption that regional brain volume can serve as in vivo surrogate of
neuronal number, which some previous studies have provided evidences [69, 70]. How-
ever, more investigations are needed to address the associations between regional brain
atrophy and regional markers of neuronal degeneration, because there is a study sug-
gesting that cortical atrophy can reflect changes in neuronal and dendritic architecture,
rather than regional neuron numbers and density [71].
Diffusion Tensor Imaging (DTI), a magnetic resonance (MR) technique, records the
random thermal motion of water molecules, i.e. Brownian motion, within tissue [72].
It is a non-invasive way to obtain information of axonal organization of the brain. In
the last decade, this technique has taken the lead to investigate white matter (WM)
microarchitecture and integrity. It has been widely employed in AD and MCI [52,73–75].
Functional MRI (fMRI) takes advantages of the blood-oxygen-level-dependent (BOLD)
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contrasts in vascular capillary network surrounding the cerebral cortex to learn neuronal
activity through non-invasive means during particular cognitive states. Several MRI
studies have been able to recognize functional alternations before the onset of cognitive
impairment or AD-related structural neurodegeneration [3, 76, 77].
Positron emission tomography (PET) and single-photon emission CT (SPECT) have
long been extensively assessed as diagnostic instruments for dementia, and both tech-
niques have given satisfying prognostic and diagnostic abilities. A few PET ligands
targeting amyloid, tau, or metabolic activity have been investigated. An early ra-
diotracer reported to bind both to amyloid plaques and NFT [78] is 2-(1-{6-[(2-[F-
18]fluoroethyl)(methyl)amino]-2-naphthy- l}ethylidene)malononitrile (FDDNP). Cerebral
metabolism, as measured by 18F -fluorodeoxyglucose (FDG)-PET imaging is found to be
decreased in AD. Several studies have reported the reductions in regional cerebral glu-
cose metabolism in MCI and AD comparing with healthy controls [79, 80]. FDG-PET
measures are strongly associated with cognitive deficits [80, 81]. Although PET is a re-
portingly promising approach for AD diagnosis, its high operational cost and restriction
to specialist centres are the largest problem that researchers are facing forward.
1.4 AD prognosis and diagnosis
In 2011, clinical diagnostic criteria for Alzheimer’s disease dementia were revised, and
research guidelines for earlier stages of the disease were characterized to reflect a deeper
understanding of the disorder. Development of the new guidelines was led by the National
Institutes of Health and the Alzheimer’s Association [82].
1.4.1 Early diagnosis
Research on new strategies for earlier diagnosis is among the most active areas in
Alzheimer’s science, with the hope that future treatments can target the disease in
its earliest stages, before irreversible brain damage or mental decline has occurred. Sev-
eral potential biomarkers are being studied for their ability to indicate early stages of
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Alzheimer’s disease. Examples being studied include beta-amyloid and tau levels in cere-
brospinal fluid (CSF) and brain changes detectable by imaging. Recent research suggests
that these indicators may change at different stages of the disease process.
Biomarker It is believed that biomarkers offer one of the most promising paths for an
easy and accurate way to detect AD before devastating symptoms begin.
Blood and urine tests It is also investigated that whether AD causes consistent,
measurable changes in blood or urine levels of tau, beta-amyloid or other biomarkers
before symptoms appear. Moreover, whether early AD leads to detectable changes
elsewhere in the body, such as the lens of the eye, has also been under investigation.
Brain imaging and neuroimaging Neuroimaging is among the most promising ar-
eas of research focused on early detection of Alzheimer’s disease. To summarize, the
following three types of neuroimaging technologies are used in AD research:
 Structural imaging provides information about the shape, position or volume of
brain tissue. Structural techniques include magnetic resonance imaging (MRI) and
computed tomography (CT).
 Functional imaging reveals how well cells in various brain regions are working by
showing how actively the cells use sugar or oxygen. Functional techniques include
positron emission tomography (PET) and functional MRI (fMRI).
 Molecular imaging uses highly targeted radiotracers to detect cellular or chemical
changes linked to specific diseases. Molecular imaging technologies include PET,
fMRI and single photon emission computed tomography (SPECT).
Genetic risk profiling Early-onset familial Alzheimer’s disease (EOFAD) is caused
by rare and highly penetrant mutations in three genes, namely: amyloid precursor pro-
tein (APP, located at chromosome region 21q21.2), presenilin 1 (PSEN1, located at
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14q24.3), and presenilin 2 (PSEN2, located at 1q42.13). Presently, more than 220 dis-
tinct disease-causing mutations have been discovered across these genes [83]. In contrast
to EOFAD, late-onset Alzheimer’s disease (LOAD) exhibits a significantly more complex
and intricate pattern of interplay between genetic and non-genetic factors. The earliest
and by far best established genetic risk factor for LOAD is the presence of one or two
copies of the e4 allele in the apolipoprotein E gene (APOE), located on chromosome
19q13.2 [84]. The second wave of genome-wide association study (GWAS) which have
led to the identification of at least nine loci linked to mostly LOAD risk: BIN1, CLU,
ABCA7, CR1, PICALM, MS4A, CD33, CD2AP, and EPHA1. Most recently, in the
largest GWAS published to date which included 74,046 subjects and a large two-stage
meta-analysis, 11 novel loci were discovered, the relevant genes are HLA-DRB5-HLA-
DRB1, PTK2B, SORL1, SLC24A4-RIN3, NME8, ZCWPW1, FERMT2 [85].
Cerebrospinal fluid (CSF) proteins CSF is fluid that supports the brain and spinal
cord. Adults have approximately one pint of CSF, which physicians can sample through a
minimally invasive procedure called a lumbar puncture, or spinal tap. Research suggests
that early stage AD may cause changes in CSF levels of tau and beta-amyloid, two
proteins that generate abnormal brain deposits strongly linked to AD.
1.4.2 Clinical diagnosis
No single test has yet existed to prove an individual is AD patient or not. The physician
may be able to make judgement about whether an individual has dementia, knowing
the exact cause can be difficult. Diagnosing AD involves a complete assessment that
considers all possible causes, as following describes:
Medical history To collect any current and past illnesses, medications, key medical
conditions affecting other family members, including whether they may have had AD or
other dementias.
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Physical exam and diagnostic tests To collect information from a physical exam
and laboratory tests, which help distinguish dementia from other diseases that have the
same symptoms. Conditions other than AD that may cause confused thinking, trouble
focusing or memory problems include anemia, infection, diabetes, kidney disease, liver
disease, certain vitamin deficiencies, thyroid abnormalities, and problems with the heart,
blood vessels and lungs.
Neurological exam During a neurological exam, the physician will closely assess the
individual for problems that may signal brain disorders other than AD. Signs of small
or large strokes, Parkinson’s disease, brain tumors, fluid accumulation on the brain, and
other illnesses that may impair memory or thinking, are all on the checklist.
Mental status tests Mental status testing evaluates memory, ability to solve simple
problems and other thinking skills.
Mini-Mental State Exam (MMSE) During the MMSE, a health professional
asks a patient a series of questions designed to assess a number of everyday mental skills.
The maximum MMSE score is 30 points. A score of 20 to 24 suggests mild dementia,
13 to 20 suggests moderate dementia, and less than 12 indicates severe dementia. On
average, the MMSE score of an AD patient declines about two to four points each year.
Mini-Cog test During the Mini-Cog, the individual is required to complete two
tasks, first to remember and a few minutes later repeat the names of three common
objects, and second to draw a face of a clock showing all twelve numbers in the right
places and a time specified by the examiner.
Brain imaging A standard AD medical tests often includes structural imaging with
magnetic resonance imaging (MRI) or computed tomography (CT). These tests are
mainly employed to rule out other conditions that may render symptoms similar to AD
but require different treatments. Structural imaging can reveal tumors, evidence of small
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or large strokes, damage from severe head trauma, or a buildup of fluid in the brain.
1.5 Current treatment
Currently and/or ’only’ approved treatments by US Food and Drug Administration
(FDA), includes five drugs that are used to treat the cognitive manifestations of AD
AChEIs–rivastigmine (Exelon), galantamine (Razadyne, Reminyl), tacrine (Cognex), and
donepezil (Aricept) and NMDA receptor antagonist–memantine (Namenda) that target
symptoms at its best [86]. Each drug acts in a different way to delay the breakdown of
Ach (a chemical in the brain important for memory). AD is associated with inadequate
levels of this important neurotransmitter. Tacrine (Cognex) is rarely prescribed due to
its serious side effects (liver damage). In general, Reminyl, Exelon and Aricept are most
effective when treatment is begun in the early stages. Memantine (Namenda) is the
only drug shown to be effective for the later stages of the disease. They have all been
shown to modestly slow the progression of cognitive symptoms and reduce problematic
behaviors in some people, but at least half of the people who take these drugs do not
respond to them. These present treatment strategies only delay the progression of symp-
toms associated with AD [87]. Much effort is being directed towards the discovery of
disease-modifying therapies which can block the progression of the disease (i.e. clinical
symptoms) and drugs targeting various molecular pathways. For development of disease
modifying therapies complete knowledge about the various metabolic pathways is essen-
tial which includes production of Aβ from APP, in vivo clearance and pathophysiological
events that leads to fibril formation and deposition into plaques [17].
1.6 Aims of this thesis
This project aims to finding biomarkers by employing machine learning approaches to
microarray transcriptomics data and proteomics data and DNA methylation data. The
underlining hypothesis is that there exists multiple biomarkers in transcriptomics, pro-
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teomics and epigenomics which show high relevance to the onset of AD, therefore can
be used for diagnosis with promising performance.
The objectives are following:
 To go through a systematic study of machine learning approaches, mostly focus
on SVM, random forests and their implementations
 To fulfil a detailed investigation of AD on its general mechanism and diagnosis
methods currently applied, understand the advantage and disadvantage
 To select different kinds of significant biomarker by employing effective and robust
feature selection methods in machine learning.
 To innovate novel methods to integrate genetics and pathway information, protein-
protein interaction information in the machine learning modelling to enhance the
performance in training and testing process.
 To develop robust application or software packages that can facilitate future re-
search of AD or dementia either by providing statistical analysis or presenting
benchmark results.
1.7 Synopsis of the thesis
This thesis is composed in the following order: Chapter 1 introduces the background
of Alzheimer’s disesae, its pathology, diagnosis and biomarker in all types. Chapter
2 introduces statistical learning approaches that is related or going to be used within
the range of the thesis. Chapter 3 discusses some novel AD transcriptomic biomarker
findings in brain, and chapter 4 discusses some interesting proteomic biomarker findings
in blood, which was published as research article with the title of ”Discovery of Novel
Biomarkers for Alzheimer’s Disease from Blood” in 2016. Chapter 5 describes applying
meta-analysis in large scale studies. The R package metaUnion that overcame the
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dimension persistency limit across all the studies in normal approaches, acted a crucial
role in a comprehensive AD brain biomarkers investigation. The work was published
with the title of ”Integrated genomic approaches identify major pathways and upstream
regulators in late onset Alzheimer’s disease” in 2015, and the R package metaUnion is
open source in Github. A systematic database for archiving and streaming analysis is
introduced in Chapter 6. Supported by powerful big data technology such as NoSQL, the
system aims to automate and unify the procedure of bioinformatic data research, from
data import and processing, to data analysis, presentation and visualization. Remarkable
extensibility for diversified experiment type is one of the highlights. Chapter 7 describes






This chapter generally discusses the main methodology used throughout the entire pro-
cess of the project - statistical learning. State-of-the-art statistical learning algorithms
and their application are also described, in addition to a brief introduction of big data
technologies in the area of database models.
2.2 Data type and technology overview
Throughout the thesis, various types of data are employed to serve the research purpose.
Microarray data extracted from RNA transcript and protein and DNA sequencing data
are the main sources that were analysed. For future extension, novel technologies such
as DNA methylation and RNA sequencing will also be potential entry points for new
research ideas.
2.2.1 Omics technology
The complete seequencing of the human genome has ushered in a new era of system
biology referred as Omics technology. The term ”omics” refers to the comprehensive
analysis of biological systems. Modern use of the term ”omics” derive from the term
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genome (hence genomics), a term derived invented by Hans Winkler in 1920, although
the use of -ome is older, signifying the ”collectivity” of a set of things. The word
”genomics” is said to be appeared in the 1980s and became widely used in the 1990s.
The first genome was completely sequenced by Sanger in Cambridge, UK, in the 1970s.
Genome is the most fundamental part of many omics.
The word ”Genomics” implies some hidden network among negetic elements. This
network is regulated by many other omics such as proteomics, transcriptomics, metabolomics
and physiomics. In this section, several omics technologies relating heavily to our re-
search are introduced.
 Genomics, the study of genes and their funciton
 Proteomics, the study of proteins
 Metabonomics, the study of molecules involved in cellular metabolism
 Transcriptomics, the study of mRNA
 Glycomics, the study of cellular carbohydrates
 Lipomics, the study of cellular lipids
Omics technologies provide the tools needed to look at the differences in DNA, RNA,
proteins, and other cellular molecules between species and among individuals of a species.
These types of molecular profiles can vary with cell or tissue exposure to chemicals or
drugs and thus have potential use in toxicological assessments. Omics experiments can
often be conducted in high-throughput assays that produce tremendous amounts of data
on the functional and/or structural alterations within the cell. ”These new methods have
already facilitated significant advances in our understanding of the molecular responses
to cell and tissue damage, and of perturbations in functional cellular systems” [88].
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2.2.2 Microarray technology
Microarray technology has become one of the indispensable tools that many biologists
use to monitor genome wide expression levels of genes in a given organism. A microarray
is typically a glass slide on to which DNA molecules are fixed in an orderly manner at
specific locations called spots (or features). A microarray may contain thousands of spots
and each spot may contain a few million copies of identical DNA molecules that uniquely
correspond to a gene (Figure 2.1A). The DNA in a spot may either be genomic DNA or
short stretch of oligo-nucleotide strands that correspond to a gene. The spots are printed
on to the glass slide by a robot or are synthesised by the process of photolithography.
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Figure 2.1: (A) A microarray may contain thousands of ”spots”. Each spot contains
many copies of the same DNA sequence that uniquely represents a gene from an or-
ganism. Spots are arranged in an orderly fashion into Pengroups. (B) Schematic of
the experimental protocol to study differential expression of genes. The organism is
grown in two different conditions (a reference condition and a test condition). RNA
is extracted from the two cells, and is labelled with different dyes (red and green)
during the synthesis of cDNA by reverse transcriptase. Following this step, cDNA is
hybridized onto the microarray slide, where each cDNA molecule representing a gene
will bind to the spot containing its complementary DNA sequence. The microar-
ray slide is then excited with a laser at suitable wavelengths to detect the red and
green dyes. The final image is stored as a file for further analysis. Image source:
https://www.mrc-lmb.cam.ac.uk/genomes/madanm/microarray
2.2.2.1 DNA microarray
Microarrays may be used to measure gene expression in many ways, but one of the most
popular applications is to compare expression of a set of genes from a cell maintained
in a particular condition (condition A) to the same set of genes from a reference cell
maintained under normal conditions (condition B). Figure 2.1B gives a general picture
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of the experimental steps involved. First, RNA is extracted from the cells. Next, RNA
molecules in the extract are reverse transcribed into cDNA by using an enzyme reverse
transcriptase and nucleotides labelled with different fluorescent dyes. For example, cDNA
from cells grown in condition A may be labelled with a red dye and from cells grown in
condition B with a green dye. Once the samples have been differentially labelled, they
are allowed to hybridize onto the same glass slide. At this point, any cDNA sequence in
the sample will hybridize to specific spots on the glass slide containing its complementary
sequence. The amount of cDNA bound to a spot will be directly proportional to the
initial number of RNA molecules present for that gene in both samples.
Following the hybridization step, the spots in the hybridized microarray are excited
by a laser and scanned at suitable wavelengths to detect the red and green dyes. The
amount of fluorescence emitted upon excitation corresponds to the amount of bound
nucleic acid. For instance, if cDNA from condition A for a particular gene was in greater
abundance than that from condition B, one would find the spot to be red. If it was the
other way, the spot would be green. If the gene was expressed to the same extent in
both conditions, one would find the spot to be yellow, and if the gene was not expressed
in both conditions, the spot would be black. Thus, what is seen at the end of the
experimental stage is an image of the microarray, in which each spot that corresponds
to a gene has an associated fluorescence value representing the relative expression level
of that gene.
2.2.2.2 Protein microarray
Protein microarrays were developed due to the limitations of using DNA microarrays for
determining gene expression levels in proteomics. They are the continuation of the DNA
array approach [89]. However, owing to fundamental biochemical differences between
DNAs and proteins, the chemical aspects of DNA microarrays cannot be simply applied
to protein microarrays, which require a more sophisticated surface and immobilization
chemistry [90]. DNAs are relatively simple polyanions and can be chemically modified
and immobilized on solid surfaces based on electrostatic interaction or covalent coupling.
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Proteins are chemically and structurally much more complex and heterogeneous. The
activity and function is critically dependent on their delicate three-dimensional structure.
Proteins tend to adsorb nonspecifically to most surfaces, which often results in the
disruption of their structure. This strong tendency can be attributed to hydrophobic,
ionic, and hydrogen bonding interactions with the solid surface.
2.2.3 Next-Generation Sequencing (NGS)
Next-Generation sequencing (NGS) technology [91] will be involved to enrich the data
with sequencing results. It is dubbed because it is a radically different approach to
decipher DNA sequences which transcends the barrier of scalability, throughput, speed
and resolution compared to traditional DNA sequencing technology.
Massively parallel, this cutting-edge DNA sequencing technology has revolutionised
genomic research. Using NGS an entire human genome can be sequenced within a single
day. In contrast, the previous Sanger sequencing technology, used to decipher the human
genome, required over a decade to deliver the final draft. In genome research NGS has
mostly superseded conventional Sanger sequencing.
There are a number of different NGS platforms using different sequencing technolo-
gies. However, all NGS platforms perform sequencing of millions of small fragments of
DNA in parallel. Bioinformatics analyses are used to piece together these fragments by
mapping the individual reads to the human reference genome. Each of the three billion
bases in the human genome is sequenced multiple times, providing high depth to deliver
accurate data and an insight into unexpected DNA variation. NGS can be used to se-
quence entire genomes or constrained to specific areas of interest, including all 22000
coding genes (a whole exome) or small numbers of individual genes.
Though being overwhelmingly advantageous in genome research, NGS has not yet
translated into routine clinical practice. This technology has huge potential to be used
in clinical genetics, microbiology studies and oncology investigations.
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2.2.3.1 Genome-Wide Association Study (GWAS)
Genome-wide association study (GWA study, or GWAS), is an examination of numerous
common genetic variants in various individuals to see if any variant is related to a trait.
GWAS typically targets on associations between single-nucleotide polymorphisms (SNPs)
and traits like specific genotyping or major diseases.
Genome-wide association studies (GWAS) are a powerful hypothesis-free tool for the
dissection of susceptibility to common heritable human diseases, including osteoporosis.
To date, more than 2000 loci for common human diseases have been identified by
GWAS. Success using the GWAS model depends on genetic risk being determined by
shared stretches of DNA carried with different frequencies in cases and controls, inherited
from ancient ancestors, termed the ”common disease–common variant” hypothesis. Not
all disease risk is caused by common variants, however, and thus GWAS will not detect
all variants involved. Successful GWAS performance requires careful quality control,
especially as the effect sizes under study are modest, and there are multiple potential
sources of error. Conservative interpretation, use of stringent significance thresholds,
and replication in independent cohorts are required to ensure results are robust. Despite
these challenging parameters, much has been learnt from GWAS and, as the approach
matures and is modified to identify a wider range of variants, significantly more will be
learnt about the etiopathogenesis of common diseases such as osteoporosis.
2.2.4 DNA methylation
Recently, a trend of investigating with the alternation of DNA methylation, which is a
biochemical process, has started. In this process, a methyl group is added to the cytosine
or adenine DNA nucleotides. Pathologic DNA methylation may increase the likelihood
of modified expression of genes in cells when cells make a division and differentiate from
stem cells into specific tissues. Therefore it is recently employed as biomarker of diseases.
This stable and heritable covalent modification mostly affects cytosines in the context
of a CpG dinucleotide in humans. It can be detected and quantified by a number of
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technologies including genome-wide screening methods as well as locus- or gene-specific
high-resolution analysis in different types of samples such as frozen tissues and FFPE
samples, but also in body fluids such as urine, plasma, and serum obtained through non-
invasive procedures. In some cases, DNA methylation based biomarkers have proven
to be more specific and sensitive than commonly used protein biomarkers, which could
clearly justify their use in clinics. However, very few of them are at the moment used in
clinics and even less commercial tests are currently available.
2.3 Data preprocessing technique
The actual expression data needs to be extracted before analysing microarray data, which
is then followed by the conduction of preprocessing for the data.
2.3.1 General data processing before experiment design
2.3.1.1 Image processing
The first step in the analysis of microarray data is to process this image. Most manu-
facturers of microarray scanners provide their own software.
Image processing includes the following procedures:
 Identification of the spots and distinguishing them from spurious signals.
 Determination of the spot area to be surveyed, determination of the local region
to estimate background hybridization.
 Reporting summary statistics and assigning spot intensity after subtracting for
background intensity.
We saw that the relative expression level for a gene can be measured as the amount
of red or green light emitted after excitation. The most common metric used to relate
this information is called expression ratio. It is denoted here as Tk and defifi ned as:
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tk = Rk/Gk (2.1)
For each gene k on the array, where Rk represents the spot intensity metric for the
test sample and Gk represents the spot intensity metric for the reference sample. As
mentioned above, the spot intensity metric for each gene can be represented as a total
intensity value or a background subtracted median value.
2.3.1.2 Transformation
To eliminate this inconsistency in the mapping interval which happens in the case of
expresson ratio, one can perform two kinds of transformations of the expression ratio,
namely, inverse transformation and logarithmic transformation.
Inverse or reciprocal transformation The inverse or reciprocal transformation con-
verts the expression ratio into a fold-change, where for genes with an expression ratio of
less than 1 the reciprocal of the expression ratio is multiplied by -1. If the expression ratio
is larger than 1 then the fold change is equal to the expression ratio. The advantage of
such a transformation is that one can represent upregulation and down-regulation with
a similar mapping interval.
However, this method also has a problem in that the mapping space is discontinu-
ous between –1 and +1 and hence becomes a problem in most mathematical analyses
downstream of this step.
Logarithmic transformation A better transformation procedure is to take the loga-
rithm base 2 value of the expression ratio (i.e. log2(expressionratio)). This has the
major advantage that it treats differential up-regulation and down-regulation equally,
and also has a continuous mapping space. For example, if the expression ratio is 1,
then log2(1) equals 0 represents no change in expression. If the expression ratio is 4,
then log2(4) equals +2 and for expression ratio of log2(1/4) equals -2. Thus, in this
transformation the mapping space is continuous and upregulation and down-regulation
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are comparable.
Having explained the advantages of using expression ratios as a metric for gene
expression, it should also be understood that there are disadvantages of using expression
ratios or transformations of the ratios for data analysis. Even though expression ratios
can reveal patterns inherent in the data, they remove all information about absolute
expression levels of the genes. For example, genes that have R/G ratios of 400/100
and 4/1 will end up having the same expression ratio of 4, and associated problems will
surface when one tries to reliably identify differentially regulated genes.
2.3.1.3 Normalization
When microarry is applied in biological studies, an ideal scenario which perfectly control
all variables cannot be expected. This may be due to various reasons, for example,
variation caused by differential labelling efficiency of the two fluorescent dyes or different
amounts of starting mRNA material in the two samples. Thus, in the case of microarray
experiments, as for any large-scale experiments, there are many sources of systematic
variation that affect measurements of gene expression levels.
Normalization is a term that is used to describe the process of eliminating such
variations to allow appropriate comparison of data obtained from the two samples.
The first step in a normalization procedure is to choose a gene-set (which consists of
genes for which expression levels should not change under the conditions studied, that
is the expression ratio for all genes in the gene-set is expected to be 1. From that set,
a normalization factor, which is a number that accounts for the variability seen in the
geneset, is calculated. It is then applied to the other genes in the microarray experiment.
Total intensity normalization The basic assumption in a total intensity normalization
is that the total quantity of RNA for the two samples is the same. Also assuming that
the same number of molecules of RNA from both samples hybridize to the microarray,
the total hybridization intensities for the gene-sets should be equal. So, a normalization







where Rk and Gk are expression intensity of red and green channel respectively for
gene k, Ngene set is the number of genes detected in the samples. The intensities are
now rescaled such that G′k = Gk × Ntotal and R′k = Rk, where R′k and G′k are the












which is equivalent to:
log2(T
′
k) = log2(Tk)− log2(Ntotal) (2.4)
This now adjusts the ratio such that the mean ratio for the gene set is equal to 1.
Mean log centering In this method, the basic assumption is that the mean log2
(expression ratio) should be equal to 0 for the gene-set. In this case, the normalization









where Rk and Gk are expression intensity of red and green channel respectively for
gene k, Ngene set is the number of genes detected in the samples. The intensities are
now rescaled such that G′k = Gk × (2Nmlc) and R′k = Rk, where R′k and G′k are the
















k) = log2(Tk)− log2(2Nmlc) = log2(Tk)−Nmlc (2.7)
This adjusts the ratio such that the mean log2 (expression ratio) for the gene-set is
equal to 0.
Other normalization methods include: linear regression, Chen’s ratio statistics and
Lowess normalization. The next step following the normalization procedure is to filter
low intensity data using specific threshold or relative threshold imposed according to
the background intensity. If the experimental procedure included a replicate, averaging
the values using the replicate data is the next step to be performed after data filtering.
Finally, differentially expressed genes are identified.
2.3.2 Missing value imputation
Despite the wide use of microarray technology, microarray data quality is often plagued
by missing value problem. It is estimated that up to 10% missing values can be con-
tained in microarray data. And even in some data sets, one or more missing values can
be found in up to 90% of genes [92]. The existence of missing values in microarray data
can contribute from a variety of reasons including failures of hybridization, inclusion of
artifacts, inadequate resolution, image noise and pollution, or spotting process deriva-
tives [93]. In a worse case, the emergence of missing values can paralyse the usage of
many analysis methods such as principal component analysis (PCA) and singular value
decomposition (SVD). In a milder case, missing values adversely influence downstream
analysis. The missing value issue has been reported to give unneglectable negative effect
on some popular algorithms, such as hierarchical clustering and support vector machine
(SVM) classifier.
To estimate the missing entries based on the incomplete gene expression data, a
number of missing value imputation algorithms were proposed. The type of information
used in the algorithm can be categorised into four different categories: 1) global approach
2) local approach 3) hybrid approach and 4) knowledge assisted approach.
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2.3.2.1 Global approach
Algorithms in this category conduct missing value imputation according to global corre-
lation information extracted from the entire data matrix. Widely used algorithms in this
category include SVD imputation (SVDimpute) [94] and Bayesian principal component
analysis (BPCA) [95]. In SVDimpute, a set of collaboratively orthogonal expression pat-
terns (eigenvectors) are found via SVD, which can then be linearly combined to estimate
the expression values of all genes within the data set. In BPCA, the expression of genes
are similarly regarded as the combination of component vectors like the SVD approach
(principal component in this context), i.e. y =
∑K
i=1wlvl + ε, where factor score wl and
residual error ε are assumed as normally distributed. An EM-like algorithm is then em-
ployed to approximate the posterior distributions of model parameters as well as missing
values.
2.3.2.2 Local approach
Different from previous mentioned global approach, algorithms in this category use only
local existing data with similar structure in the data set for imputation. The genes that
are used to compute missing values is only those exhibits high correlation with the target
gene with missing values. Algorithms like K nearest-neighbour imputation (KNNimpute)
[94], least square imputation (LSimpute) [96], local least square imputation (LLSimpute)
[97] belong to this category.
KNNimpute [94], is among the earliest and most well-known missing value imputation
algorithms. KNNimpute exploits pairwise information between the target gene with
missing value and the K reference genes which identified as nearest neighbours to impute
the missing values. The missing value j in the target gene is approximated by the
weighted average of the jth component of the K reference genes. The weights are
defined proportional to the inverse of the Euclidean distance between the target and
the reference genes. Several transformations to the original KNNimpute algorithm have
been suggested [98, 99].
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The concept of least square regression has also been widely adopted in many imputa-
tion algorithms. In least square imputation (LSimpute) [96], the K most correlated genes
with the target gene are first selected by absolute Pearson correlation values. These ref-
erence genes x are assumed to be related with target gene y by a linear regression model
y = α + βx + ε, by which a least square estimate of missing value is obtained. Lastly,
the K estimates are combined linearly to produce the final estimate.
2.3.2.3 Hybrid approach
Depending on the nature of dataset to be either heterogeneous or homogenous, the
favourable selection of imputation algorithm will be either a local approach or a global
approach. Jornsten et al [100] proposes a hybrid approach named LinCmb that captures
and utilizes both global and local correlation information in the data. The algorithm
starts by obtaining estimates from five different imputation algorithms - SVDimpute,
BPCA, KNNimpute, row average and GMCimpute – where the first two methods are
global correlation based while the last three emphasize local correlations. The weighted
average of the five estimates computed by the five algorithms are to be used as the
final missing value estimate. To obtain the optimal weight set, LinCmb generates fake
missing entries at the positions where true values are known and then uses the con-
stituent methods to estimate the fake missing entries. The weights are then calculated
by conducting a least square regression on the estimated fake missing entries.
2.3.2.4 Knowledge assisted approach
The idea of this category of imputation algorithms is the inclusion of domain knowledge
or external information into the calculation process. The use of domain knowledge has
the potential to remarkably enhance the imputation accuracy beyond what is achieved by
purely data-driven approaches, particularly for data sets with small number of samples,
much noise, or high missing rate. Algorithms in this category can exploit information
such as the knowledge about the biological process in the microarray experiment [101],
or the underlying biomolecular process as annotated in Gene Ontology (GO) [102] etc.
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2.3.3 Normalization, filtering and averaging
Normalization is a type of transformation applied to the data that adjusts the individual
hybridization intensities so that the data can align with a commonly agreed assumption as
much as possible. Normalization is usually the first transformation the data undergoes.
There are several reasons for the need to implement a normalization, including the
unbalanced quantities of starting RNA, differences in labelling, detection efficiencies
between different fluorescent dyes, and systematic biases.
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2.3.3.1 Total intensity normalization
This method is based on the assumption that an approximately same number of labelled
molecules from each sample should hybridize to the arrays, which therefore leads to the
inference that the total sum of hybridization intensities in the arrays should be the same






Where Gi and Ri are the measured intensities for gene i (for instance, the green and
red intensities in a two-color microarray), and Narray is the total number of elements
presented in the microarray. Using the normalization factor either one or both intensities










Such that the mean ratio is equal to 1.
2.3.3.2 LOWESS normalization
Apart from a total intensity normalization mentioned above, a number of alternative
methods are available, such as linear regression analysis [103], log centering, rank invari-
ant methods [104], and Chen’s ratio statistics [105]. However, none of these methods
address the issue of systematic biases that the log2(ratio) values have a systematic de-
pendence on intensity, which is reported in several studies [106, 107]. Locally weighted
linear regression (LOWESS) [108] analysis has been proposed [106,107] to remove such
an effects in microarray data.
Model-based methods, such as neural networks and the mixture of Gaussians, use the
data to build a parameterized model. After training, the model is used for predictions
and the data are generally discarded. In contrast, ’memory-based’ methods are non-
parametric approaches that explicitly retain the training data, and use it each time a
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prediction needs to be made. LOWESS, on the other hand, is a memory-based method
that performs a regression around a point of interest using only training data that are
’local’ to that point. In locally weighted regression, points are weighted by proximity
to the current x in question using a kernel. A regression is then computed using the
weighted points.
For clarification, a special ratio-intensity (RI) plot is introduced to expose and track
the intensity-dependent effect, where the measured log2(Ri/Gi) for each element on the
array as a function of the log10(Ri ×Gi) is plotted.
Image source: [109]
Figure 2.2: An R-I plot displays the log2(Ri/Gi) ratio for each element on the array as
a function of the log10(Ri × Gi) product intensities and can reveal systematic intensi-
tydependent effects in the measured log2(ratio) values. Application of local lowess can
correct for both systematic variation as a function of intensity and spatial variation on
a DNA microarray. Figure on the left indicates the original data without normalization,
figure on the right indicates the data normalized by LOWESS
2.3.3.3 Intensity-based filtering of array elements
Another kind of systematic bias appears when measured log2 ratio values increases as the
measured hybridization intensity decreases. This is easy to understand because relative
error increases at lower intensities where the signal approaches background. A widely
used method to tackle this issue is to use only array elements with intensities that are
remarkably different from background. Other methods include the use of absolute lower
thresholds for acceptable array elements or percentage-based cut-offs where some fixed
proportion of elements is abandoned.
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2.3.3.4 Replicate filtering
Replication is necessary for finding and mitigating the variation in any experimental
arrays, and there is no exception for microarrays. Biological replicates employs RNA
independently obtained from different biological sources and carry out a measure to both
of the natural biological variability in the system under study, or any random variation
designed in sample preparation. Technical replicates offers information on the natural
and systematic variability that appears in assay processing. A commonly used technical
replication in two-color microarray array analysis is dye-reversal or flip-dye analysis [110],
which comprises duplicating labelling and hybridization by swapping the fluorescent dyes
used for each RNA sample.
In the ideal case, if a gene (presented in a pair of samples) does not have a preference
over the dye they are attaching to, the following equation will be true





) = 0 (2.10)
Where A and B are two samples for gene i, and A1i and A2i is the expression of that
gene in sample A before and after dye swap, likewise for B1i and B2i.
However in reality, experimental variation will make lead to a distribution of the log
of the product ratios. So for this distribution, mean and standard distribution can be
calculated, the results of which can help us make a decision on whether to keep the
samples or not.
2.3.3.5 Averaging over replicates
To decrease the complexity of the data set, averaging over the replicate measures is a
good choice. With the same replicate settings as mentioned before of two samples, A









Where A and B are two samples for gene i, and A1i and A2i is the expression of that
gene in sample A before and after dye swap, likewise for B1i and B2i.
2.4 Statistical learning
2.4.1 Statistical learning overview
Statistical learning, or specifically speaking, machine learning, is an adaptive process that
enables computers to and learn by analogy, learn by example, learn from experience. In
bioinformatics research, a number of machine learning approaches have been developed
and applied to discover new meaningful knowledge from the biological databases, to
analyse and predict diseases, to group similar genetic elements, and to find relationships
or associations in biological data. Supervised learning is often used in the machine learn-
ing process in biomarker discovery. A general summary of machine learning in biomarker
discovery is illustrated in the Figure 2.3. The workflow includes data acquisition, pre-
processing of data, feature selection, classification and interpretation and validation of
prediction model.
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Figure 2.3: AD Biomarker discovery and validation project plan, which indicates the
primary procedure for a full lifecyle of a study unit. It depicts the procedure from data
acquisition, preprocessing of acquired data, feature selection with statistical approaches,
to classification model training, assessing and result interpretation.
Generally, there are three sorts of machine learning algorithms; supervised learning,
unsupervised learning and reinforcement learning. The difference between supervised
learning and unsupervised learning is that the training samples of the former type of
learning contains features values of items and associated ”correct” class membership.
For reinforcement learning, there will never be correct input or output presented, it is
concerned with the problem that how a software agents could behave under a specific
environment so as to gain the maximum predefined reward. Among these three types
of learning, it is supervised learning that applied most frequently in the discovery of
biomarkers, especially for the diagnosis of diseases such as cancer.
2.4.2 Supervised learning
Supervised learning is the machine learning task to obtain a solution (usually a function)
from labelled training data. The training data is comprised of a set of training examples.
In supervised learning, each example consists a pair of variables, one is the explanatory
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variables and the other is signal variable. The set of explanatory variables is typically
an input object vector and the signal variable is a desired output value that can be
regarded as the label of a particular example. Through analysing the training data, a
supervised learning algorithm produces an inferred function that can be used for mapping
new sample, in other words, making prediction based on its input vector.
State-of-the-art supervised learning algorithms include artificial neural networks (ANN),
k nearest neighbour (KNN), logistic regression, decision trees, linear or quadratic discrim-
inant analysis (LDA/QDA), support vector machines (SVMs), kernel matching pursuit
(KMP), logical analysis of data (LAD), stepwise discriminant analysis, partial least square
projection, Naive Bayes, rule induction, and ensemble algorithms (e.g. boosting, bagging
or random forest) combined with various base classifiers.
2.4.2.1 Decision tree
Decision trees are tree-like programs that classify instances by grouping them based on
feature values. Each node in a decision tree is a feature to be classified, while each
branch represents a value that is used as a measure to categorise an instance. Instances
are sorted starting from the root node and classified according to their feature values.







































































































































































































































































































































































































































































































































































































Figure 2.4: An example decision making procedure of a decision tree. For prediction,
a new sample with unknown class label will go through the process of being classified
into different nodes in the tree. Starting from node ’at1’, where the attribute ’at1’ of
the sample’s will determine which node is the next destination. A same iteration repeats
until it reaches the ’leaves’ which determine the prediction by ’Yes’ or ’No’ labels. Image
source: [111]
For the example of the decision tree depicted in Figure 2.4, the instance <at1 = a1,
at2 = b2, at3 = a3, at4 = b4> would sort to the nodes: at1, at2, and finally at3, which
would classify the instance as being positive (represented by the values “Yes”). For the
purpose of constructing optimal binary decision trees, theoreticians have endeavoured to
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Table 2.2: An example of training set of decision tree. For each column, it represents
an ’attribute’ or ’feature’, and the ’Class’ column represents the class label which is
necessary in all training data.
at1 at2 at3 at4 Class
a1 a2 a3 a4 Yes
a1 a2 a3 b4 Yes
a1 b2 a3 a4 Yes
a1 b2 b3 b4 No
a1 c2 ba3 a4 Yes
a1 c2 a3 b4 No
b1 b2 b3 b4 No
c1 b2 b3 b4 No
search for efficient heuristics of solving the problem.
The efficiency of decision tree requires that the root node of the tree should be the
feature that best divides the training data set. Numerous methods were invented to
the root node feature. Myopic measures such as information gain and gini index [112]
estimate each attribute independently, whereas RefliefF algorithm [113] completes the
estimation in the context of other attributes and their intercorrelations. Nonetheless,
no single best method was found by a majority of studies to be universally robust [114].
Therefore, a selection of metric with comparison of individual methods is still an impor-
tant step before constructing decision trees.
2.4.2.2 Random forest
Random forest is an algorithm for classification developed by Leo Breiman [115] that uses
an ensemble of decision trees [111,112,116]. Each of the classification tress is built using
a bootstrap sample of the data, and at each split the candidate set of variable is a random
subset of variables. Thus, random forest uses both bagging (bootstrap aggregation), a
successful approach for combining unstable learners [111, 117], and random variable
selection for tree building. Each tree is unpruned (grown fully), so as to obtain low-bias
trees; at the same time, bagging and random variable selection result in low correlation
of the individual tress. The algorithm yields an ensemble that can achieve both low bias
and low variance (from averaging over a large ensemble of low-bias, high-variance but
43
low correlation trees).
2.4.2.3 Logistic regression and discriminant analysis
Discriminant analysis Fisher’s linear discriminant analysis [118] is designed to find
linear combinations, xw, of n-dimensional predictor variable values x = (x1, . . . , xn), to
make large ratios of between-group to within-group sums of squares. For an N× (n+1)
learning set data matrix, the ratio of between-group to within-group sums of squares is
denoted by w′Bw/w′Ww, where B and W represent the n × n matrices of between-
group and within-group sums of squares and cross products and w represent coefficients.
The up-limit of w′Bw/w′Ww can be inferred from performing eigendecomposition of
W−1B. Suppose matrix W−1B eigenvalues is denoted by λ1 ≥ λ2 ≥ . . . ≥ λs, with
corresponding linear independent eigenvectors v1, v2, . . . , vs. The discriminant variables
are denoted as µl = xvl, l = 1, . . . , s on condition that w = v1 maximizes w
′Bw/w′Ww.
Linear discriminant analysis (LDA) and the related Fisher’s linear discriminant are
straight-forward methods in statistics or machine learning aiming to find the best lin-
ear combination of features to separate two or more classes of instances [119]. LDA
specifies in working on observations with continuous quantites, while Discriminant Cor-
respondence Analysis [120] is better dealing with categorical variables.
For a two-classes separating problem, LDA construct a hyperplane between the
instances from two classes which can be described by a linear discriminant function
v1x1 + v2x2 + . . . + vnxn + c. The function output is equal to zero at the hyperplane.
Meanwhile, two pre-conditions need to be fulfilled before training such a model:
 multivariate normal distribution in both datasets
 homogeneity of both covariance matrices
For discriminant analysis, the hyperplane is defined by the geometric means between
the centroids of the two datasets. In normal practice, the variables are usually normalized
first into standard means (µ = 0) and variances (σ2 = 1) and the Mahalanobis distance
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(an ellipsoid distance determined from the covariance matrix of the dataset) is more
favourable than the Euclidean distance [121].
Logistic regression The paradigm of logistic regression [122] is represented as
p(C = 1|x) = 1/[1 + e−(β0+∑ni=1 βixi)] (2.12)
where x denotes an instance to be classified, and β0, β1, . . . , βn are the parameters
of the model. These parameters should be estimated from the data so that a concrete
model is acquired. The parameter estimation is completed in assist by the maximum
likelihood estimation method. Since the system of n+1 equations and n+1 parameters
to be solved does not have an analytic solution, the maximum likelihood estimations
are performed iteratively. The Newton–Raphson procedure is a standard in this case.
The modelling process is based on the Wald test and on the likelihood ratio test. The
search in the space of models is usually carried out with forward, backward or stepwise
approaches.
2.4.2.4 Neural networks and perceptrons
Neural networks as an artificial intelligence technique is inspired by the idea of mathemat-
ically modelling human intellectual abilities by means of biologically plausible engineering
designs. The processing procedure from input to output is subdivided into several layers,
in such a way that normally only units situating in two consecutive layers are binding to
each other. By processing the input layer by layer, the output value which could be used
as the criterion of prediction is calculated.
Single layered perceptrons The simplest neural network, called perceptron [123],
deploys a single neutron to train classifier with a threshold activation function and sep-
arating two classes by a linear discrimination function.
A single layer perceptron can be described as follows:
Suppose x1 through xn are input feature values, and w1 through wn are connection
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weights that are typically real numbers within the interval of -1 to 1. The perceptron
first calculates the sum of weighted inputs
∑
i xiwi and then the decision is made by
comparing the sum with an adjustable threshold θ. If the sum is above θ then the output
is 1, otherwise 0.
The most popular way that the perceptron algorithm is adopted to learn from a batch
of training observations is to run the algorithm iteratively onto the training set until it
manages to find a prediction vector which is fully correct on classifying all the training
set. This prediction rule is then employed in the process of prediction of the test set.
WINNOW [124], whose name is derived from the fact that it had been designed for
efficiency in separating relevant from irrelevant attributes, is among the first algorithm to
be programmed based on perceptron idea that perform as a classifier model. It is designed
to update the weights of each feature by either a promotion parameter α (α > 1) or
demotion parameter β (0 < β < 1). After the invention of WNNOW, a number of other
algorithms have been developed such as those by Auer and Warmuth [125]. Later, a
newer algorithm called voted-perceptron [126] improves the prediction performances on
test set by including the information of prediction vectors after each mistake has been
made.
Multilayered perceptrons Single layered perceptron can only classify linearly sepa-
rable sets of instances, which otherwise will never classify all the instances properly if
the data is not linearly separable. Multilayered perceptrons, also commonly known as
Artificial Neural Network (ANN), have been developed to tackle the issue of linearly
unseparable datasets [127].
A multi-layer neural network comprises numerous neurons concatenated together in
a pattern of connections (Figure 2.5). Neurons are usually categorised into three types
of layers: input layers, which receive information at the start of learning process; output
layers, where the results of the processing are reported; and layers in between known as
hidden layers. In particular, feed-forward ANNs (Figure 2.5) only allows data processing
flow to travel one way only, from input to output.
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Figure 2.5: An artificial neural network is an interconnected group of nodes, similar to
the vast network of neurons in a brain. Here, each circular node represents an artificial
neuron and an arrow represents a connection from the output of one artificial neuron to
the input of another. A weighted summation of input from top layers forms the output
of the bottom layers, with the leftmost head as raw input and the rightmost bottom as
output. Image source: [111]
During the process of classification, the signals propagates across the net from the
input layer to the output layer. The activation values are initialized randomly in the input
units which are then sent to each of the hidden units to which it is connected. Each of
the activation values of these hidden units are computed and passed on to the output
units. The activation values are all calculated according to a simple activation function.
The function sums together the contributions from all connected units in the upstream,
by multiplying the weight of the connection between the sending and receiving units (see
Figure 2.5) and the sending unit’s activation value.
The ANN model is trained by continually exposing the instances of the training set
to the net. By comparing the desired output with the current output in the training
process, all the weights in the net are modified slightly in the direction that would draw
the output closer to the desired one. The network can be trained via several selection of
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algorithms [128]. Nonetheless, the most widely used algorithm to compute and update
the values of the weights is the Back Propagation (BP) algorithm.
In practice, the size of the hidden layer should be determined carefully, because
undermining it can result in poor approximation and generalization ability of the model,
while exaggerating it can lead to overfitting and complicate the search for the global
optimum. A number of studies has excellent argument relating to this topic [129, 130].
A commonly known huge drawback of ANN is the speed of training. Since the
BP algorithm requires a number of weight adjustments before acquiring a good weight
configuration. One of the approaches for acceleration is to estimate optimal initial
weights [131]. Another approach is weight-elimination algorithm that automatically
derives the optimal topology with the benefit of avoiding overfitting [132]. Some mixture
of other algorithms like genetic algorithms have also been used to train the weights [133]
and to find the architecture [134] for the ANN model. Some researchers also attempt
to train ANN with Bayesian methods [135].
2.4.2.5 Support Vector Machine (SVM)
The goal of support vector machines (SVM) [136] is to find the separating hyperplane
with the largest margin (see Figure 2.6) which is defined by the positive distance between
vector and the decision hyperplane. It originates from the reason that the larger the
margin is, more confidence should be cast on the result of classification.
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Figure 2.6: A demonstration of finding hyperplane with SVM model. In this example,
two groups are separated by SVM, where the hyperplane (the diagonal line) separating
two samples (black solid nodes and white unfilled nodes) with the maximum margin
between the closest support vectors (highlighted with bolden edge of nodes which lie on
dash lines parallel to the hyperplane). Image source: [111]
Suppose the training data is linearly separable and there exists a pair of (ω, b) such
that
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ωTxi + b ≥ 1, for all xi ∈ P
ωTxi + b ≤ −1, for all xi ∈ N
(2.13)
So that the decision rule is defined as
fω,b(x) = sgn(ω
T + b) (2.14)
Where ω is the weight vector, xi is variables of sample i and b is the bias. Therefore,
an optimum separating hyperlplane can be found by minimizing the squared norm of the







Txi + b) ≥ 1, i = 1, . . . ., l
(2.15)
Where yi is the class label or dependent variables of sample i. For linearly separable
data, the data points that lie on the margin of the optimum separating hyperplane is
known as support vectors. The solution thus is represented as a linear combination of
only these points.
However, for the cases that cannot be linearly separable, SVM may not be able
to find any separating hyperplane at all. This issue can be addressed well by using a
soft margin that accepts limited number of misclassifications on training instances [137].
The approach to realize it is to introduce positive slack variables ξi for each instance I
= 1,. . . .,N in the constraints
ωTxi + b ≥ 1− ξ, for yi = +1 and ξ ≥ 0
ωTxi + b ≤ −1 + ξ, for yi = −1 and ξ ≥ 0
(2.16)
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Where the µi are the Lagrange multipliers introduced to enforce positivity of the ξi,
and C is the parameter to reversely adjust margin size.
Another solution to address the case of inseparability of instances is to project the
data onto a higher dimensional space where a new hyperplane is defined. With such a
mapping to other spaces (possibly infinite), a linear separation in transformed feature
space corresponds to a non-linear separation in the original input space. The application
of kernel function is capable of achieving the goal. The kernel function is a special
class of functions that allow inner products to be calculated directly in original input
space, without actually performing the mapping or transformation into new features,
the number of which is usually infinite [138].
It is very important to find such kernel functions that match the definition mentioned
above. Genton [139] discussed several classes of kernels and their application in various
domains, though not addressing the issue of suitability of functions to different type of
problems. In the field of machine learning, commonly used kernels include the Gaussian
and Laplace kernels, i.e.,









Recently, Muandet et al [140] provided a review of kernel mean embeddings of dis-




Unsupervised learning targets on finding the hidden pattern or structure of the unlabelled
data. Because the examples for the learner are without class labels or ”responsive”
variables, no error or reward signal is given to assess a potential solution. This is the
major difference between supervised learning and unsupervised learning. Unsupervised
learning is closely associated with the problem of density estimation in statistics [141].
Nonetheless, unsupervised learning also includes many other algorithms or techniques
that endeavour to generate conclusions or explanations, or to explain principal features
of the data.
2.4.3.1 Clustering
Clustering is a technique partitioning a set of elements into subsets based on the differ-
ences between them. Especially, it is the process of grouping similar elements together.
In clustering, no class information is provided and that is the main difference from su-
pervised learning.
The clustering of genes in expression profiles is the most typical example of appli-
cation of clustering in bioinformatics. As in microarray assays, the expression values
for thousands of biomolecules in a limited number of samples are acquired. Extracted
from these data, an interesting and intriguing piece of information is which molecules
are coexpressed in the different samples. In practice, genes with similar expression level
in all samples are amalgamated into one single cluster. Cluster analysis, also dubbed
data segmentation, carries a variety of goals. By segmenting a collection of objects into
clusters, those within each clusters are more closed associated to one another than those
affiliated in other clusters. Sometimes the task of clustering is extended to arrange the
clusters into a natural hierarchy, which involves iterative grouping of clusters to identify
”clusters of clusters”.
In all, the core idea of cluster analysis is to reveal the degree of similarity or dissimi-
larity between objects in interest.
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Partition clustering Partition clustering specifies in obtaining a division of the data.
Each point is classified into a unique cluster. Though commonly the number of clusters
(see Figure 2.7 (a) k=4) is fixed, some algorithms are able to search for the optimal
number of clusters while assigning objects to different clusters.
(a)
(b)
Figure 2.7: Examples of clustering results from different approaches a) partition cluster-
ing - a division of the set of data objects into non-overlapping subsets (clusters) such
that each data object is in exactly one subset. b) hierarchical clustering - a set of nested
clusters that are organized as a tree. Image source: [111]
One of the most popular iterative descent clustering methods is the K-means algo-
rithm [142]. The objective of the algorithm is to group the data into K clusters such that
the within-group sum of squares is minimized. A demonstration of the simplest form
of K-means algorithm is by repeating the following two steps as depicted in Figure 2.8:
1) Assign objects to groups under the criterion that an object is assigned to the group
with closest Euclidean distance 2) calculate new group means based on the previously
updated assignments from step 1. The iteration ends when the class state of objects
reach equilibrium.
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Figure 2.8: A visual procedure of applying k-means algorithm clustering approach.
K-means clustering is an algorithm to classify or to group the objects based on at-
tributes/features into K number of group. source: [111]
Hierarchical clustering Hierarchical clustering approaches [143] are the most popular
methods to generalize data structures in the bioinformatics field. A hierarchical tree
Figure 2.7 (b) is a nested set of partitions demonstrated by a tree diagram or dendrogram.
Strategies for hierarchical clustering are normally split into two types, “agglomer-
ative” which is a “bottom up” approach that construct the tree from bottom to top
by merging clusters along with higher hierarchy, or “divisive” which is a “top down”
approach splitting the initial single cluster into groups. Generally, divisive algorithms
are computationally inefficient. A measure of the distance or dissimilarity between two
merged clusters determines which groups should be merged, or how the clusters should
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be split. The matrix wrapping the dissimilarity information between pair of clusters is
called dissimilarity matrix.
The following measures of distances between clusters are most commonly applied
 single-linkage: the distance between two groups is the distance between their
closest members
 complete-linkage: the distance between the two farthest points
 Ward’s hierarchical clustering method [144]: at each stage of the algorithm, the
two groups that produce the smallest increase in the total within-group sum of
squares are amalgamated
 centroid distance: defined as the distance between the cluster means or centroids
 median distance: distance between the medians of the clusters
 group average linkage: average of the dissimilarities between all pairs of individuals,
one from each group
2.4.3.2 Principal component analysis (PCA)
Principal component analysis (PCA) is a multivariate technique that analyses a data
matrix where instances are described by multiple inter-related quantitative dependent
variables. It is likely to be the oldest multivariate technique. In fact, its origin can
be traced back to over a century ago to Pearson [145] or even further [146]. Yet the
term principal component was coined by Hotelling [147] who formalized its modern
instantiation. Recently, Abdi and Williams [148] had a comprehensive review of the
method.
The goals of PCA includes
 extracting the most significant and important information from the data matrix
 compressing the size of the data set by filtering out redundant information
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 simplifying the description of the data set
 Analysing and decomposing the structure of the instances and the variables.
To realize these goals, new variables called principal components, which are formed
by linear combinations of the original variables, are computed by PCA. It is required that
the first principal component have the largest possible variance (i.e., inertia). As a result,
this component will be able to explain or represent the most variance (the largest part
of the inertia) of the data table. Under the constraint of 1) being orthogonal to the first
component 2) to have the largest possible inertia, the second component is computed.
The rest of components are computed likewise. Factor scores, which is the projections
of the observations onto the principal components in a geometrical sense, are the values
of these newly transformed variables for the observations.
Brief introduction of finding the components To find the components, singular
value decomposition (SVD) of the data table X is executed.
X = P∆QT (2.19)
where P and Q are the matrix of left and right singular vectors respectively, and
∆ is the diagonal matrix of singular values. The matrix Q provides the coefficients of
the linear combinations used to calculate the factors scores. Note that ∆ is equal to
the diagonal matrix of the (nonzero) eigenvalues of XTX and XXT. The factor scores
denoted F is computed as
F = P∆ = P∆QTQ = XQ (2.20)
Interpreting PCA There are several aspects of information from the data table that
can be extracted from the PCA results.
 The importance of a component can be obtained by evaluating its inertia, or
more accurately, the proportion of the total inertia reflected or represented by this
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component. The simplest way to get inertia is via the eigenvalue which is equal
to the sum of the squared factor scores for a particular component.
 The contribution of an observation to a component can be obtained by the ratio
of the squared factor score of this observation by the eigenvalue associated with
that component.
 The squared cosine which indicates the importance of a component for a particular
observation. It represents the contribution of a component to the squared distance
of the observation to the origin.
 The correlation of a component and a variable is dubbed loading in PCA frame-
work.
2.4.3.3 Genetic programming
Genetic programming (GP) is used as the feature selection algorithm. It performs better
in classification with smaller amount of features compared to IG and REFS-F using NB,
SVMs and J48. GP also outperforms NB and J48 as a classification method and has
better performance in some cases, such as mining Mass Spectrometry data [149].
2.4.4 Probabilistic models
Different from logic-based algorithms like decision trees, perceptron-based algorithms
like ANN or SVM, statistical learning approaches are characterized by mounting on an
explicit probability model. These approaches delivers an output of probability that an
instance belongs in each class, instead of simply a classification.
2.4.4.1 Bayesian machine learning
Bayesian learning is termed to represent the application of probability theory to learn-
ing from data [150]. The probability approach to modelling is conceptually very simple
compared to other machine learning paradigms. First, probability distributions are used
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to describe all the uncertain unobserved quantities within the model as well as their re-
lationship to the data itself. Then the basic probability rules are applied to infer the un-
observed data from the observed one. The behaviour of learning happens when the prior
probability distribution (defined before observing the data) is transformed into posterior
distributions (after observing the data). The Bayes rule can be generally summarised as




y∈Y P (x, y)
(2.21)
Where P (x) and P (y) are the unconditional probability, P (x|y) is the conditional
probability of x given y, P (x, y) is the probability that both x and y occur. Some
replacement can be made to describe its application to machine learning
P (θ|D,m) = P (D|θ,m)P (θ|m)
P (D|m)
(2.22)
Where D denotes the observed data, θ denotes the unknown parameters of a model,
conditioning all terms on m which is the class of models in interest, P (D|θ,m) is the
likelihood of parameters θ in model m, P (θ|m) is the prior probability and P (θ|D,m)
is the posterior probability.
After the learning occurs and the prior knowledge is transformed into the posterior
knowledge about the parameters, this posterior is now the prior to be used in the future
data.
Naive Bayes classifier Naive Bayes (NB) is a very simple case of Bayesian networks
which comprises directed acyclic graphs with only one single unobserved node and several
observed nodes. A strong assumption is raised forward that the child nodes are strictly
independent to one another in the context of the unobserved node [151]. Therefore, the















By comparing the two probabilities, the classifier makes a decision of predicting the
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class label to be either i (if R > 1) or j. Cestnik et al [152] were among the first to use BN
in machine learning community. Further study [153] suggested using Laplace estimators
or adding m-esimate to avoid the impact from a probability of 0 to the computation of
probabilities P (X, i).
While having the advantage of a short computational time, the biggest problem that
the algorithm facing, is the strong assumption of independence among child nodes which
is seldom the case. As a result, NB classifiers are usually less accurate than most other
more sophisticated algorithms (such as ANNs). Many enhancement has been made on
the original model in order to address the issue. Friedman et al [154] proposed some
dependencies between features with the limitation that each feature can be related to only
one other feature. Another attempt is the proposal of semi-naive Bayesian classifier [155]
where attributes are further partitioned into independent groups.
2.4.4.2 Gaussian processes
Gaussian processes are a very flexible non-parametric model for unknown functions,
which are commonly used in regression, classification, and other applications that require
inference on functions [156].
2.4.5 Model evaluation and accessing methods
Once a classification model is trained and constructed, we need to assess its performance
in regards to prediction accuracies. Some conventional measures are developed for this
purpose.
2.4.5.1 Error rate and ROC curve
The error calculations are based on the confusion matrix (Table 2.3). Each cell in
the matrix represents the number of samples fallen into that particular category. For
example, the value of TP represents the number of instances whose true class is positive
and predicted by the classification model to be positive. Therefore, the total number of
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Table 2.3: Confusion matrix in a two classes problem. The column represents the
prediction to be positive or negative, whereas the row represents the true label being
positive or negative. The value in each cell represents the number of samples falling into
the category, eg. TP means the number of positive samples that are predicted to be





Positive TP: True positive FN: False negative
Negative FP: False postive TN: True negative
instances in the validation set is
N = TP + FP + TN + FN (2.24)


























TP + TN + FP + FN
(2.25)
To fine-tune a classifier, another method is to plot the receiver operating charac-
teristics (ROCs) curve [157], which reveals hit rate versus false alarm rate, namely,
1− specificity = FP/(FP + TN) versus sensitivity = TP/(TP + FN), and has a
form similar to Figure 2.9.
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Figure 2.9: An example of ROC curve. The true positive rate (Sensitivity) is plotted
in function of the false positive rate (100-Specificity) for different cut-off points of
a parameter. Each point on the ROC curve represents a sensitivity/specificity pair
corresponding to a particular decisiont hreshold. The area under the ROC curve (AUC)
is a measure of how well a parameter can distinguish between two diagnostic groups
(diseased/normal). Image source: [111]
Each classification algorithm has a parameter, or in other words threshold of decision,
which subject to changes so that classifying decisions can be made and consequently
yielding different pairs of true positives versus false positives. Normally increasing the
number of TP will also increase FP, and vice versa. As a result, a trade-off is often
required to achieve the application aim to produce predict result that is within the level
of error expectation, and the trade-off can be visualised as a point on this curve. The area
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under the ROC curve is commonly employed as a measure of performance for machine
learning models [158].
2.4.5.2 Estimating the classification error
An unneglectable issue relating to a designed classifier is how to calculate its error rate
when it is applied to classify new instances that has not been used in the training process.
A popular method to estimate the error is by k-fold cross-validation [159]. To start
with, all of the samples are partitioned into k folds where each fold is left out of the
training process of the classifier and used as “stranger” dataset in the classifier testing
process. The estimated error is the overall proportion of errors across all folds. A special
case for this method occurs when k equals the total number of samples, which is dubbed
as leave-one-out cross validation, where a single instance is left out each time as the
testing dataset.
Another popular method for error estimation is the bootstrap methodology [160]. For
this method, a resampling strategy is implemented based on the notion of “empirical
distribution” where the bootstrapped samples are drawn with replacement by equal
probability. The bootstrap zero estimator and the 0.632 bootstrap estimator [161] are
used.
In bioinformatics, an overview was provided by Baldi et al. [162] of various methods
to evaluate the accuracy of classification algorithms. The implementation of the previous
error estimation methods has mostly focused on the analysis of supervised models specific
for microarray data. In this sense, Michiels et al. [163] utilize multiple random sets for
predicting cancer outcome by microarrays. Ambroise et al. [164] reported a 10-fold cross
validation outperforms a leave-one-out cross validation, in a gene selection issue built
upon microarray gene profiles. In regards to the bootstrap approach, the so-called 0.632
bootstrap error estimator proposed to tackle overfitted prediction is suggested. It has also
been reported [165] that the 0.632 bootstrap estimator as a standout estimator in small-
sample microarray classification. These same authors [166] have then developed a novel
method called bolstered error estimation which bypass the performance of bootstrap in
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feature ranking performance. Fu et al [167] proposed a method combining bootstrap
and cross-validation which show very good results.
2.4.6 Meta-analysis
Different from machine supervised machine learning which focuses on prediction, meta-
analysis comprises statistical methods for contrasting and combining results from differ-
ent studies, in the hope of identifying patterns among different study results, sources of
disagreement among those results, or other interesting relationships that may come to
light in the context of multiple studies. The information extraction from accumulating
mass of microarray data by meta-analysis can reconstruct cellular pathways or transcrip-
tion factor network, leading to a more reliable understanding of the underlying biology.
In the first application of meta-analysis to microarray, Rhodes et al [168] combined
four data sets on prostate cancer to determine genes that are differentially expressed
between benign prostate tissue and clinically localized prostate cancer. Current R pack-
ages to conduct meta-analysis for microarray studies include meta [169], metafor [170],
metaMA [171], MAMA (depreciated), and scores of other packages, each of them is
designed for specific type of input data and output data, with various objectives and
algorithms in data processing.
2.5 Biomarker discovery by machine learning
2.5.1 Feature selection methods
Feature selection is extremely important for the classification that involves large num-
bers of features in the dataset. The need of feature selection is especially urgent for
some cases, for example, microarray data based classification, where numerous noisy
and redundant genes are presented in the dataset. Also, despite the small sample size
retrieved from microarray data, it represents the state of a cell at a molecular level and
plays gradually important roles in medical diagnosis. Therefore, many techniques are
63
developed and employed to work out how to select features efficiently and accurately.
The technique for feature selection can be categorized into three main methods – fil-
ter methods, wrapper methods and embedded methods. Filter method selects only the
highest ranking features based on general characteristics of the training data without
influencing any learning algorithm. Moreover, it requires comparatively short computing
time than other feature selection methods. Several kinds of filter methods are frequently
used in microarray data to identify informative genes, such as Bayesian Network Infor-
mation Gain (IG), Signal-to-Radio (SNR) and Euclidean Distance, among which IG has
been reported to be the superior technique. Except for parametric techniques, some
non-parametric techniques, for example, threshold number of misclassification, Pearson
correlation coefficient and Significant Analysis of Microarray (SAM), are also applied for
feature selection. Univariate filter method satisfies the need for validation of experimen-
tal results from biology and molecular domain experts and consumes less computational
time. Nonetheless, the major drawback is the selected genes are most possibly redun-
dant. Unlike the filter method which sort out meaningful genes independently, a wrapper
method unifies the feature selection process with a classification algorithm. The learning
algorithm which the model uses to train itself has great impact on the result of the feature
selection process. Consequently, wrapper approach acquires more accuracy at the ex-
pense of computational cost. Genetic Algorithm (GA) is a randomized search algorithm
that has been utilized for binary and multiclass cancer discrimination [172, 173]. The
prime disadvantage of GA is that it has a higher risk of over-fitting than filter methods
and is very computationally intensive. In terms of the specificity to learning algorithm,
embedded methods are identical to wrapper methods. But a progressive advantage of
this technique lies in the fact that it is more computationally simple than wrapper meth-
ods. Support Vector Machine (SVM) method of Recursive Feature Elimination (RFE)
is one of those embedded methods that are used for gene selection.
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2.5.2 Machine learning in practice
A common case for microarray data is that there exist a number of unannotated datasets
that cannot contribute to the supervised classification using microarray data. Likewise,
unsupervised learning algorithm cannot fully take advantage of the annotated datasets.
It is reported that semi-supervised algorithms can address these situations. Blum and
Mitchell [174] first introduced a co-training algorithm which enhanced the performance
of classifier when there are both labelled and unlabelled samples. Another SSL algorithm
is proposed [175] where the example data is comprised of DNA microarray expressions
and phylogenic reconstructions. Lately, a Bayesian Semi-Supervised approach coined
BGEN (Bayesian GENeralization) [176] was introduced whose predictions were proved
to be more accurate than that from either K-means clustering or SVM classification.
Harris and Ghaffari constructed a new SSL method classifying three cancer groups with
both labelled and unlabelled data [177]. The new method shows improvement in the
accuracy comparing to classifying solely with labelled data.
Extra-Trees Decision Trees is the learning algorithm which was used in a recent
study [178] to define protein profiles of asthma-related inflammation and remodelling by
ranking the potential biomarkers according to their importance. In that study, surface-
enhanced laser desorption/ionization-time of flight-mass spectrometry (SELDI-TOF-MS)
on lung samples is employed as input for machine learning and the discovery of several
new key biomarkers that are likely to participate in the formation of asthmatic phenotype
suggests that SELDI-TOF-MS is a useful tool to identify new potential therapeutic
targets in inflammatory diseases.
Unlike standard approaches to estimate variable importance that contributed solely
from the estimation of the conditional expectation of the outcome provided the biomarker
and covariates, the approach of targeted maximum-likelihood estimation target the re-
gression estimate specifically at the parameter of interest. In the case of a reported study
about biomarker discovery of treatment of antiretroviral-resistant HIV infection [179],
several ML algorithms are used to seek specific mutations which can reduce clinical
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virologic response to antiretroviral regimens. It turns out that better performance if
acquired by means of a targeted maximum-likelihood estimation compared to a standard
approach.
It was proved that classifiers trained by combinatory algorithms have good perfor-
mance in some studies. Wang et al [180] conducted a study which investigates the gene
expression profiles in zebrafish treated with endocrine-disrupting chemicals of different
modes of action. After testifying various combinations of gene feature selection/class
prediction algorithms, it turns out that a classifier that is yielded by genetic algorithm
and SVM is the best in terms of accuracy.
Among all of the developed supervised learning algorithms, support vector machine
(SVM) and random forest (RF) exhibit promising classifying ability, stability in the ex-
pense of comparatively low computational cost, which make them two of the most pop-
ular algorithms applied in the studies of disease classification, prediction and biomarker
discovery.
An SVM model is a representation of the examples as points in space, mapped so
that the examples of the separate categories are divided by a clear gap that is as wide as
possible. After training, new examples are mapped into that same space and predicted
to belong to a category based on which side of the gap they fall on. Random forest
is an algorithm for classification is an ensemble learning method for classification (and
regression) operated by constructing a multitude of decision trees at training time and
outputting the class that is the mode of the classes output by individual trees. There
are many successful applications of SVM and random forest in disease diagnosis [181].
Guyon et al [182] utilized SVM as classifier training model to discover two genes that
yield zero leave-one-out error in a leukemia cohort, and found out four genes with 98%
accuracy in a colon cancer cohort. Furey et al [183] presented a method to analyse
microarray expression data using SVM, with comparable performance in compared with
another method which is based on perceptron algorithm in ovarian cancer datasets.
Akay F. [184] built a SVM classifier for Wisconsin breast cancer dataset (WBCD) by
only 5 features with as high as 99.51% classification accuracy. D-Uriarte R et al [185]
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proposed a gene selection method based on random forest, with which a prediction model
is trained with very small sets of genes while preserving predictive accuracy. Random
forests are sets of ensemble learning methods for classification combining bagging idea
and the random selection of features so as to build a collection of decision tress and
outputting the class that is the mode of the classes output by individual trees. In
Zhang’s study [186] about identifying CSF biomarkers that distinguish Alzheimer (AD)
and Parkinson Diseases (PD), random forest was used as the statistical analysis method
to analyse the data, which validated a proteomics-discovered multianalyte profile (MAP)
in CSF that is highly effective in classifying PD and moderately effective at identifying
AD.
2.6 Big data technologies
We have entered an information driven era. The trend led by advancing hardware
technologies and the rampage of internet in modern world has brought new scope of
technology revolution in the broad aspect of information technology. The maturation
of technology brings explosive boost of data volume. The data is being yielded at an
exponential speed through various disparate potential resources and sensors, scientific
instruments, and internet especially the social media, etc. The unprecedented outburst
of information and virtual fortune challenged both the infrastructure and the paradigm
of acquiring, storing and analysing data. Consequently, the large, complex, structured
or unstructured, and unharmonized data has attracted significant attention.
Under the enormous focus, some modern data models that claim to process the
extremely large data such as Big Data in a reliable and efficient way has come into
horizon. NoSQL, largely being translated as “not only SQL”, is a fashionable database
“genre” that intends to be non-relational, highly scalable, efficiently distributed, and
mostly open-source. They are often labelled as schema-free, straightforward API, simple
replication, etc. Numerous potential data models are developed in the past few years
but still the warehouse is growing to meet more challenges. The main mentality of
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evolving NoSQL database capacity is very clear. The massive, complex, and fast-pace
data production requires more efficient query (more queries) development that retrieves
most accurate information (better results) with best optimal latency [187].
2.6.1 Data challenges
The mammoth growth of the modern data casts doubts on the computing capacity and
efficiency of the existing database prototypes. In general, the concern that Big Data era
is facing can be described to have four aspects of the data: volume, velocity, variety and
veracity. All of the four concerns are briefly described here
 Volume of data The industries are inundated with vast volume of data of all types.
The data is enlarging easily from terabytes to even petabytes. Tweets from the
social media network alone consume up to 12 terabytes of data every day.
 Velocity of data The data collected at the enterprises is at an extremely high speed.
A slight delay can make a huge impact on the analysed output. For the example
of fraud detection, the 5 million trade transactions influx of data every day must
be analysed instantly in order to identify the potential frauds.
 Variety of the data All of the possible types of data will be emerging and needed
to be analysed – text, audio, video, log file, etc. A combinatory study of different
types of data is also of high chance to report valuable information to the enterprises.
 Veracity of the data Data is not always trustworthy. It is especially crucial to
have true output from input full of suspicion the decision making is based on such
information.
2.6.2 NoSQL data models
The following section discusses some of the best database models that are considered
to be reliable and efficient in the Big Data arena.
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2.6.2.1 BigTable
BigTable, exclusively exploited by Google for managing various important projects, is
designed as a distributed storage system to manage the petabytes size of the data, dis-
tributed across several thousand commodity servers and allows further horizontal scaling.
The BigTable copes with latency and data size issues with high efficiency. Underpinned
by the Google File System (GFS) [188] for log and data files storage and Google Sorted
String Table (SSTable), it is a compressed, proprietary with high performance storage
system.
The BigTables are intensively used by Google for its different applications such as
Gmail [189], YouTube [190], Google Maps [191], etc.
2.6.2.2 Cassandra
Originally invented by Lakshman and Malik in 2011 [192], Cassandra is a distributed,
open source data engine that deal with a gigantic amount of data of petabytes level,
distributed across several commodity servers. The infrastructure selection of data clusters
spanning multiple data centres guarantee the reliable support, high data availability
and no single point of failure by Cassandra. The durable write function supported by
memtable, which is a special memory space in the infrastructure of Cassandra acting as
an intermediate station whenever a write operation occurs, help avoid the risk of losing
data during hardware failure. Though being a member of NoSQL family, Cassandra
does not support the joins and subqueries but is equipped with SQL-like languages
called Cassandra Query Language (CQL).
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Figure 2.10: Writing path in Cassandra.Cassandra processes data at several stages on
the write path, a) Logging data in the commit log b) Writing data to the memtable c)
Flushing data from the memtable d) Storing data on disk in SSTables. Image source:
[187]
2.6.2.3 HBase
HBase is a non-relational, column-oriented, open source, and distributed database man-
agement system [193] written in Java. HBase employs Hadoop Distributed File System
(HDFS) underneath. It is envisioned to manage massive sparse datasets and follows the
master-slave concept which is a model of communication between devices where one
has unidirectional control over other devices. Though being a member of NoSQL family,
HBase is a column-oriented data model that consists of the sets of tables, consisting
of rows and columns. Like traditional databases, HBase assigns a primary key in each
table that is used to access the data. HBase provides the function of grouping many
columns (attributes) together into what are called column families that is open to join
in anytime, with elements of a column family stored together.
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2.6.2.4 MongoDB
MongoDB, etymologically derived from the word ”humongous”, is an open source,
document-oriented NoSQL database that has lately gaining popularity in the data in-
dustry [194]. It is known as one of the most widely used NoSQL databases that inherit
the master-slave replication. The responsibility of master is to implement the operations
of reads and writes, whereas the role of slave is to duplicate the data fetched from
master, to execute the read operation, and data backup. The slaves do not participate
in write operations, but may select an alternate master in case of the current master
failure. MongoDB uses binary encoded format of JSON documents called BSON behind
the scenes. As a member of NoSQL family, no fixed schemas is required in contrast to
the traditional relational databases. Numerous search refinement options like searching
by fields, range queries, regular expression, or even the user-defined complex JavaScript
functions are allowed in the query system of MongoDB.
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Figure 2.11: MongoDB architecture. MongoDB is a document database that provides
high performance, high availability, and easy scalability. Some of its characteristic in-
cludes sharding, replication, the concept of collections and documents, etc. MongoDB
has flexible schema, document structure, and atomicity of write operations. Image
source: https://chiruideas.weebly.com/mongo-db.html
2.7 Methods in plan
2.7.1 Statistical approaches
In this thesis, the following statistical approaches are employed to achieve the research
goals,
Random Forest Firstly, it is an ensembling-learning model which aggregate multiple
machine learning models (decision tree in this case) to improve performance. Thus,
a good combination of low variance and low bias can be expected from this model.
Secondly, Random Forest is able to intepret classifying performance on a feature-by-
feature basis, avoiding the mystification of feature performance explanation that appears
in other models such as SVM.
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Support Vector Machine Firstly, it has a regularisation parameter, which helps avoid-
ing over-fitting to a manipulatable extent. Secondly, the fact that it uses kernel facilitates
expert knowledge about the problem to be built in via engineering the kernel. Thirdly,
an SVM is defined by a convex optimisation problem (no local minima) for which there
are efficient methods. Lastly, it is an approximation to a bound on the test error rate.
Meta-analysis This method provides approaches to summarize and integrate results
from multiple studies, and thus more general conclusions can be made by this analysis
as it escape from the bottleneck of lack of coorperation between difference studies in
terms of drawing conclusions.
2.7.2 Technology and software
And the following technology or software are used to serve for the research purposes,
R Entirely open source, R has the most comprehensive statistical analysis package
available by far. There are large number of communities that strive to develop the
various aspects of this tool. The graphical representation of R is extremely exemplary
which makes it surpass other statistical and graphical packages.
Python is chosen among the rest of programming languages for the following reasons.
 Python is a programming language that is much easier to build prototypes com-
pared to other languages, due to its simplicity and flexibility.
 Abundant Python libraries for data science such as Numpy, Scipy, Pandas, etc.,
and sufficient community support
 On developing extensive large scale applications, Python and Django in combina-
tion offer speed of development, flexibility, scalability and robust applications. The
technology stack helps develop cost-effective application
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MongoDB Like other NoSQL databases, MongoDB are more scalable and structurally
schema-free compared to traditional relaional databases. Apart from these legacy ad-
vantages, MongoDB provides document oriented storage, replication, auto-sharding, and
indexing on any attributes. These features are greatly beneficial for database performance
in production, and more than adequate to serve a research application.
Ingenuity Pathway Analysis IPA is excellent in uncovering the significance of Omics
data and identify new targets or candidate biomarkers within the context of biological
systems. It has broadly been adopted by the life science research community and is cited
in thousands of articles for the analysis, integration, and interpretation of data derived
from Omics experiments, such as RNA-seq, small RNA-seq, microarrays including miRNA
and SNP, metabolomics, proteomics, and small scale experiments.
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Chapter 3
Prominent AD classifier enhanced by
addition of covariate information
3.1 Abstract
In this chapter, transcriptomic AD biomarkers in brain are investigated. First, the impacts
of covariate such as age, gender and APOE genotype information to the performances
of AD classifiers were studied, with a result showing that the inclusion of age and APOE
genotyping into the prediction model could improve classifiers performance. Then, a
random forest based feature selection method was employed to select a panel of 26 RNA
transcripts that has promising classification ability between AD patients and healthy
controls.
3.2 Background
AD prognosis and diagnosis has always been hard. Like other neuro-degenerative dis-
eases, the awareness of progression of the disease rely heavily on symptoms like long or
short term memory loss, ambiguity, mood swing, etc.
In this study, the impacts of covariate to the performances of AD classifiers are
evaluated, by comparing support vector machine (SVM) models trained with and without
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covariates.
The interest of including age in the prediction model is obvious, since aging is closely
linked with dementia. Cognitive impairment appears both in the process of normal aging
and neurodegenerative diseases (especially AD). Major studies has been targeting on
trying to distinguish cognitive impairment attributable to normal aging from those that
suggest AD pathology [195, 196]. Age correction is a common approach to address
the issue before analysing the experiment data. Recently studies show that AD first
symptoms are age dependent [197], with disparity in the first cognitive and behavioural
symptom experienced by AD patients. To understand the effect of age into the studies,
several groups of researchers designed and examined different age correction methods
for imaging data such as MRI [198, 199], sequencing data such as SNP [200].
The presence of an ε4 APOE allele was proved to be significantly associated with AD
[201,202]. It is reported to be the strongest known susceptibility variant for AD [203–205]
and this finding has been confirmed by genome-wide association studies [206,207]. There
are three major isoforms of the APOE protein that are encoded by three alleles of the
APOE gene (ε2, ε3 and ε4). As a result, APOE genotyping information has excellent
potential to be one of the indicator variables for discriminating case and control samples.
Another factor to be investigated is gender. As per the report of US Institute of
Medicine in 2012, ”sex” refers to the classification of living things as male or female
according to their reproductive organs and functions assigned by chromosomal comple-
ment, whereas ”gender” refers to a person’s self-representation as male or female or
to how that person is responded to by social institutions on the basis of that presenta-
tion [208]. To avoid confusion, ”gender” here refers to ”sex” in the above definition.
Though not proved to be a direct risk factor of AD, gender are reported to interact
with other biological factors and gender-related factors. For example, majority of studies
and a large meta-analysis [204] showed higher age-specific odds ratios of AD in women
compared with men both for carriers of one ε4 allele and for carriers of two ε4 alleles.
Other studies also showed that female ε4 allele carriers had greater hippocampal atrophy,
more changes in the default mode connectivity, more cortical atrophy and worse memory
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performance compared with men [209–211]. On the other hand, gender-related factors
such as education, physical activity and occupation are also unneglectable. These all
sum up to a plausible assumption that gender is also likely to be a risk factor, with
more complicated interactions with other risk factors so that the effect might not be as
obvious as a single direction. Therefore, more validation is needed in terms of gender
effect on AD, and we were keen to include this factor in the validation process as well.
Despite the associations between the three covariates with the onset of the disease,
none of the previous studies so far included both these covariates and the biomolecu-
lar expression profiling together as prediction/diagnosis model input. In this study, we
evaluated the impact of covariates by parameterising them instead of eliminating their
effects in the pre-processing. Age, gender and APOE genotyping information were com-
bined to form different covariate variables groups, and their contribution to improve the
predictive performances were evaluated respectively.
In this chapter, our main aims are the followings:
1. To investigate whether the inclusion of covariate information of individuals such
as age, gender and APOE genotyping information will enhance the performance
of prediction models
2. To apply feature selection methods to try to discover informative RNA that are
AD related, and build a prediction model based on selected RNA
4. To investigate the biological linkage between selected RNA and AD
3.3 Materials and Methods
In this study, our main objective is to investigate and find out informative RNA biomarkers
related to AD. In addition, covariates impact to the performance of prediction models
are also investigated. Due to the limit of covariate data availability, we only included
three covariates in this study: age, gender, APOE genotyping.
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All simulations and analyses were carried out with R (R Development Core Team),
using packages varselRF [185] for random forest backward elimination, e1071 [212] for
SVM.
Figure 3.1: Work flow of study. The entire study contains covariate impact investigation,
best feature set search, classifier modelling and evaluation, functional annotation and
SNP enrichment investigation.
The work flow of the entire study was demonstrated in Figure 3.1.
3.3.1 Dataset overview
We tried to select the dataset that fit the purpose of our study. The dataset should
match all the following requirements
 It is RNA expression profile extracted from human brain
 There are both AD and healthy control samples
 Apart from age and gender, APOE genotyping information should also be provided
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Sample count 187 health control, 176 LOAD samples
Age range 65-102
Gender 190male, 173 female
With APOE genotyping information Yes
 Sample size should be as large as possible
With the application of the above requirements as dataset filters, we selected an
RNA transcript expression profile for a total of 363 subjects summarized in the GEO
(http://www.ncbi.nlm.nih.gov/geo/) series with accession number of GSE15222.
This is the only dataset that matches all the requirements. The data set included
187 health control samples and 176 LOAD samples, with age (ranging from 65 to 102),
gender (190 male and 173 female samples), and APOE genotyping information (category
in detail: ε2/ε2, ε2/ε3, ε3/ε3, ε2/ε4, ε3/ε4, ε4/ε4) available (see Table 3.1).
A quick check about the distribution of samples between different conditions was
also conducted, the result of which is shown in Table 3.2 and Figure 3.2
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Figure 3.2: Sample age distribution across GSE15222 between AD and control. The
horizontal axis indicates a sequence of samples sorted by age in a descending order. Red
marks AD samples and blue marks healthy control samples.
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We also employ PCA to identify the principle components and review if there are
any outstanding features that represent a large portion of the data variance. The result
is shown in Figure 3.3
Figure 3.3: PCA analysis result. Top two PCs are shown and they account for below
40% of variation of data together.
The result of PCA indicates that to accounts for over 80% variance of the entire
data, at least the top 22 components will need to be included. Therefore, there is no
prominent compoenents (and thus feature) that can explain a significant portion of the
data variance.
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Table 3.3: Odd ratios for six allele combinations [204]







3.3.2 Data collection and processing
We downloaded normalized data directly from Myers’ lab (http://labs.med.miami.
edu/myers/LFuN/LFuN.html), which includes 8650 genes were presented after the rank
invariant normalized data was filtered by detection score and number of missing values
[213]. This dataset has missing values because any intensity where the Illumina detection
score (The detection score is a probability of expression beyond negative controls for each
gene, calculated based on a normal distribution modelled using signals from 27 negative
control probes) was less than 0.99 was coded as null, we applied k-nearest neighbour
imputation (see section 2.3.2.2) with the following parameter settings (k = 10, rowmax
= 0.5, colmax = 0.8, maxp = 1500, rng.seed=362436069) to treat missing values. The
expression data were then log 10 transformed. The data collection and processing were
carried out with R [214].
Covariate quantification The value of covariate gender were set to 0 and 1 rep-
resenting male and female, whereas the APOE genotype consisting of six categories
(ε2/ε2, ε2/ε3, ε3/ε3, ε2/ε4, ε3/ε4, ε4/ε4) were assigned with their respective odd ra-
tios (OR) [204] (see Table 3.3).
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3.3.3 Model catalog
The investigation covers covariate impact studies, performance assessment of proposed
model consisting shortlisted RNA transcripts and the addition of covariates to those
models. Besides, some benchmark models needs to be built. Therefore, the concept
of a ”random” model is developed, referring to models in which the features (including
RNA probes in the microarray experiment and covariates) are selected randomly, instead
of having a scheduled algorithm or plan behind. Finally, 24 models are built with each
having different experiment contexts and different features selected for the model training
and testing, which are listed as follows:
 7 models with only covariates (age, gender, APOE, age+gender, age+APOE,
gender+APOE, age+gender+APOE)
 8 models, all containing proposed informative RNA transcript set (P-RNA-S) which
is selected programatically by feature selection algoirthm, and differnt combination
of covariates (P-RNA-S, P-RNA-S+age, P-RNA-S+gender, P-RNA-S+APOE, P-
RNA-S+age+gender, P-RNA-S+age+APOE, P-RNA-S+gender+APOE, P-RNA-
S+age+gender+APOE)
 8 models, all containing randomly selected RNA transcript set (R-RNA-S), and dif-
fernt combination of covariates (R-RNA-S, R-RNA-S+age, R-RNA-S+gender, R-
RNA-S+APOE, R-RNA-S+age+gender, R-RNA-S+age+APOE, R-RNA-S+gender+APOE,
R-RNA-S+age+gender+APOE)
 1 model trained in the validation from blood samples
3.3.4 RNA selection methods




In contrary to Random Forest based selection, this method selects RNAs with a stochas-
tic approach. Thus, the underlying idea of this method cannot be interpreted with
conceivable logic or path.
3.3.4.2 Random Forest based selection
A feature selection method - Random Forest backward elimination (RFBE) [185] was
conducted in the training set of each fold to select the best genes (mtryFactor=1,
ntree=20, ntreeIterat=1000, vars.drop.frac=0.2).
Random forest backward elimination In this study, we used a random forests
backward elimination method (RFBE) [185] to select significant genes which show strong
relevance to the disease. This method employs the rank of variable importance of the
tree with least out-of-bag (OOB) error among the forest to eliminate least important
features in each iteration. Eventually the smallest feature subset upon which the tree is
built with its error in a tolerable range is selected (see Algorithm 1).
input the full data matrix with all features present;
while remaining feature size is larger than preset threshold (eg. 25) do
build a forest with remaining features;
rank feature importance with OBB errors from each tree;
select top features (eg. top 20%);
drop unselected features;
end
Algorithm 1: Random forest backward elimination feature selection method
The foregoing workflow was repeated 1000 times to get an abundant group of poten-
tial feature sets, among which the best one will be used to train a prediction model. To
unbiasedly assess the classifying performance of these feature sets, we trained a classifier
with each of them by SVM model and assessed their training and testing accuracies. A
performance index (PI) of this gene subset was then calculated as a weighted sum of its









where ntraining and ntesting are the input sample size of training and testing, N is sample
size of the entire dataset, Atraining and Atesting are the training and testing accuracies.
We then selected the transcript subset with highest performance index in the 1000 trials.
3.3.5 Model building and assessment
Once the a set of RNA set is shortlisted, cross validations are conducted and iterated to
get assessment result for different models. These results are then used to intepret the
questions we have suggested earlier in this chapter. To summarize:
 How are the proposed RNA features performing in classifying AD and control
samples, comparing to other models
 Are the covariates contributing to the classifying performance? If so, which co-
variates are the most effective in improving the model performances?
3.3.5.1 The cross-validation cycle
The build-and-test cycle was conducted with every abovementioned model a) split sam-
ples into training and testing sets, b) filter data with selected features, c) a model was
learned from the training set, d) assess the above generated model with the testing set.
Sample splitting Because we applied a five-fold cross validation (CV) approach (see
definition in section 2.4.5.1), so for each of the five folds, four subsets are used for
training and the remaining subset for testing.
Filter data to lower dimension As previously discussed in Section 3.3.3, we have 24
models in total to be trained and tested. For each model, there is different composition
of selected features which are employed in the model training process. For instance,
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the feature of model ”proposed+age+apoe” consists of age, APOE genotyping, and
an RNA set selected by a pre-designed algorithm discussed in Section 3.3.4.2, whereas
that of model ”random+gender” consists of gender and an RNA set selected randomly
(discussed in Section 3.3.4.1).
Model training All the models are trained by Support Vector Machine (SVM), with
a default gamma (=1/featurenumber) and a cost equal to 0.1.
Model assessment To assess the performances of all the models, metrics derived
from the confusion matrix are calculated in each execution of the procedure, and an
average and standard deviation were calculated. These include accuracy, SN, SP, PPV,
NPV, AUC.
The procedure of the above descibed five-fold cross validation is repeated 200 times
for each model to make more generalised conclusions.
3.3.5.2 Hypothesis testings
Part of the assessment in this study is about examing hypothesis of existence of im-
provement between models. Suppose we are comparing the performance between model
A and model B and the latter is in favour in our assumption. The following hypothesis
is definend
 H0 There is no accuracy/AUC improvement in training or testing
 Ha The accuracy/AUC of model B is greater than that of model A
We then examined the hypothesis by one-way two-sample t-test to get the respective
p-values.
3.3.6 IGAP (International Genomics of Alzheimer’s Project)
International Genomics of Alzheimeŕs Project (IGAP) [85] is a large two-stage study
based upon genome-wide association studies (GWAS) on individuals of European ances-
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try (http://web.pasteur-lille.fr/en/recherche/u744/igap/igap_download.php).
In stage 1, IGAP used genotyped and imputed data on 7,055,881 single nucleotide poly-
morphisms (SNPs) to meta-analyse four previously-published GWAS datasets consisting
of 17,008 Alzheimer’s disease cases and 37,154 controls (The European Alzheimer’s dis-
ease Initiative – EADI the Alzheimer Disease Genetics Consortium – ADGC The Cohorts
for Heart and Aging Research in Genomic Epidemiology consortium – CHARGE The
Genetic and Environmental Risk in AD consortium – GERAD). In stage 2, 11,632 SNPs
were genotyped and tested for association in an independent set of 8,572 Alzheimer’s
disease cases and 11,312 controls. Finally, a meta-analysis was performed combining
results from stages 1 & 2.
We hypothesize that SNPs are more enriched in the regions of proposed genes than
that of those selected randomly. Hence, we conducted a potential SNP enrichment
investigation in order to examine the hypothesis that SNPs around these genes have
more p-values in AD-associated genetic variants than SNPs around genes selected by
chance. We employed the two-stage GWAS meta-analysis result (Lambert, Jean-Charles,
et al) to test the hypothesis. We first extracted IGAP SNPs in the 200kbp and 500kbp
up/down stream of the proposed genes. For each gene, a search for SNP records in
the data source (200kbp/500kbp up/down) was carried out. After the candidate GWAS
SNP group for the region of selected genes were found and congregated, we corrected
the association p-values by the number of SNPs extracted or by the number of SNPs
not in linkage disequilibrium (LD, r2 < 0.5) calculated by SNAP online tool (http:
//www.broadinstitute.org/mpg/snap/). SNPs with corrected p-value < 0.05 and
have predicted function will be the potential candidate SNPs. Afterwards, we test the
above-mentioned hypothesis under the following procedure:
a) Randomly select equal number of genes from the genome, get their SNPs in region
and calculate test statistics ts = −log10(p− values);
b) Get the median and average of ts;
c) Repeat step a) and b) 1000 times to get the distribution of median and average
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of ts (imputated ts);
d) Calculate the average and median of ts of SNPs from proposed genes (observed
ts);
e) Get empirical p-value by counting the number of cases when imputated ts is larger
than observed ts;
In the final stage of this study, function annotation for the selected subset of genes
was conducted. Because the 26 genes identified are not suitable for pathway enrichment
analysis, DAVID (http://david.abcc.ncifcrf.gov/) was used for annotation and to learn
the possible biological functions or pathways encrypted in these genes.
3.3.7 Validation in blood
The proposed RNA set was also validated in a blood dataset with GEO series number
GSE85426. This dataset was refined by keywords ”Alzheimer”, ”blood” and ”RNA” in
ArrayExpress (https://www.ebi.ac.uk/arrayexpress/). The RNA was extracted
from peripheral blood cells, reverse-transcribed and labelled, then analysed for gene
expression using GeneSpring GX12 (Agilent Technologies, USA). The dataset included
90 non-demented control and 90 AD samples, with age (ranging from 64 to 94), gender
(92 male and 88 female) information provided. Since APOE information is not provided
in this dataset, we chose not to include any covariate information in the validation.
The proposed RNA set, all identified with official gene symbol, were first mapped
to Agilent probe IDs, and then the workflow described in section 3.3.5 was followed to
obtain assessment result for the blood dataset.
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3.4 Result
3.4.1 Classifier modelling and evaluating
We searched for the best feature set in the data set for classification. We discovered
an SVM model parameterized with 26 RNAs which shows promising accuracies for both
training and testing. In table 3.5, proposed model is trained with the 26 selected RNA.
Table 3.5 shows that on average, the proposed model outperforms random models
(mean training/testing accuracy of proposed model: 0.888/0.859, of random model:
0.813/0.765, p-value=0 for both training and testing) without the addition of covari-
ates. The proposed model with covaraites presents excellent classifying ability, with
average training/testing accuracy of 0.914/0.876, SN 0.884/0.842, SP 0.943/0.907,
PPV 0.936/0.898, NPV 0.897/0.862, AUC 0.961/0.942 for the entire dataset.
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Table 3.4: Selected genes used in training the prediction model
Gene Name Importance Fold Change P Value
ZNF264 4.94E-03 2.053 7.90E-19
ZDHHC23 2.32E-03 0.622 3.70E-28
SPOP 1.94E-03 1.405 3.20E-20
NRCAM 1.68E-03 0.727 5.00E-23
DSTYK 1.58E-03 1.382 2.20E-25
ABCC12 1.39E-03 0.645 1.80E-22
SRGAP1 1.34E-03 2.057 4.90E-19
NEUROD6 1.20E-03 0.485 2.20E-21
CHMP4B 1.18E-03 0.796 3.00E-23
C19ORF30 1.07E-03 0.597 2.30E-11
MRPL24 8.26E-04 0.527 8.00E-21
VEZF1 7.87E-04 1.629 2.40E-17
LETMD1 7.64E-04 0.817 8.00E-22
DDX23 6.64E-04 1.279 4.90E-19
PPEF1 6.34E-04 0.523 2.80E-28
KCTD13 6.25E-04 0.76 7.10E-16
ZHX3 6.02E-04 1.406 6.90E-21
FLJ37464 4.93E-04 0.744 9.80E-15
SGIP1 3.74E-04 0.645 1.80E-22
CASP8AP2 1.14E-04 1.98 1.10E-10
TCF3 1.06E-04 1.47 1.20E-20
LANCL2 0.00E+00 0.696 2.20E-26
KCNF1 0.00E+00 0.636 1.10E-20
RAB29 0.00E+00 1.775 5.50E-16
TUBB2A 0.00E+00 0.63 1.40E-18
STX1A 0.00E+00 0.739 5.10E-16
Fold change for each gene is calculated by the quotient between the means of expression values
from both conditions (AD and health control, mean of AD as numerator) for each gene. (see
Method). P-value is calculated as the p-value of the two-tail two-sample t-test for expression
values from both conditions for each gene.
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Figure 3.4: Heat map of expression level in data set for the 26 selected genes. The
yellow bar on top of the heatmap represents AD sample block and blue bar represents
normal health control sample block. Expression values are normalised by row.
3.4.2 Covariate impact investigation
The result of covariate impact investigation is shown in Table 3.5. Among the three
covariates (age, gender, APOE), APOE has the best performance as a standalone clas-
sifier, with nearly 75% of both training and testing accuracy on average. Statistics also
suggest that adding only age as a factor in the prediction model would improve the train-
ing accuracy of proposed model (p-value = 1.73× 10−5), but not the testing accuracy
(p-value= 1). A same difference in performance was observed in random model (p-value
= 2.31× 10−5 for training and 2.09× 10−1 for testing). In terms of adding gender as
an input variable in the model, there is a slight increase in training accuracy for both
proposed and random model (p-value = 7.77× 10−2 for random and 2.61× 10−13 for
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proposed), but the drop regarding testing accuracy demonstrates that the improvement
hardly exists (p-value=8.77× 10−1 for random and 1.65× 10−1 for proposed model).
It shows that gender as a factor is very unlikely to be relevant to the onset of AD and
therefore lack of diagnostic value. The most remarkable enhancement is generated by
including APOE as a factor in the classifier modelling process, with convincing support
from statistics of both random and proposed model (random: training=0, testing=0;
proposed: training=0, testing=0). It implies APOE is a significant risky factor for the
onset of AD with distinctive classifying ability.








TN 0.558+/-0.017 0.660+/-0.047 0.462+/-0.024
TS 0.558+/-0.048 0.660+/-0.080 0.462+/-0.088
apoe
TN 0.741+/-0.012 0.687+/-0.018 0.791+/-0.015
TS 0.741+/-0.047 0.687+/-0.071 0.791+/-0.061
gender
TN 0.524+/-0.011 0.252+/-0.256 0.781+/-0.222
TS 0.498+/-0.028 0.225+/-0.232 0.756+/-0.251
age +
gender
TN 0.557+/-0.016 0.640+/-0.050 0.480+/-0.037
TS 0.542+/-0.053 0.622+/-0.094 0.467+/-0.085
age +
apoe
TN 0.741+/-0.012 0.687+/-0.018 0.791+/-0.015
TS 0.741+/-0.047 0.687+/-0.071 0.791+/-0.061
apoe +
gender
TN 0.741+/-0.012 0.687+/-0.018 0.791+/-0.015




TN 0.741+/-0.012 0.688+/-0.018 0.791+/-0.015
TS 0.741+/-0.047 0.687+/-0.071 0.791+/-0.061
proposed TN 0.888+/-0.010 0.863+/-0.016 0.912+/-0.012
Continued on next page
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TS 0.859+/-0.037 0.826+/-0.060 0.891+/-0.049
proposed +
age
TN 0.889+/-0.010 0.867+/-0.016 0.910+/-0.013
TS 0.856+/-0.037 0.827+/-0.062 0.884+/-0.051
proposed +
gender
TN 0.890+/-0.010 0.863+/-0.016 0.915+/-0.012
TS 0.860+/-0.036 0.824+/-0.060 0.893+/-0.049
proposed +
apoe
TN 0.908+/-0.009 0.882+/-0.016 0.933+/-0.011
TS 0.879+/-0.036 0.844+/-0.060 0.911+/-0.046
proposed TN 0.914+/-0.010 0.884+/-0.017 0.943+/-0.013




TN 0.910+/-0.009 0.886+/-0.016 0.933+/-0.011




TN 0.892+/-0.010 0.871+/-0.016 0.912+/-0.013




TN 0.915+/-0.010 0.885+/-0.017 0.943+/-0.014
TS 0.874+/-0.036 0.842+/-0.060 0.905+/-0.049
random
TN 0.813+/-0.025 0.783+/-0.035 0.840+/-0.032
TS 0.765+/-0.051 0.736+/-0.079 0.793+/-0.071
random +
age
TN 0.815+/-0.024 0.792+/-0.034 0.836+/-0.033
TS 0.766+/-0.051 0.744+/-0.078 0.787+/-0.073
random +
gender
TN 0.813+/-0.025 0.784+/-0.035 0.841+/-0.032
TS 0.764+/-0.051 0.734+/-0.079 0.792+/-0.071
random TN 0.848+/-0.022 0.824+/-0.028 0.870+/-0.029




TN 0.853+/-0.021 0.834+/-0.027 0.872+/-0.029
TS 0.804+/-0.046 0.787+/-0.070 0.821+/-0.068
Continued on next page
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TN 0.848+/-0.022 0.824+/-0.028 0.871+/-0.029




TN 0.816+/-0.024 0.794+/-0.033 0.836+/-0.033




TN 0.855+/-0.021 0.834+/-0.027 0.874+/-0.028
TS 0.804+/-0.046 0.786+/-0.071 0.822+/-0.068
blood
TN 0.679+/-0.018 0.656+/-0.051 0.701+/-0.039
TS 0.615+/-0.075 0.580+/-0.120 0.650+/-0.104
Abbreviations: TN - training TS - testing








TN 0.535+/-0.014 0.592+/-0.026 0.579+/-0.015
TS 0.537+/-0.043 0.592+/-0.063 0.579+/-0.060
apoe
TN 0.756+/-0.014 0.729+/-0.012 0.766+/-0.012
TS 0.759+/-0.058 0.731+/-0.048 0.766+/-0.047
gender
TN NaN+/-NA 0.531+/-0.017 0.520+/-0.016
TS NaN+/-NA 0.506+/-0.024 0.497+/-0.056
age +
gender
TN 0.536+/-0.014 0.587+/-0.023 0.581+/-0.015
TS 0.523+/-0.049 0.570+/-0.065 0.565+/-0.061
age + TN 0.756+/-0.014 0.729+/-0.012 0.799+/-0.012
Continued on next page
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apoe TS 0.759+/-0.058 0.731+/-0.048 0.799+/-0.048
apoe +
gender
TN 0.756+/-0.014 0.729+/-0.012 0.773+/-0.014




TN 0.756+/-0.014 0.729+/-0.012 0.800+/-0.012
TS 0.759+/-0.058 0.731+/-0.048 0.797+/-0.048
proposed
TN 0.903+/-0.012 0.876+/-0.013 0.934+/-0.007
TS 0.879+/-0.048 0.847+/-0.045 0.911+/-0.032
proposed +
age
TN 0.901+/-0.013 0.880+/-0.013 0.939+/-0.007
TS 0.873+/-0.049 0.847+/-0.047 0.918+/-0.031
proposed +
gender
TN 0.906+/-0.012 0.877+/-0.013 0.935+/-0.007
TS 0.882+/-0.048 0.846+/-0.045 0.911+/-0.032
proposed +
apoe
TN 0.926+/-0.011 0.894+/-0.013 0.954+/-0.006
TS 0.902+/-0.046 0.864+/-0.046 0.932+/-0.027
proposed + TN 0.936+/-0.013 0.897+/-0.014 0.961+/-0.005




TN 0.925+/-0.011 0.897+/-0.013 0.955+/-0.006




TN 0.903+/-0.013 0.883+/-0.013 0.941+/-0.007




TN 0.937+/-0.014 0.897+/-0.014 0.963+/-0.005
TS 0.895+/-0.048 0.861+/-0.046 0.944+/-0.025
random TN 0.823+/-0.031 0.805+/-0.027 0.879+/-0.022
TS 0.773+/-0.063 0.764+/-0.056 0.837+/-0.050
random +
age
TN 0.820+/-0.031 0.811+/-0.026 0.881+/-0.022
TS 0.770+/-0.063 0.769+/-0.056 0.838+/-0.049
Continued on next page
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TN 0.824+/-0.031 0.806+/-0.027 0.879+/-0.022
TS 0.772+/-0.063 0.763+/-0.056 0.836+/-0.050
random +
apoe
TN 0.857+/-0.028 0.841+/-0.023 0.917+/-0.015




TN 0.860+/-0.028 0.848+/-0.022 0.922+/-0.014




TN 0.858+/-0.029 0.841+/-0.023 0.917+/-0.015




TN 0.821+/-0.031 0.812+/-0.026 0.882+/-0.022




TN 0.863+/-0.028 0.849+/-0.022 0.923+/-0.014
TS 0.810+/-0.060 0.806+/-0.053 0.887+/-0.039
blood
TN 0.688+/-0.020 0.672+/-0.026 0.765+/-0.013
TS 0.626+/-0.083 0.612+/-0.077 0.700+/-0.077
Abbreviations: TN - training TS - testing
3.4.3 Validation in blood
The validation result in blood samples shows no significant classification performance,
with an average training/testing accuracy 0.679/0.615 (See table 3.5).
3.4.4 Function annotation and pathway analysis for selected genes
DAVID for the 26 genes revealed a set of significant molecular biological functions and
pathway information. The presence of KCTD13, KCNF1 and SPOP cast strong support
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for the involvement of BTB/POZ (Broad-Complex, Tramtrack and Bric a brac, also
known as poxvirus and zinc finger) domain (DAVID calculated p-value=3.0× 10−2). The
nucleus activity function (DAVID calculated p-value=3.9× 10−2) is also in list because
of the presence of DDX23, LANCL2, CASP3AP2, NEUROD6, KCTD13, SPOP, TCF3,
VEZF1, ZNF264 and ZHX3.
Figure 3.5: Confidence view of the protein-protein interaction network inferred from 26
genes. Stronger associations are represented by thicker lines. Different colours implicate
different clustering which was calculated by a 10-means clustering method.
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Table 3.7: Protein’s annotation for clusters in the PPI network. This table corresponds
to Figure 3.5 that displays only COG/KOG ID. The bolden genes are among the selected
26 genes.
COGs/KOGs Gene Symbol Protein Group Description Cluter
COG1100 ARL6, DIRAS3,
etc.





ABC-type multidrug transport system,




Serine/threonine protein kinase 1
COG5048 ZNF511 FOG- Zn-finger 1
COG0513 DDX1, DDX50,
etc.
Superfamily II DNA and RNA helicases 1
COG0639 PPEF1, PPEF2,
etc.
Diadenosine tetraphosphatase and re-









KOG2408 PXDN, LPO, etc. Peroxidase/oxygenase 2
KOG0192 MLKL, DSTYK,
etc.





Cdc42-interacting protein CIP4 2
KOG1516 CEL, NLGN1,
etc.
Carboxylesterase and related proteins 3
Continued on next page
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Table 3.7 – Continued from previous page
COGs/KOGs Gene Symbol Protein Group Description Cluter
KOG3513 NRCAM,
CNTN1, etc.
Neural cell adhesion molecule L1 3
KOG3545 OLFML2A,
LPHN1, etc.




















Transcriptional repressors of the











Transcription factor TCF-4 4
KOG0810 STX1B, STX3,
etc.
SNARE protein Syntaxin 1 and related
proteins
5





t-SNARE complex subunit, syntaxin 5
Continued on next page
99
Table 3.7 – Continued from previous page
COGs/KOGs Gene Symbol Protein Group Description Cluter
KOG3713 KCNF1,
KCNS1, etc.
Voltage-gated K+ channel KCNB/KCNC 5
COG0227 MSRA Ribosomal protein L28 6
COG0198 MRPL24,
RPL26L1, RPL26
Ribosomal protein L24 6
3.4.5 SNP enrichment investigation
The result of SNP enrichment investigation managed to support the hypothesis that
SNPs around these genes have more p-values in AD-associated genetic variants than
SNPs around genes selected by chance. It suggests that the regions of the selected 26
genes prone to suffer more phenotyping mutations than that of normal genes. Figure
3.6 demonstrates the position where the observed average and median ts (marked with
blue lines) locate among the distribution of average and median ts imputed by chance.
The result reveals that the observed average ts are large enough(p-value=3.6× 10−2,
3× 10−2, 2.2× 10−2, 3.9× 10−2 for 200k up/down search in stage 1 & 2 combined data,
500k up/down search in stage 1 & 2 combined data, 200k up/down search in stage 1
data, and 500k up/down search for stage 1 data only, corresponding to subgraph a− d
in Figure 3.6) to support the existence of the hypothesis. Comparatively, the statistics
of median ts support the hypothesis as well (p-value=4.2× 10−2, 3.8× 10−2, 7× 10−3,
2.4× 10−2 for 200k up/down search in stage 1 & 2 combined data and 500k up/down
search in stage 1 & 2 combined data, 200k up/down search in stage 1 data, and 500k









Figure 3.6: Average and median imputed test statistics (ts = −log10pvalue) distribution
and observed test statistics from 26 selected transcripts. Vertical coordinate represents
the occurrences of imputated average or median ts, horizontal coordinates represents av-
erage or median ts. The value of observed ts is marked with blue line. (a)Average, stage
1&2, 200kbp (b)Average, stage 1&2, 500kbp (c)Average, stage 1, 200kbp (d)Average,
stage 1, 500kbp (e)Median, stage 1&2, 200kbp (f) Median, stage 1&2, 500kbp (g)
Median, stage 1, 200kbp, (h)Median, stage 1, 500kbp
3.5 Discussion
We investigated the effect which three covariates (age, gender, APOE genotype) have
made on the prediction model. We quantified the six categories of APOE genotype
with their reported odd ratios. The idea orginates from the findings in previous studies
[215–220] which suggest that ε4 presents a more than threefold increase in LOAD risk
when compared to the common ε3, while carries of ε2 are exposed to lower risk of LOAD
compared to non-carriers.
It is the first time that covariates such as age, gender and APOE genotype are to
be parameterized in the process of modelling. We obtained better result when age and
APOE genotype were included in our model. The enhancement the model acquired by
including age as variable reveals the fact that there are still undiscovered biomolecule
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markers which can fully express the age difference between individuals so as to make bet-
ter predictions. Meanwhile, it is a novel attempt to employ genotyping information to
achieve classification of disease status. APOE genotype information illustrated promis-
ing classifying ability. Thus further studies should be focusing not only on expression
intensities but also exploiting the potential of genotyping information in terms of disease
prediction.
We employed the method of RFBE to select significant genes before training the
classifier. 26 out of 8650 genes were collected, with which we trained a prediction model
with as high as 85% testing accuracy. It was a successful application of RFBE in terms
of feature size and accuracy. Nevertheless, there are defects for the method itself. One
main defect is that the variable importances are fixed. Variable importances are the
measurement that determines what features are to be kept or eliminated. Despite their
essence, they are not recalculated in each loop when some features are eliminated. An-
other defect of the method is the ignorance of link between features. According to the
philosophy of Random forest, when calculating the variable importance, the interactive
effect between variables will be ignored and variables are regarded independent, which is
obviously against the actual situation. The interaction and co-effects of genes are defi-
nitely elements to be paid attention to in AD development. Some studies had dovated
their attention this issue by various approaches. Tan et al [221] intergrated DEG anal-
ysis with Graqm-Schmidt process to identify genes that are both significant and highly
informative for predicting tumour survival. A kernel-based multivariate feature selection
method was proposed [222] to discover nonlinear correlations among features as well as
between feature and target. Recently, a new hybrid method using Independent compo-
nent analysis (ICA) and Artificial Bee Colony (ABC) was reported to have the ability
to generate small subsets of genes and improve classification accuracy of classifier built
upon Naive Bayes (NB) [223]. These above-mentioned methods all take into account
the inter-correlation of genes when reducing the dimension, but the application of these
models on dementia still need further investigations.
BTB/POZ domain is suggested to be a function cluster in the 26 genes with high
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confidence, among which a gene member KCTD13 was reported to be the major driver
for the neurodevelopmental phenotypes associated with the 16p11.2 copy number variant
(CNV) [224]. It was also found to locate in a chromosomal rearrangement hotspot and
dosage-sensitive loci, in which a rare duplication on chromosome 16p11.2 was identified
in patients with psychosis in AD [225]. Another gene detected in the BTB/POZ domain,
KCTF1, was listed in the genes whose expression is remarkably altered during senescence
in both human and mouse cortex [226]. However, SPOP has not been reported to be
associated with the pathology of any neurodegenerative diseases.
Apart from the likely appearance of BTB/POZ domain, functional annotation from
DAVID also suggested that four genes encoding zinc finger proteins, vascular endothelial
zinc finger 1 (VEZF1), zinc fingers and homeoboxes 3 (ZHX3), zinc finger protein 264
(ZNF264) and zinc finger DHHC-type containing 23 (ZDHHC23), were found among
26 genes.
We studied the protein-protein interaction network encoded by the 26 genes with
STRING (https://tring-db.org). 54 proteins appeared to match the input of 26 genes
in STRING database. The protein network is not enriched in interactions and 223
interactions were observed. The network was displayed with highest confidence (0.900)
and zero interactor shown (See Figure 3.5.). There are basically 7 clusters found in
the network (marked with different colors in Figure 3.5., nodes/proteins in every cluster
annotated in Table 3.7.). In cluster 1 (nodes marked with pink in Figure 3.5), the
polymorphisms of a homolog B of GTPase SAR1 (COG1100) was found recently to be
associated with reduced risk of AD among APOE ε4 non-carriers [227]. FOG (Friend of
GATA) is a zinc finger protein family with FOG-1 (friend of GATA-1) reported to form
a complex during normal function with Retinoblastoma-associated proteins (RbAp48),
whose deficiency or loss of function is related with AD [228].
Proteins of tubulin family appear in cluster 2 (nodes marked brown in Figure 3.5).
The role of tubulin acetylation in AD has been investigated by several studies and it has
been suggested that changes in the levels of this post-translational modification (PTM)
are involved in the pathogenesis of AD [229–233]. However, whether this PTM has
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detrimental or beneficial effects has not yet been clarified. Our study found out that
tubulin β-2A encoder gene TUBB2A has been down-regulated in AD patients (see Figure
3.4), which supports the notion of a beneficial effect of tubulin β-2A to the pathology
of AD. In addition, because the aggregation and hyper-phosphorylation of tau protein
in degenerated neurons is a symbol of neurodegenerative disorder and tau protein is
normally associated with microtubules (MTs), whether pathological changes of tubulin
PTMs have disrupted the interactions of tau protein with MTs is a question worth to
be addressed.
Of note, the basic helix-loop-helix (bHLH) family of transcription factors which has
been shown to control critical aspects of development in many tissues emerge in cluster 4
(nodes marked blue in Figure 3.5). The reactivation of heart and neural crest derivatives
expressed transcript 2 (HAND2) is reported to cause cardiac dilation and required for
heart disease [234]. Transcription factors of NeuroD family is reported to be involved
in glucotoxicity-induced beta cell dysfunction which is a critical factor in the develop-
ment of type 2 diabetes [235]. NeuroD is also reported to increase the differentiation
efficiency of mouse embryonic stem cells into insulin-producing cells [236], regulate neu-
ronal migration [235] and regulate cell fate and neurite stratification in the developing
retina [237]. The variety of tissue and functions with which these transcription factors
are associated implies the possibility of links between diseases, for example, diabetes with
AD, or heart failure with AD. More cross-disease investigations are needed to unveil the
potential pathological relations.
Cluster 5 (nodes marked yellow in Figure 3.5) is a congregation of N-ethylmaleimide-
sensitive factor attachment protein receptor (SNARE) proteins which play crucial roles
in synaptic vesicle trafficking and release, influencing the transportation of neurotrans-
mitter. Syntaxin 1 (KOG0810 in Figure 3.5) is among a set of core neuronal SNARE
molecules that directly mediate fusion of synaptic vesicles with the presynaptic mem-
brane [238]. More evidences are revealing the connection between SNARE proteins and
AD pathology. PICALM is a gene locus discovered by GWAS with affirming associ-
ation with LOAD, appears to take part in directing the trafficking of SNARE protein
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VAMP2 [207]. The t-SNARE complex deficit present in Lewy vody variant (LBV) is re-
ported to be associated with the presence of LB-related pathology [239]. These findings
cast light on the discovering new biomarker of AD in SNARE proteins.
In the process of testing the hypothesis that both training and testing performance of
the model obtain improvements after including a combination of covariates as training
and testing input, the p-values are calculated by a two-sample t-test. Yet, it is not
a strict test in this case as we assumed without any further testing that the standard
variances between the two samples were equalled.
The dataset GSE15222 itself cast some limitation on the study. Firstly, we only
compared the difference between AD and control samples, however mild cognative im-
pairment (MCI) was ignored. Secondly, some other quantitative measurement such as
braak stage or amyloid level were not availble. Thirdly, no information about cell type
was given in the meta information, so the possibility that all the observed difference was
contributed from the variety of cell type cannot be eliminated. Lastly, the study only
focus on biomarker in brain but the discovery of biomarkers in blood is the ultimate
goal. Although it is pleasant to identify biomarkers in brain and validate in blood, it is
also important to look into blood samples for discovery. As the validation of proposed
biomarkers in blood suggests, changes in brain can be different from that in blood. Al-
though that proves what happens in blood cannot mirror what is happening in the brain,
they can still make a good biomarker.
Another limitation of the study is the lack of validation of the quantification method
for APOE genotyping information. The numeric order of allele combinations assigned is
solely determined by the previous conclusion drawn for single allele (ε2, ε3 or ε4). The
effect of allele combinations is however not studied. In our study, more weight on AD
risk was delegated to ε4. This partly contribute to the decision to assign greater numeric
value for ε2/ε4 compared to ε3/ε3. But it is an assumption that has not been verified.
Therefore, more validation on the AD risk of different allele combinations is needed.
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3.6 Conclusion
Covariate addition of age, gender and APOE genotype are able to improve the perfor-
mance of AD classifier. With a random forest based feature selection method, a small
subset of genes are discovered to be highly informative and found to be enriched in SNP.
The SVM model trained by selected genes has remarkable performance in distinguish-
ing between case and control in the dataset. It is of high research value to continue
validating the selected features in more AD datasets.
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Chapter 4
Discovery of Novel Biomarkers for
Alzheimer’s Disease from Blood
4.1 Abstract
This chapter catalogues and discusses the investigation of blood-based AD biomarkers.
It is based on the author’s publication [240]. Following the construction of a knowledge
feature pool under comprehensive knowledge collections, two novel SVM-based feature
selection methods were proposed to select significant serum proteins with or without the
constraint of feature pool, and a panel of only two and three proteins were identified to
have good diagnostic ability. A surprising and novel statistical pattern was recognised.
4.2 Background
Although a number of genetic and cerebrospinal fluid (CSF) biomarkers for AD have been
discovered in recent decades, few have been reported from the blood that have relevance
to the disease [241]. There is thus a lack of robust and reliable blood-based biomarkers
for AD diagnosis [34, 242]. With the expanding capacity of protein arrays and mass
spectrometry-based detections, recent studies of blood profile biomarkers have attempted
to address this problem. Ray and colleagues [56] were the first to use a profiling approach,
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and they identified an 18-plasma protein profile that classified AD patients from healthy
control subjects with high specificity. However, the result cannot be replicated. The
same group later analyzed independent samples with different bioinformatics approaches
and discovered that the majority of those 18 proteins were relevant to the levels of
Aβ or tau proteins in CSF [243]. Since these two studies, many profiling approaches
have proposed protein panels with promising diagnostic ability, but the main issue has
been reproducibility [58]. The problem of reproducibility has been addressed by Hu
and colleagues [57] and Doecke and colleagues [59] using two well-characterized and
large clinical cohorts to identify a series of inflammatory mediators associated with the
onset of AD. Doecke and colleagues [59] and O’Bryant and colleagues [60] also reported
diagnostic accuracy across cohorts (AUC=0.88, SN=0.75 and SP=0.91). In addition,
researchers in plasma proteomics have used cross-validation across various cohorts to
overcome the overfitting problem in high-dimensional studies. Molecules that have raised
great hopes among these investigators include apolipoprotein E (APOE), NT-proBNP
(N-terminal prohormone of Brain Natriuretic Peptide) and pancreatic polypeptide. It
is been suggested that because AD is a mitochondrial dysfunction and immune system
relevant disease [244, 245] focusing on genes involved in relevant pathways [246] may
help in biomarker discovery [247]. However, few previous studies have used biological
information in their modelling.
In the past decade, neurofilament light protein (NFL) is the only CSF biomarker for
which the transition from CSF to blood has been relatively uncomplicated, but for tau
and Aβbiomarkers, there is a signal also in blood, albeit with a smaller effect size than
what can be obtained using the corresponding CSF measure.
To establish reliable blood biomarkers for Aβ pathology in AD has always been
difficult. Aβ proteins can be measured in plasma yet historically its correlation with
AD and/or cerebral β-amyloidosis has been weak or even absent [248]. Plasma Aβ
concentrations have been described as potentially affected by yield in platelets and other
extra-cerebral tissues and the measurements have been complicated by matrix effects
from plasma proteins [249]. Nonetheless, recent mass spectrometric studies indicates
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that a ratio of a certain amyloid-β protein precursor (AβPP) fragment (AβPP669-
711; an Aβ peptide that extends over the BACE1 cleavage site of AβPP with 3 amino
acids), to Aβ42 or Aβ42/Aβ40 identifies individuals cerebral β-amyloidosis with excellent
sensitivity and specificity [250,251]. Pilot data suggest associations of the concentrations
of a number of plasma proteins (e.g., pancreatic polypeptide Y, IgM, chemokine ligand
13, interleukin 17, vascular cell adhesion protein 1, α2-macroglobulin, apolipoprotein A1,
and complement proteins) with amyloid burden in the brain [252–254]. However, these
data ought to be interpreted cautiously, because they are derived from multi-marker
panels and as a mechanistic understanding of the associations is currently lacking.
CSF assays for T-tau and NFL were recently developed into ultrasensitive blood
tests using Simoa technology [255]. Plasma or serum NFL concentration is associated
with CSF and most CSF findings have been reproduced in blood [256]. Recent data
suggest that serum NFL effectively signals onset of neurodegeneration in FAD [257] and
Huntington’s disease (HD) [258]. Plasma NFL concentration elevates in patients with
Charcot-Marie-Tooth disease and correlates with disease severity, showing that peripheral
nervesmay also release NFL [259].
For tau, the situation is promising but less clear. The correlation with the corre-
sponding CSF concentration is absent [54] or weak [260]. Plasma T-tau concentration
in AD is increased but the effect size is smaller than in CSF and there is no detectable
increase in the MCI [?,54]. Altogether, the published studies on plasma T-tau as an AD
biomarker so far acknowledged the feasibility of targeting on a predictive tau signal in
blood. But the lack of correlation of plasma with CSF T-tau implies that investigation
should shift to additional tau biomarkers in plasma.
In this chapter, existing biological knowledge of potential AD biomarkers is taken
into consideration to construct a knowledge feature pool for a series of feature selec-
tion methods. We first established a feature pool comprising of numerous AD related
biomarkers and then designed two novel SVM-based feature selection methods, which
we used to select several panels of biomarkers. Finally, we validated the classifying per-
formance of these panels with other serum and RNA expression cohorts. We found that
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a panel of only two or three proteins gave us good diagnostic ability.
In this chapter, our main aims are the followings:
1. To develop feature selection methods that include the consideration of feature-
feature interation within the dicision making
2. To search for proteins that have good classifying ability between healthy individuals
and AD patients, and build prediction models based on those proteins
3. To investigate the biological linkage between selected features and AD
4.3 Materials and Methods
4.3.1 Data collection and pre-processing
We searched against Gene Expression Omnibus (GEO) (http://www.ncbi.nlm.nih.
gov/geo/) for datasets with entries containing keywords ”protein” and ”blood” (search
conducted in June 2015). Three datasets were chosen among the returned datasets:
GSE29676, GSE39087 and GSE5281. GSE29676 consists of serum samples from 50
AD, 40 non-demented controls (NDC), 30 breast cancer (BC) and 29 Parkinson’s dis-
ease (PD). The data were generated by a Invitrogen ProtoArray v5.0 protein platform
including 9486 unique human protein antigens [261]. GSE39087 is also a human serum
protein microarray dataset generated by the same platform as GSE29676 and contains
36 AD cases, 57 controls, 48 Parkinson disease, 18 breast cancers, and 7 multiple scle-
roses [262]. GSE5281 is an RNA microarray dataset from brain tissues, with 87 AD
cases and 74 controls. Each sample was collected from different brain regions compris-
ing entorhinal cortex (EC), hippocampus (HIP), medial temporal gyrus MTG), posterior
cingulate (PC), superior frontal gyrus (SFG), and primary visual cortex (PVC) [263].
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Figure 4.1: Workflow of Support Vector Machine Forward Selection (SVMFS). The
selection starts with an empty aggregate of selected protein. In each iteration, one
particular protein which yields the most improvement of the LOOCV accuracy of the
model is selected. If no improvement is found in all the candidate proteins, the iteration
breaks and no more proteins are added into the model, so the current model will be the
final selection.
The normalized expression data of GSE29676 and GSE39087 were downloaded di-
rectly, then expression values smaller than 1 were set as 1 and 2-based logarithm trans-
formation was conducted. To eliminate the potential bias caused by age and gender,
the expression value was corrected using the following method. First, for each protein,
a robust linear regression (rlm function in MASS R package [264]) was applied with the
logarithm transformed expression value as the dependent variable and age and gender as
the explanatory variables. Second, the sum of the intercept and residual was employed
as the corrected expression value for that protein in each sample and used in subsequent
analyses. For GSE5281, an age-gender-bias correction was also conducted on the normal-
ized data before matching the probes with corresponding proteins. We used GSE29676
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as the discovery dataset for biomarker identification, and GSE39087 and GSE5281 as the
two validation datasets. Only AD and Control subjects were included in any subsequent
analysis.
4.3.2 Feature candidate pool
In this study, we are going to investigate whether a feature selection under the context of
existing biological knowledge will improve the resulta and yield better classifying models.
Therefore, for comparison, we have two feature pools that the features can be selected
fromL: whole-range feature pool and knowledge-based feature pool
4.3.2.1 Whole-range feature pool (WRFP)
As described in section 4.3.1, the dataset includes 9486 unique human protein antigens,
and this is dubbed throughout the study as whole-range feature pool (WRFP).
4.3.2.2 Knowledge-based feature pool (KBFP)
In contrast with WRFP which includes all the available features within the dataset, a
knowledge-based feature pool is a protein subset of WRFP with more biological
meanings realting to AD. To collect all the AD-related genes or protein, we compre-
hensively searched the literature and online databases to construct a knowledge fea-
ture pool for the AD-related biomarkers. The text mining for AD biomarkers was con-
ducted by searching publications on PubMed in December 2014 (http://www.ncbi.
nlm.nih.gov/pubmed), producing a set of 611 genes. 172 genes were discovered from
(a) large genome wide association study (GWAS) papers [83–85] and their first neigh-
bors in a protein-protein interaction (PPI) network [265], and (b) AD-related genes
and protein database in Alzforum (http://www.alzforum.org/). We collected 84
genes from a human AD real-time PCR array functional gene grouping (http://www.
sabiosciences.com/rt_pcr_product/HTML/PAHS-057Z.html) and 876 genes in the
Ingenuity Pathway Analysis (http://www.ingenuity.com/) tool filtered by keyword
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“Alzheimer biomarker”. From these searches a total of 1915 unique genes were placed
in our knowledge-based gene pool.
4.3.3 Feature selection
We proposed a novel method – Support Vector Machine Forward Selection (SVMFS) –
for selecting the best AD-related protein set for training our classification model (Figure
4.1) The framework of our method is built upon that of the Support Vector Machine
(SVM) model. Throughout the study, we adopted the default settings of the SVM
model in the e1071 R package [266] (gamma=1/feature number, cost=1, type=C-
classification, kernel=radial). For a given protein set, an SVM model can be trained,
whose leave-one-out cross validation (LOOCV) accuracy was then used as the evaluation
score. The evaluation score improvement was calculated by comparing the evaluation
scores of the previous protein set with the evaluation score of the updated protein set
containing a selected additional protein. An alternative feature selection method was
also used – SVM Top Forward Selection (SVMTFS). In this alternate method a ranking
list for all the proteins based on the LOOCV accuracy of their respective single-protein
SVM model was made.
The only difference between these two methods lies in the selection of the protein to
be included in the next round. In SVMFS, the optimal protein among the rest is selected;
in SVMTFS, the next protein in the ranking list based on the LOOCV is selected.
The abovementioned methods are applied to both WRFP and KBFP.
4.3.4 Classifier training and assessing
We conducted a cross-validation using the GSE29676 dataset on the protein sets dis-
covered by our novel feature selection approach, and the 10 biomarkers discovered by
Nagele and colleagues (named here as Nagele model) [261]. We trained classifiers with
60 samples (randomly selected, 30 each in AD and healthy samples) and then testing
the classifiers with the remaining samples (10 AD and 20 healthy samples). The cross-
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validation was repeated 5000 times for the calculation of average sensitivity, specificity,
positive predictive value (PPV), negative predictive value (NPV), false discovery rate
(FDR) and false omission rate (FOR) [267]. The ROC curve performance area under
the curve (AUC) was plotted using the pROC R package [268].
4.3.5 Biomarker validation
We conducted both biomarker validation and classification model validation. Classifiers
trained in discovery in the GSE29676 dataset were then tested for performance in the
GSE39087 dataset. We also did cross-validation using GSE39087 of the features iden-
tified by GSE29676, i.e. randomly selecting 20 AD and 20 healthy in GSE39087 as
training samples and the remainder as testing samples, and repeating 5000 times.
For GSE5281, target proteins identified in discovery dataset were matched with cor-
responding probes by their corresponding genes. An SVM classification model was built
in the six different brain regions separately and LOOCV accuracy was used to assess the
performance of the model in each region.
4.4 Result
Employing SVMFS and SVMTFS to select features in the KBFP and full feature pool re-
spectively, we discovered three different protein sets that showed promising performance
in discriminating AD patients from healthy individual as measured by LOOCV accuracy.
Table 4.1 shows the LOOCV accuracy for each of the top 20 features (proteins) used
in a single feature SVM model in discovery dataset. We found the following models
(protein sets) whose classifying performance is shown in Table 4.2.
 A two-feature model selected in WRFP by SVMFS had 98.8% SVM-LOOCV accu-
racy and consisted of ECH1+NHLRC2 (enoyl coenzyme A hydratase 1 peroxisomal
plus NHL repeat containing 2).
 A three-feature model selected in KBFP by SVMFS had 96.5% SVM-LOOCV ac-
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Table 4.1: Top 20 proteins with largest LOOCV accuracy
NCBI Accession ID Protein Name LOOCV Accuracy
BC011792.1 ECH1 96.5%
NM 004502.2 HOXB7 96.5%





NM 176884.1 TAS2R43 95.4%
PV3366 ERBB2 94.2%
NM 201278.1 MTMR2 94.2%
BC038406.1 C3orf20 94.2%
NM 152776.1 MGC40579 94.2%
NM 014110.3 PPP1R8 93.0%
XM 294794.1 LOC339065 93.0%
NM 019891.1 ERO1LB 93.0%
BC068078.1 NPM2 93.0%
NM 002613.3 PDPK1 93.0%
NM 031268.3 PDPK1 93.0%
BC032101.1 JAGN1 93.0%
NM 000963.1 PTGS2 93.0%
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curacy and consisted of ERBB2+FN1+SLC6A13 (v-erb-b2 erythroblastic leukemia
viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)
transcript variant 2, fibronectin 1, plus solute carrier family 6 (neurotransmitter
transporter, GABA), member 13).
 A two-feature model selected in WRFP by SVMTFS had 97.7% SVM-LOOCV
accuracy and consisted of ECH1+HOXB7 (homeobox B7).
Evaluation by cross-validation in the same dataset showed a good performance of
these models (Table 4.2). The average sensitivity and specificity of models ECH1+NHLRC2,
ECH1+HOXB7, and ERBB2+FN1+SLC6A13 all reached at least 88%. Among the se-
lected proteins, an interesting statistical pattern for the expression level was discovered
in ECH1, HOXB7 and ERBB2 (Figures 4.5 and 4.6). In each of these three proteins, the
normal expression range has two thresholds (one upper limit and one lower limit). To
the best of our knowledge, such biomarkers with banded distributions between healthy
and AD samples have not previously been reported. Typically there is a binary separation
between AD and healthy samples with only one threshold.
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Figure 4.2: ROC curves of the three proposed models in the cross-cohort validation
using GSE39087. The curves were plotted with the best performed classifiers across all
models during the validation.
4.4.1 Cross-cohort validation
The cross-validation using cohort GSE39087, which is also a serum protein microar-
ray data, showed that the three models still maintained good classification ability,
with SVM-LOOCV accuracies of 88.9% (ECH1+NHLRC2), 97.8% (ECH1+HOXB7),
and 74.4% (ERBB2+FN1+SLC6A13). Model ECH1+HOXB7 outperformed the oth-
ers in this process of validation, with over 95% in sensitivity and specificity (Table
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4.2). Model ECH1+NHLRC2 also exhibited good predictive performance except for a
decreased sensitivity, which could result from the relatively small training sample size.
Despite the seemingly good result in cross-validation using GSE39087, the performances
of models deteriorated when they were trained and tested by different cohorts (AUC:
ECH1+NHLRC2: 89.5%, ECH1+HOXB7: 66.1%, ERBB2+FN1+SLC6A13: 75.1%,
see Figure 4.2). This could be an indication of over-training in those models, espe-
cially for model ECH1+HOXB7. The reason for this could be different experimental
environments between the two cohorts.
We also investigated the distribution pattern for all the proteins using dataset GSE39087
and found that ECH1 still maintained its banded distribution, while in ERBB2 and
HOXB7 more spread of control is found (Figure 4.7 & Figure 4.8). The disparity may be
caused by the different data processing methods employed by GSE29676 and GSE39087;
the former dataset were characterized into disease and control groups and then linearly
normalized while the latter dataset were normalized via the compare-function embedded
in Invitrogen’s Prospector [269].
We conducted LOOCV separately for our three proposed protein sets in the six
different brain regions of dataset GSE5281 (thus 18 models were evaluated in total).
The result shows that our three models maintain excellent overall classification ability in














































































































































































































































































































































































































Figure 4.3: Up/down regulation for ECH1, HOXB7 and ERBB2 in GSE29676. Horizon-
tal coordinate represent AD samples and vertical cooridinate represents three proteins.
Expression values are scaled by rows for each protein, and red/green indicate relatively
up/down regulated expression.
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Table 4.3: Accuracy performances of our three proposed models in dataset GSE5281
(see Methods for full name of brain regions)
EC HIP MTG PC SFG VCX
ECH1 + NHLRC2 95.5% 78.3% 60.0% 57.1% 68.0% 50.0%
ECH1 + HOXB7 86.4% 87.0% 80.0% 85.7% 68.0% 40.0%
ERBB2 + FN1 + SLC6A13 90.9% 56.5% 88.0% 81.0% 60.0% 43.3%
Figure 4.4: Up/down regulation for ECH1, HOXB7 and ERBB2 in GSE39087. Horizon-
tal coordinate represent AD samples and vertical cooridinate represents three proteins.










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The original study of dataset GSE29676 reported 10 autoantibodies as diagnostic AD
biomarkers [261]. The authors constructed a descending ranked list sorted by the dif-
ference in prevalence between AD and healthy groups using Predictive Analysis for Mi-
croarrays (PAM), and then the top 10 features were selected. This method of feature
selection did not take the combinatory effect of feature sets into consideration, as each
autoantibody was selected exclusively according to their own discriminant ability between
groups. To overcome the weaknesses in feature selection, we used a SVM radial kernel
embedded feature selection method, which not only compensates for the ignorance of
combinatory effect of significant differentiator feature sets, but also adds the ability to
discover complex patterns in the data. More importantly, in the original study the pre-
dictive models were trained and validated in samples that were randomly selected, only
once, which may lead to uncertain results. In contrast, our study has cross-validation
by repeating the sampling for 5000 times to compensate for any uncertainty in boot-
strapping. Also, the impact of age and gender on the prediction models were ignored in
Nagele’s study. In a later re-examination by the same researchers, those two factors (age
and gender) were identified to strongly influence the number of autoantibodies detected
using protein microarrays [262]. We eliminated such effects by simulating a robust linear
regression model between age, gender and the expression value. The expression value
was then corrected by summing the intercept and the residue.
We also see a potentially novel pattern of expression in AD and healthy samples with
two boundaries. An assumption can be made that there is a normal level of protein
expression in healthy individuals. The LOOCV accuracies of those proteins with this
particular pattern suggest that any subject with an abnormal expression level, either
being up or down regulated, can be diagnosed as having AD with high confidence.
The existence of upper and lower bound of normal expression in these proteins can
have multiple possible explainations. Firstly, it can imply the potential to subdivide AD
into two or more categories, where the samples with increased expression level affiliate
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with one category while those with less expression level affiliate with the other.
A second and more likely explaination to the banded distribution of AD samples, is
that there are regions of potential protein quantitative trait locus (pQTL) that varies in
degree, attributing to the pathology of AD.
The sample expression distribution of the corresponding genes to the six proteins are
also examined, the results of which are shown in Figure ??. The figures show that the
banded pattern disappear in probes mapped to ECH1, HOXB7 and ERBB2. It excludes
the possibility of a genetic cause for a banded distribution pattern found in blood samples.
Furthermore, in the cross validation in brain, a better overall performance of three models
in region EC is observed (see Table 4.3). A likely explanation about the discrepancy of
performances between difference regions, is that EC is the first area of the brain to be
affected in Alzheimer’s disease [270], so it is reasonable that the alternation of genes
happen more frequently in this region than in other regions.
Furthermore, we find a correlation between the expression levels of the proteins with
two boundaries in our study. For instance, in the dataset GSE29676, the AD sample
group with a down-regulated expression level of protein ECH1 also have down-regulated
HOXB7 and up-regulated ERBB2 (Pearson correlation r=0.99 for ECH1 & HOXB7; r=-
0.95 for ECH1 & ERBB2; and r=-0.94 for ERBB2 & HOXB7, see Figure 4.3). The same
situation was observed in the dataset GSE39087 (see Figure 4.4). These observations
suggest that there is an underlying linkage between the upstream activities of these
proteins. We predict that further investigations will reveal co-expression, regulation or
antagonistic relation between the precursor molecules of those proteins, at the level either
of transcription or translation.
Considering the proteins in our panels, ECH1 is a gene encoding a member of the
hydratase/isomerase superfamily. The gene product shows high sequence similarity with
the enoyl-coenzyme A (CoA) hydratases of several species, especially within a con-
served domain that is characteristic of these proteins. The encoded protein contains
a C-terminal peroxisomal targeting sequence that localizes to the peroxisome. Its rat
ortholog is a delta3,5-delta2,4-dienoyl-CoA isomerase that functions in the auxiliary step
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of the fatty acid beta-oxidation pathway. This transcript was reported to be significantly
up-regulated in response to neuronal silencing in the rat [271] but no linkage to AD or
dementia has been reported previously. HOXB7 is a member of the Antp homeobox
family and encodes a protein with a homeobox DNA-binding domain. It is included in a
cluster of homeobox B genes located on chromosome 17. The encoded nuclear protein
functions as a sequence-specific transcription factor that is involved in cell proliferation
and differentiation. HOXB7 is age-repressed in mesenchymal stromal cells and conversely
age-induced in hematopoietic progenitor cells [272]. ERBB2 is a member of a family
of single-transmembrane receptor tyrosine kinases called ERBB and plays the main role
in mediating Neuregulin-1 (NRG1) function [273, 274]. NRG1 participates in numerous
neurodevelopmental processes, and is implicated in nerve cell differentiation and synapse
formation [275, 276], radial glia formation and neuronal migration [277, 278], oligoden-
drocyte development and axon myelination [279,280], axon navigation [281], and neurite
outgrowth [282, 283].
Our findings suggest that the combined expression levels of ECH1, HOXB7 and
ERBB2 have good potential to be an indicator of AD pathology. ECH1 and HOXB7
are expressed in almost all tissues and are enriched in the central nervous system, while
ERBB2 is absent from many tissues and is not detected in the central nervous system
(http://www.proteinatlas.org/). Whether these proteins can pass the blood brain
barrier is yet to be investigated.
We note that our approach is different from the recursive feature elimination (RFE)
method, which searches features starting from the sorted full feature space and elimi-
nates features by a certain number or proportion in each iteration [261]. In contrast,
our approach searches features by including important and informative features in each
iteration. Such methods are greedy and may achieve global solutions, but are compu-
tationally expensive. To overcome this, we restricted our method to include just one
feature in each iteration and terminated the searching when the improvement of predic-
tion model caused by including a new feature was less than a predefined threshold (zero
in the study).
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4.5.1 Limitation of the study
There are some limitations throughout the study. A major obstacle in cross validating
the models between GSE29676 and GSE39087 is that no raw data was provided, thus,
the disparity or bias caused by difference in data pre-processing cannot be eliminated.
This could have also contributed to the discovery of the wider spread of control samples
found in protein ERBB2 and HOXB7 in GSE39087.
A second limitation of the study is the absence of braak stage data that can indicate
the extent of AD pathology, which can possibly provide more possible explanations on
different performances among different brain regions in the validation, since AD onset is
a process that render sequential effect of different brain regions.
Another limitation lies on the fact that no blood cell type information is provided in
any datasets analysed in the study. Thus, the effect of abundance of particular blood
cell type cannot be eliminated.
We predefined a knowledge-based feature pool (KBFP) based on existing knowledge
about AD pathology before feature selection was conducted. However, this feature pool
is imperfect in the following perspectives. Many of the features collected are only brain
specific and thus alternations of biomolecules oriented from blood may not be fully
included. As some genes or proteins are altered in blood in AD but in a peripheral
response to AD pathology, they do not mirror what has happened or going to happen in
brain, but they are still equally good biomarkers. In other words, biomarkers fallen into
this category are missing in KBFP. We also consider to include the 26 genes discovered
in brain RNA biomarker study described in Chapter 3 into the pool to further improve
its diversity.
4.6 Conclusion
The inclusion of existing biological knowledge and use of a novel feature selection method
has allowed us to find several protein models that have a promising ability to distinguish
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AD patients from healthy individuals. We also find a new statistical pattern involving
both upper and lower bounds to expression in our model. The reproducibility of these
findings needs now to be tested in larger cohorts.
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Chapter 5
MetaUnion R package development
5.1 Abstract
This chapter describes the development of R package metaUnion - an advanced meta-
analytic approach applicable for microarray data. This package is designed to overcome
the defects appear in other similar meta-analytic packages, such as the neglection of
missing data, the inflexibility of feature dimension, and the lack of functions to support
post-analysis summary. metaUnion has been applied in a study to identify differentially
expressed genes as part of the integrated genomic approaches. Genes like NEUROD6,
ZCCHC17, PPEF1 and MANBAL were identified to be potentially implicated in LOAD.
The result of thefuncz study was published in 2015 [265]. In addition, a part of functions
in metaUnion is also applied and programmatically embedded in the data analysis process
of biomarker database Alzexpress that will be discussed in Chapter 6. The package is now




Meta-analysis is a statistical method that allows an analyst to combine effect sifunczzes
across different studies into one meaningful estimate. In contrast to results from a
single primary study, results from a meta-analysis deliver better generalizability, greater
precision, and the ability to explore heterogeneity across studies [284, 285].
The conventional meta-analytic model calculates an average effect size by weighting
each effect with the inverse of an effect size’s variance (i.e., the squared standard error).
The idea is that studies with a smaller variance have a greater impact on the average
effect size relative to studies with a larger variance. This is referred to as a fixed-effect
estimate [284]. An alternative and widely-used approach takes into account the variance
between studies to estimate a random-effects meta-analytic model. Compared to a
fixed-effect meta-analytic estimate, the random-effects meta-analytic estimate will have
a greater confidence interval and the weights of each study will be similar [286].
Recent advances in meta-analytic methods have brought positive evolvement to the
models. For instance, in tackling the issue of multiple effect sizes for one study, robust
variance estimation can be used to incorporate all effect sizes into one model [287],
whereas traditional methods only use priori decision rules to choose one effect size or
simply average all the effect size in one study. Other multivariate meta-analytic ap-
proaches was also suggested [288], which require that the user know the covariance
structure of effect sizes within each study.
Similar progresses have been made for a number of common application issues. To
implement structural equation modelling with meta-analytic correlation matrices, a two-
step modelling approach was designed by Cheung [289]. The first step is the synthesis of
correlation matrix, and the second step is to conduct the usual structural equation models
such as factor analysis or latent variable modelling, with the correlation matrix prepared
by the first step. The framework was extended by Polanin et al [290] extended this
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framework to accommodate complicated datasets with manifold levels of dependency.
R package metaSEM developed by Cheung et al [289] allows users to conduct a meta-
analytic structural equation model. Another advance is the application of network model
by means of network meta-analysis, where the objective is to concurrently contrast
multiple interventions. Albeit not as fashionable in the social or educational sciences,
network meta-analyses are now becoming popular in medicine [291].
5.2.2 Application in genomics and microarray
With the advent of novel high throughput technology and chronic accumulation of mi-
croarray based biological studies, meta-analysis is becoming more important in biomarker
discovery.
Microarray analysts are always facing a challenging task in terms of how to extract,
compare and consolidate information from a magnificent amount of data. However,
this is tampered by the complicated experimental protocols and designs embedded in
microarray data. The main reason is the lack of normalised standards for microarray
experiments for which heterogeneous datasets are generated. Under that condition,
direct comparison is impossible. To solve the conflict of research interest and experiment
reality, an approach combining results from different microarray datasets is quested.
Numerous R packages are developed for the purpose of conducting meta-analysis on
genomic and microarray data. MADAM [292] provides the ability to calculate effect sizes,
run fixed- or random-effects models, and also the functions to create some plots. The
metaARRAY package [293] is specifically for large-scale meta-analysis of microarray data
with a Bayesian framework. An author-written demonstration of the package capabilities
using publicly available data is also included. The metaDE package [294] enables users
to conduct 12 types of meta-analysis to discover differential expressed genes. Users are
also provided with the option to choose which test statistic to calculated according to
the outcome variable and choose corrections for one-sided tests. To date, the metaDE






































































































































































omission of missing data. The imputation of missing data is designated for any gene
with less than 30% missing data. In metaUnion, instead of imputation, the effect is
reflected in the result by linking the missing data with the weighting coefficients during
the combination. The metaMA package [171] searches for differentially expressed genes
via merging either p values or t-test statistics in both paired and unpaired data. A
demonstration vignette is also embedded using publicly available data for this package.
Package metaRNAseq [295] shares similar functionality yet targeting on applying to
RNA sequencing experiments. The MAMA package [296] relies on several R packages
GeneMeta [297], metaMA, and metaARRAY.
Methodology wise, Choi et al [298] and Rhodes et al [168] were among the first
authors to explore the practise of meta-analysis in the context of microarray data to find
differentially expressed (DE) genes. Part of Choi et al [298] methods are applied in the
Bioconductor package GeneMeta [297]. These approaches utilize either the effect size
calculation [298] by inter-study variation modelling or the combination of p-values [168].
Conlon et al [299] and Scharp et al [300] also suggested to employ Bayesian methods to
combine microarray data.
5.2.3 Defects in existing packages
Nonetheless, many defects appear when current meta-analysis R packages are used in
practice. First, current R packages cannot handle data from different studies with dif-
ferent dimensions. Second, the presence of null values in the input data is ignored by
directly omitting cases with missing value in these packages, which bias the true result
of meta-analysis. Third, the output of result is not user-friendly and intuitive due to the
unobvious illustration of p-values, z-scores and regulation direction for each feature in
each study. Finally, a union calculation of targeted features selected by different effect
size calculation methods is not provided. To improve the usability and practicability of
meta-analysis for bioinformatics research, a new meta-analysis package metaUnion was
developed to fix the existing deficiencies of current packages. It will be able, first, to
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handle data from different studies with different dimensions; second, to rectify the num-
ber according to the number of missing value in the input; third, to provide the result
of p-values, z-scores and effect sign for each feature; last, to provide a union calculation
of targeted features selected by three different algorithms.
5.3 Statistic
The basic methodology of meta-analysis has been introduced in section 2.4.6.
The analysis of gene expression array data has always been centring on a fundamental
question, which is whether the level of expression is significantly different in samples from
two different conditions. Statistical hypothesis testing is a powerful approach to answer
this question.
In metaUnion, two types of hypothesis tests are chosen to conduct differentially ex-
pressed gene analysis. Users are provided two options - student’s t-test and a moderated
t-test - where they can choose either approach to conduct DEG analysis.
5.3.1 Student’s t-test
A t-test is most commonly employed when test statistics follows a Student’s t-distribution
under null hypothesis. In a t-test, the well-known t-statistics is measured as the extent
of difference between two populations, in the form of








where, c and t represent different experiment conditions to be compared with each other,
and for each m =
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degress of freedom. The advantage of using t-test comparing to the above-mentioned
fold change approach, is that the means between different populations are adjusted
by empirical standard deviations, therefore the fixed fold-threshold issue can be ad-
dressed. [301] However, limited by the high expense and tediousness of experiments, the
sample numbers nc and nt is often very small. Thus the variance is often significantly
underestimated.
5.3.2 Moderated t-test in R package limma
Another approach to conduct DEG analysis is the moderated t-test implemented in
R package limma. This [302] is an R/Bioconductor software package that integrate
linear modelling with complex experimental design analysis, remarkably developed with
information borrowing to tackle the problem of small sample size in differential expression
in array or sequencing studies.
The highly parallel nature of gene expression experiments entitled this package to
borrow information between genes in a method commonly known as empirical Bayes. The
coefficients inferred by linear models fitted to each gene provide additional information
needed in Bayesian method to moderate residual variances.
This function fits multiple linear models by weighted or generalized least squares. It
accepts data from a experiment involving a series of microarrays with the same set of
probes. A linear model is fitted to the expression data for each probe. The expression
data should be log-ratios for two-color array platforms or log-expression values for one-
channel platforms
E(yg) = Xαg (5.3)
where E(yg) is the logarithm transformed expression levels, X is a design matrix of
full column rank and α is a coefficient vector. Certain contrasts of the coefficients are
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assumed to be of biological interest and their coefficients are extracted by
βg = C
Tαg (5.4)
where C is the contrast matrix. The target hypothesis to be tested is whether individual
contrast values βg are equal to zero. Some distributional assumptions are customised
for the convenience of hypothesis testing.






Where dg is the residual degrees of freedom for the linear model for gene g.
b) It is assumed that the variances of linear coefficient estimators αg and that of the








where Vg is a positive definite matrix not depending on s
2
g. Let vgj be the jth diag-
onal element of CTVgC. The contrast estimators are assumed to be approximately




β̂gj|βgj, σ2g ∼ N(β, vgjσ2g) (5.8)
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follows an an approximate t-distribution on dg degrees of freedom.
To describe how the unknown coefficients βgj and unknown variances σ
2
g vary across
genes, prior distributions for these sets of parameters are defined. To describe how
the variances are expected to vary across genes, prior information is assumed on σ2g







In regards to the prior information of βgj, it is assumed it complies with a normal
distribution with mean equal to zero and unscaled variance v0j, i.e.,
βgj|σ2g , βgj 6= 0 ∼ N(0, vgjσ2g) (5.11)
Swapping the related parametrizations from those proposed by Lonnstedt and Speed
[303], where dg = f, vg = 1/n, d0 = 2v, s
2
0 = a/(d0vg) and v0 = c, the posterior mean of
σ2g given s
2











The posterior values shrinks the observed variances towards the prior values with the
extent of shrinkage in relation to the relative sizes of prior and observed degrees of
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Which is proved to follow a t-distribution under the null hypothesis H0 : βgj = 0 with
degrees of freedom dg + d0. Different from the fully Bayesian approach which allows
users to choose the hyperparameters such as d0, s
2
0, v0j, the empirical Bayes approach
estimate them from the data.
5.3.3 Statistics in metaUnion
Meta-analysis has been widely used in medicine and health policy to interpret contradic-
tory results from various studies. And microarray experiments are a typical example of
small sample size designs. The package metaUnion aims to provide users a robust tool to
conduct meta-analysis with the option of choosing the methods desired to calculate the
statistics. Compared with other meta-analysis packages such as metaMA, metaUnion
improves the compatibility with microarray experiments by unlimiting the dimension of
input expression value matrix. This improvement allows results from different microarray
platform to be able to analysed together, which magnificently enlarge the sample sizes
that the results are based on. Large samples consequently reduces the skewness of result
caused by extreme samples and increases the liability of the conclusions. The package
also takes the absence of expression values in each study into consideration, by adjusting
the weights that are used during the intercourse of parameters estimation.
5.3.3.1 Effect size calculation
The following assumption is established for the calculation of effect size. Let Ysigr
and Ysjgr be the expression levels for gene g in conditions i and j for study s and
replicate r. The data are assumed to be normally distributed as Ysigr ∼ N(µsig, σ2sg)






Therefore, the effect sizes can be linked to the test statistics calculated in student’s




with ñ = ninj/(ni + nj) where ni (respectively, nj) is the number of replicates in condition
i (respectively j). The unbiased estimators of effect size d can be defined as












where m is the number of degrees of freedom. For limma [302], m equals to the sum of
prior degrees of freedom and residual degrees of freedom for the linear model for gene
g. For student’s t-test, degrees of freedom are m = ni + nj–2.
Variances of effect sizes are also needed to apply meta-analysis procedure. As de-
scribed by Marot et al [171], the exact form of the variances for effect sizes is inferred









5.3.3.2 Effect size combination
The hierarchical model described by Choi et al [298] is adopted in order to combine
effect size and obtain a test statistics for differential expression
dsg = θsg + esg, esg ∼ N(0, ω2sg)
θsg = µsg + vsg, vsg ∼ N(0, τ 2g )
(5.19)
where dsg is the estimation of the effect size for study s and gene g, τ
2
g represents
between-study variance while ω2sg are the within-study variances. The within-study vari-
ance has been estimated in the same stage as the estimation of the effect size. An
estimation of the between-study variances τ 2g can be obtained using the method of mo-
























where ω2sg + τ
2
g is equivalent to the var(d) in equation 5.18 and dsg is estimated in









The z-score is assumed to follow a normal distribution after an investigation by a q-q
plot.
5.3.3.3 P-value combination
To combine p-values many authors such as Rhodes et al [168] and Hu et al [305] utilized
Fisher’s combined probability test across studies. However, the main drawback of this
approach is that over- and under-expressed genes are treated separately. Marot et al [171]
hence suggested to use the inverse normal method that is symmetric in the perspective
that P-values near zero are accumulated in the same way as P-values near unity [306].
The inverse normal method refers to the averaging of transformed individual p-values
to normal scores. This procedure was first introduced by Stouffer et al (1949) [307]
and Liptak [308]. An alternative method to implement the inverse normal method is












Where n(s) is the number of replicates without null expression values for gene g in
study s, and p̃g(s) is the one-sided p-values for each study, for the purpose of avoiding
directional conflicts. Under the null hypothesis, Sg follows a standard normal distribution
[171], thus an overall two-sided p-value can be inferred by
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pg = 2(1− φ(|Sg|)) (5.25)
5.3.3.4 Special one-study case
In the case that expression values exist in only one study, the test statistic is assumed to
follow a normal distribution. The p-value for the only-existing study is assigned as the
p-value for meta-analysis, and the meta-analysis z-score can be inferred by




Where t̃ is the test statistic, and p̃g(s) is the two-sided p-value, both calculated from
that single study. sign() is a function to persist the sign of test-statistics.
5.4 Functions in the package
5.4.1 inputExpCheck
inputDataCheck is a pre-check function for input datasets. Auto-run in function meta-
Analysis(). Checks if the information in the input data list matches, and filters out
probes without annotations or with multiple Entrez ID annotations. We use Entrez ID




inputList A list object containing lists for respective studies. Each list of
a particular study contains an expression matrix and a sample in-
formation vector. The expression matrix is constructed with each
row representing a gene (probeset) and each column representing a
sample. The order of the columns should be [case samples][control
samples][two additional columns]. The two additional columns ap-
pended at the end indicate the gene Entrez ID (this column must be
named as “Entrez.Gene”) and then the gene symbol. The sample
information vector contains two elements, the first one represents
the number of case samples and the second one represents the
number of control samples.
Value A filtered data list with complete gene annotations (Entrez gene ID) and cor-
rect format for ongoing meta-analysis. The following probesets are excluded from the
list: those which are expressed in less than 2 samples in each group; those which are
unannotated or annotated in the wrong format.
5.4.2 metaAnalysis
Apply limma or student t-test to each probe and calculate statistics to identify differen-
tially expressed genes in each study, followed by meta-analysis combining effect-size or
p-value from different studies. Detailed procedure pipeline is shown in Figure 5.1
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Figure 5.1: Meta-analysis pipeline of metaUnion. A three-study example is used for
illustration. As depicted, two options are subjected to users’ changes - 1) the method to
conduct differentially expressed genes analysis with either student’s t-test or moderated
t-test; 2) the method to combine outcomes from every study with either effect size





dataList A list object containing lists for respective studies. Each
list of a particular study contains an expression matrix and
a sample information vector. The expression values should
have been log 2 transformed. The expression matrix is
constructed with each row representing a gene (probeset)
and each column representing a sample. The order of the
columns should be [case samples][control samples][two ad-
ditional columns]. The two additional columns appended
at the end indicate the gene Entrez ID (this column must
be named as “Entrez.Gene”) and then the gene symbol
(this column must be named as ”Symbol”). The sam-
ple information vector contains two elements, the first one
represents the number of case samples and the second one
represents the number of control samples.
uniqGeneSelMethod Specifying the method used to select a gene if multiple
entries correspond to one single gene, with ”dprime” as
default. Methods are as follows: logFC: select entry with
largest absolute fold change; t: select entry with largest
absolute t score; pval: select entry with smallest p value;
n: select entry with largest number of expressed samples;
df: select entry with largest absolute degree of freedom; d:
select entry with largest absolute delta; vard: select entry
with largest absolute vard; dprime: select entry with largest
absolute dprime; vardprime: select entry with largest abso-
lute vardprime. If two entriesy share the same value, then
the one with the smaller row index in the expression matrix
will be selected.
Continued on next page
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Table 5.2 - - Continued from previous page
calWithLimma Specifying which method (student’s t-test or moderated t-
test) will be used to calculate the statistics for each study,
default TRUE using limma (moderated) t-test. If using
t-test for calculation, the statistics of probesets whose ex-
pressed sample number in either case or control group is
less than 2 will all set to NA and these probesets will be
excluded if expCheckInput() function is triggered before-
hand.
combinedPval Choosing whether to combine p-value or effect size to ex-
ecute meta-analysis, default FALSE combining effect size.
filterData Choosing whether to filter input data or not by using func-
tion inputExpCheck(), default TRUE (do filtering).
Value A matrix summarizing the following information for each probe: EntrezID, gene
official symbol, FoldChange in each study, effect-size in each study, test two-tailed p-
value in each study, z-score after meta-analysis, p-value after meta-analysis, effect, sig-
nificance, Bonferroni corrected p-value after meta-analysis. Probes expressed in less
than 2 case/control samples will be ignored. Here ”effect” indicates the direction of
gene regulation, e.g. symbol ”+”, ”-” and ”?” represent a gene being up-regulated,
down-regulated or missing in that study. In ”significance” tab, symbol ”!”, ”#” and
”?” represent a gene being significant, not significant and missing in that study, where
genes with p-value <= 0.05 are considered significant.
5.4.3 metaInfoStat
metaInfoStat is to summarize the input data list and calculate the number of genes
found in all studies.
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Usage metaInfoStat(inputList, metaResult, filterData=TRUE)
Arguments
inputList A list object containing lists for respective studies. Each list of a
particular study contains an expression matrix and a sample infor-
mation vector. The expression values should have been log 2 trans-
formed. The expression matrix is constructed with each row repre-
sents a gene (feature) and each column represents a sample. The
order of the column should be [case samples][control samples][two
additional columns]. The two additional columns appended at the
end indicate the gene Entrez ID (this column must be named as
“Entrez.Gene”) and then the gene symbol (this column must be
named as ”Symbol”). The sample information vector contains two
elements, the first one represents the number of case samples and
the second one represents the number of control samples.
metaResult A meta-analysis result list generated by function metaAnalysis().
filterData Specifying whether to filter unannotated or multi-annotated probes
or not, default TRUE (do filtering).
Value A list containing two matrices. One matrix summarizes the general information
about the input data list, including number of genes, and number of case and control
samples in each study. The other matrix displays the numbers of found in all studies (n)
and to how many are found in n-1, n-2 studies etc.
5.4.4 metaZscoreQQplot




metaResult A meta-analysis result list generated by function metaAnalysis()
mainTitle Main title of the Q-Q plot figure
savefile File name
width Width of the figure, default 500
height Height of the figure, default 500
Value A Q-Q plot figure of meta-analysis z scores.
5.4.5 sortMetaStat
inputDataCheck is to extracts top ranking genes according to different measurements.
Usage sortMetaStat(metaResult, displayNumber, decreasing=FALSE)
Arguments
metaResult A meta-analysis result list generated by function metaAnalysis()
displayNumber Displays gene number
decreasing Ranking by increasing or decreasing order, default FALSE (increas-
ing order)
Value A short-listed metaResult with specified number of genes ordered by Bonferroni
corrected p-values, and the -abs(metaZscore) as the second measurement.
5.5 Demo data Alzdata
A dataset for easy demonstration of all the usages in metaUnion is attached. The dataset
is a subset of a larger aggregate of datasets investigated by Li et al [265].
Usage data(Alzdata)
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Format List of 6 studies: gse5281, gse48350, gse15222, gse33000, gse44772, gse36980,
which are a subset of microarray datasets downloaded from GEO (http://www.ncbi.
nlm.nih.gov/geo/).
Each list of studies contains two data frames as the following:
expression.mat A data.frame, each object/row represents a probeset and each
variable/column represents a sample. The two additional columns appended at the end
indicate the gene Entrez ID (this column must be named as “Entrez.Gene”) and then
the gene symbol.
sample.info A data.frame with 1 object of 2 variables, numbers of case and control
sample.
Source Datasets are trimmed from original studies, including only probesets for the
top 30 differential expressed genes (DEGs) identified in our study [265] and the 50-150
randomly selected probesets from the original dataset.
5.6 Application in biomarker mining
One of the aims for metaUnion is to maximize the number of samples that are included
in meta-analysis, such that those DE genes which are not commonly shared by all studies
will not be omitted in the course of analysis. This advantage of metaUnion has been
exploited in a study conducted by Li et al [265], where integrated genomic approaches
pioneered by meta-analysis identified major pathways and upstream regulators in LOAD.
158
5.6.1 Method and Approach
5.6.1.1 Dataset selection and probeset pre-filtering
Before the study, datasets to be investigated were narrowed down by the following
criteria,
 Late-onset Alzheimer’s disease (LOAD) related mRNA expression studies.
 Data extracted from human post mortem brain tissues in either brain region super
frontal gyrus (SFG) or prefrontal cortex (PFC), since both of which are part of the
brain frontal lobe.
With the above criteria, six profile datasets with GEO accession number of GSE15222,
GSE36980, GSE44770, GSE5281, GSE33000 and GSE48350 were selected.
Both GSE48350 and GSE5281 datasets were generated from the Affymatrix HG-
U133-plus2 platform (GEO platform ID: GPL570) which contains 54675 probesets, con-
taining 252 and 161 profiles respectively. Raw data were extracted from CEL files and
then normalized using RMA (Robust Multi-array Average) method programmed in the
affy2 R package (http://www.bioconductor.org). A pre-filtering process was carried
out to preclude probesets in each studies by consecutively applying the following filters:
 Probes with more than 10% absent calls (present/absent call by affy mas5 algo-
rithm) across samples.
 Probesets with average expression level (after log2 transformation) lower than
three.
The latest version of probesets annotation file was downloaded from Affymetrix NetAffx
Analysis Centre (http://www.affymetrix.com/analysis/index.affx).
GSE36980 was generated from the Affymatrix Human Gene 1.0 ST platform (GEO
platform ID: GPL6244) containing 79 profiles. Raw data were extracted from CEL
files followed by an RMA normalization on the transcript level. A same pre-filtering
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process described above in the pre-processing of GSE48350 and GSE5281 is implemented.
Microarray annotation database package hugene10sttranscriptcluster.db [309] in R was
used for annotating this dataset.
The common platform to generate GSE44770 and GSE33000 datasets is the Rosetta/Merck
Human 44k microarray platform (GEO platform ID: GPL4372), containing 39302 probe-
set. These two datasets contain 230 and 623 case-control profiles respectively. Processed
data are used without any pre-filtering.
GSE15222, containing 363 profiles, was generated from the Illumina microarray plat-
form (GEO platform ID: GPL2700) including 24354 probesets. A sub-dataset down-
loaded from Dr Myer’s lab (http://labs.med.miami.edu/myers) was used in the
study. In the sub-dataset, probesets are defined to have null values if their relevant
detection scores were less than 0.99. The sub-dataset therefore contains 8650 probesets
resulting from a pre-filtering schema - probesets with more than 30% null values were
excluded.
5.6.1.2 Sample filtering
In this study, the samples to be investigated are filtered by the following rules:
 Only samples that are collected from brain region PFC are retained to be investi-
gated because maximum number of gene expression profiles can be obtained for
this region. Samples collected from other regions are abandoned.
 Only samples with age information are included.
 Only samples aged between 65 and 95 years old are included to reduce the analysis
bias because Alzheimer’s disease is age-related.
After the above region and age control, a total number of 212 controls and 450 cases
were left for the remaining analysis.
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Table 5.3: Meta-analysis dataset meta information
Platform Study EntrezGene Case Control Sum
GPL570 GSE5281 13424 23 9 32
GPL570 GSE48350 14903 21 23 44
GPL2700 GSE15222 3995 30 37 67
GPL4372 GSE33000 21576 249 88 337
GPL4372 GSE44770 21576 116 39 155
GPL6244 GSE36980 18922 11 16 27
Total 6 23530 450 212 662
5.6.1.3 Annotating probesets
Throughout the study, each probeset in every dataset is mapped to Entrez Gene IDs (as
gene IDs). Those probesets without corresponding gene IDs were discarded. Further-
more, if a gene has more than one relevant probesets, the probeset having the largest
absolute estimated effect size would be kept and the rest were discarded.
Table 5.3 lists the numbers of case and control samples, and the number of unique
genes in each study used for the meta-analysis.
5.6.1.4 Conduct meta-analysis
With pre-processed datasets described above, both the effect-size based and p-value
based meta-analysis method programmed in metaUnion were applied. Relevant statisti-
cal p-values were obtained by assuming a normal distribution with Bonferroni correction
for multiple testing to identify combined-study DEGs.
5.6.2 Meta-analysis Result
Meta-analysis was implemented on previously selected six studies containing 450 AD
and 212 healthy human brain tissue samples from the frontal cortex, summing up to
include 23530 unique genes shown in Table 5.3 . After Bonferroni correction, 3124
differentially expressed genes (DEGs) were identified (with 1358 up-regulated and 1766
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down-regulated). Only 3838 out of the 23530 genes (16.3%) appear in all six studies
(the common genes), among which only 918 (23.9%) were found to be DEGs. More
composition information of the 3124 DEGs is captured - 1582 (50.6%) genes were
found in five studies; 242 (7.7%) in four; 213 (6.8%) in three and 169 (5.4%) in two
studies. Obviously, if only common genes were to be investigated, most of the DEGs
(the top 30 of 3124 DEGs can be viewed in Table 5.4 would be neglected (See Figure 5.2
(a)). The results of an alternate p-value based meta-analysis approach with Bonferroni
correction also suggested similar results (see Table 5.5). 3315 DEGs were identified
by this approach, with 3123 overlapping with the effect-size approaches (representing
99.9% and 94.2% of the DEGs identified separately). Also, high level of overlapping
between DEGs identified by the effect-size approach and the p-value approach is shown
in Figure 5.2 (b). This indicates a good homogeneity between two approaches.
(a) (b)
Figure 5.2: DEGs distribution comparison from different sources and methods. (a) DEGs
identified from all and common genes (b) DEGs identified by effect-size and p-value
combination
Once the meta-analysis was conducted, ensuing result presentation can be done by
other functions in metaUnion. For instance, function sortMetaStat can sort the meta-
analysis result by specific metric assigned by the user, and then a table similar to what
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is presented in Table 5.4 can be generated where the top 30 DEGs are displayed. And
meta z-score QQ plot can be generated by function metaZscoreQQplot (See Figure 5.3)
Table 5.4: Top 30 DEGs identified by effect-size based approach
Symbol metaZscore metaPval effect significance metaPvalBonf
NEUROD6 -9.93 <2.22E-16 - - - - - - !#!!!# <2.22E-16
ZCCHC17 -8.91 <2.22E-16 - - - - - - !#!!!# <2.22E-16
PPEF1 -8.90 <2.22E-16 - - - - - - !#!!!# <2.22E-16
C1QA 8.77 <2.22E-16 ?+++++ ?#!!!# <2.22E-16
MANBAL -8.76 <2.22E-16 - - ?- - - ##?!!# <2.22E-16
BDNF -8.74 <2.22E-16 - - ?- - - !#?!!# <2.22E-16
CRH -8.73 <2.22E-16 - - ?- - - ##?!!# <2.22E-16
ITPKB 8.69 <2.22E-16 ++++++ !#!!!# <2.22E-16
FAM211A -8.68 <2.22E-16 - - ?- - - ##?!!# <2.22E-16
FKBP5 8.59 <2.22E-16 ++++++ ##!!!# <2.22E-16
PCYOX1L -8.58 <2.22E-16 - - - - - - !#!!!# <2.22E-16
MS4A6A 8.57 <2.22E-16 ++++++ ##!!!# <2.22E-16
DUSP4 -8.51 <2.22E-16 - - ?- - - !#?!!# <2.22E-16
TM7SF2 -8.49 <2.22E-16 - - ?- - - !#?!!# <2.22E-16
SEMA3F 8.47 <2.22E-16 ++++++ ##!!!# <2.22E-16
TRIP10 8.42 <2.22E-16 ++++++ !#!!!# <2.22E-16
LHFPL2 8.40 <2.22E-16 ++++++ ##!!!# <2.22E-16
NREP -8.40 <2.22E-16 - - - - - - !#!!!# <2.22E-16
ARF5 -8.35 <2.22E-16 - - - - - - !#!!!# <2.22E-16
ST6GAL2 -8.33 <2.22E-16 - - ?- - - ##?!!# <2.22E-16
GPCPD1 -8.31 <2.22E-16 - - ?- - - !#?!!# <2.22E-16
DOK3 8.30 <2.22E-16 ++?+++ ##?!!# <2.22E-16
Continued on next page
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Table 5.4 - - Continued from previous page
Symbol metaZscore metaPval effect significance metaPvalBonf
KCNF1 -8.30 <2.22E-16 - - - - - - !#!!!# <2.22E-16
NFKBIA 8.28 2.22E-16 ++?+++ !#?!!# 5.22E-12
ST8SIA5 -8.26 2.22E-16 - - ?- - - !#?!!# 5.22E-12
NUPR1 8.19 2.22E-16 ++++++ !#!!!# 5.22E-12
DPH2 -8.15 4.44E-16 - - ?- - - ##?!!# 1.04E-11
CCKBR -8.14 4.44E-16 - - - - - - !#!!!# 1.04E-11
LATS2 8.13 4.44E-16 ++?+++ !#?!!# 1.04E-11
HIST1H2BD 8.11 4.44E-16 ++++++ ##!!!# 1.04E-11
Note: ’-’, ’+’ and ’?’ in effect column represent down-regulated, up-regulated, and
missing in data. ’ !’, ’#’ and ’?’ in significance represent gene being significantly
differentially expressed, insignificantly differently expressed, and missing in data. The
smallest value displayed is 2.2E-16 and those smaller than the value are marked as
<2.2E-16.
Table 5.5: Top 30 DEGs identified by p-value based approach
Symbol metaZscore metaPval effect significance metaPvalBonf
NEUROD6 10.15 <2.22E-16 - - - - - - !#!!!# <2.22E-16
ZCCHC17 8.99 <2.22E-16 - - - - - - !#!!!# <2.22E-16
PPEF1 8.97 <2.22E-16 - - - - - - !#!!!# <2.22E-16
ITPKB -8.95 <2.22E-16 ++++++ !#!!!# <2.22E-16
BDNF 8.85 <2.22E-16 - - ?- - - !#?!!# <2.22E-16
MANBAL 8.85 <2.22E-16 - - ?- - - ##?!!# <2.22E-16
C1QA -8.85 <2.22E-16 ?+++++ ?#!!!# <2.22E-16
Continued on next page
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Table 5.5 - - Continued from previous page
Symbol metaZscore metaPval effect significance metaPvalBonf
CRH 8.82 <2.22E-16 - - ?- - - ##?!!# <2.22E-16
FAM211A 8.79 <2.22E-16 - - ?- - - ##?!!# <2.22E-16
FKBP5 -8.69 <2.22E-16 ++++++ ##!!!# <2.22E-16
PCYOX1L 8.68 <2.22E-16 - - - - - - !#!!!# <2.22E-16
MS4A6A -8.67 <2.22E-16 ++++++ ##!!!# <2.22E-16
TM7SF2 8.66 <2.22E-16 - - ?- - - !#?!!# <2.22E-16
DUSP4 8.62 <2.22E-16 - - ?- - - !#?!!# <2.22E-16
SEMA3F -8.59 <2.22E-16 ++++++ ##!!!# <2.22E-16
ARF5 8.54 <2.22E-16 - - - - - - !#!!!# <2.22E-16
LHFPL2 -8.49 <2.22E-16 ++++++ ##!!!# <2.22E-16
TRIP10 -8.48 <2.22E-16 ++++++ !#!!!# <2.22E-16
NREP 8.47 <2.22E-16 - - - - - - !#!!!# <2.22E-16
GPCPD1 8.44 <2.22E-16 - - ?- - - !#?!!# <2.22E-16
ST6GAL2 8.42 <2.22E-16 - - ?- - - ##?!!# <2.22E-16
NFKBIA -8.42 <2.22E-16 ++?+++ !#?!!# <2.22E-16
DOK3 -8.40 <2.22E-16 ++?+++ ##?!!# <2.22E-16
NUPR1 -8.39 <2.22E-16 ++++++ !#!!!# <2.22E-16
KCNF1 8.39 <2.22E-16 - - - - - - !#!!!# <2.22E-16
ST8SIA5 8.37 <2.22E-16 - - ?- - - !#?!!# <2.22E-16
LATS2 -8.33 <2.22E-16 ++?+++ !#?!!# <2.22E-16
GSG1 8.23 2.22E-16 ???- - - ???!!# 5.22E-12
DPH2 8.23 2.22E-16 - - ?- - - ##?!!# 5.22E-12
HSPB3 8.20 2.22E-16 -?- - - - !?!!!# 5.22E-12
Note: ’-’, ’+’ and ’?’ in effect column represent down-regulated, up-regulated, and
missing in data. ’ !’, ’#’ and ’?’ in significance represent gene being significantly
differentially expressed, insignificantly differently expressed, and missing in data. The
smallest value displayed is 2.2E-16 and those smaller than the value are marked as
<2.2E-16. 165
Figure 5.3: Normal Q-Q plot for the meta-analysis. Source: [265] Q-Q plot of the
metaZscore calculated for those 3838 common genes across six studies (a); and those
missing in at least one study (b); all 23530 genes (c). The distributions are approximated
to normal distribution with two fat tails. Clearly the normality of the overall metaZscore
is improved by merging data from those incompleted genes (missed in at least one study)
to common genes. metaZscore of sample-size weighted P-value combined meta-analysis
has similar normality (d).
5.6.3 Discussion
Both effect size and p-value combination aim to generate conclusions that summarize
results from different studies. They differ from each other by how new hypothesis is
constructed. Effect size combination reconstruct the null hypothesis by establishing a
model which contains withiin-study and between-study variance, while p-value combina-
tion estimate a t-statistic by reverting p-values from each study and then aggregating
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them. No logical impropriety exists in any of the two approach, and their linkage to the
biological reality still needs to be investigated and clarified.
There are some limitation of metaUnion. No moderator analysis, publication bias
and sensitivity analysis provided, as well as the lack of consideration in different types
of effect sizes such as dependent effects, fixed effect and random effects. Also, there is
no consideration about how to eliminate duplication of gene records, which at this stage
has to be treated by the user before the processing by the main meta-anlaysis function.
5.7 Summary
In this chapter, the design, development and validation of novel R meta-analytic package
metaUnion is described. Specifically aiming to compensate the defects found in similar
predecessor packages in meta-analysis, metaUnion addresses the several issues which had
been neglected in aspects such as missing data treatment and the fixed feature dimension
requirement. metaUnion also provides additional functions for users to conduct post-
calculation analysis easily. The validation of metaUnion reveals that it is a powerful R
package with notable advantages can be summarised as follows:
 metaUnion can retain a maximum number of genes to be included in the analysis,
thus a large proportion of DEGs that do not commonly probed across all the studies
are not neglected - more than 70% in the validation test.
 metaUnion provides useful functions for downstream analysis once the major meta-
analysis is completed. It provides the functions to sort the result table by specific
measurement and to plot Q-Q plot.
In conclusion, metaUnion has advanced features compared to other existing meta-
analytic R packages and is likely to gain popularity in conducting meta-analysis in mi-
croarray studies in the future.
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Chapter 6
AlzExpress: an advanced biomarker
database with meta-analysis for
dementia
6.1 Abstract
This chapter describes the development of AlzExpress - a database to provide neuro-
degenerative disease association references for molecules in the interest of the researchers
and users. AlzExpress offers the functionality of query on biomolecule, such as RNA, pro-
tein, and provides reference for researchers to identify differentially expressed molecules
(DEM) in different categories of samples, with high statistically significance. It also
provides meta-analysis to combine statistics from separate studies in order to general-
ize the conclusions made the and improve the reliability. It is the first system with a
web-based interface to integrate DEM analysis and meta-analysis, in additional to some
dataset meta-information and overlapping DEMs between different categories of studies.
By virtue of the fashionable NoSQL technology for data management, the system shows




The advent of high throughput microarray data has provided an effective method to
search targets for drug discovery and diagnostics, and also explosively increases the
volume of information for researchers in life science. Dementia and neurodegenerative
disease studies are one of the beneficiaries of it, especially Alzheimer’s disease (AD)
studies, as it is one of the most challenging modern medical topics. The prosperity of
data allows researchers to integrate the experimental data, analyse according to different
study purposes and eventually develop into data-driven web servers/software founded on
the basis of systematically designed databases.
6.2.1 Existing databases relating to AD research
With the booming wealth of information about putative AD susceptibility genes, it
was increasingly difficult for researchers to follow and interpret the updates of genetic
association studies about the disease. In 2007, Bertram et al [310] created a publicly
available and persistently updated database AlzGene (http://www.alzgene.org), for
the purpose of cataloguing all the genetic association studies in the field of AD. A
comprehensive meta-analyses was conducted for polymorphisms existing in at least three
case-control samples. Apart from the well-established association between ε4 allele of
APOE, a dozen of potential AD susceptible genes were identified (ACE, CHRNB2, CST3,
ESR1, GAPDHS, IDE, MTHFR, NCSTN, PRNP, PSEN1, TF, TFAM and TNF).
In 2014, Bai et al [311] initialized a database AlzBase (http://alz.big.ac.cn/
alzBase) integrating several categories of information about AD from multiple sources,
where elucidating the evolution of molecular pathway in AD is the main focus. Plenty
of information is enclosed
 Gene dysregulation in AD and closely associated processes and diseases such as
aging and neurological disorders
 Correlation between gene dysregulation and AD progression
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 Plentiful annotations on the functional and regulatory information
 Gene-wise network relationship. A comprehensive summary for the top ranked
genes is also provide in AlzBase
AlzBase allows researchers to prioritize genes from their own study and propose novel
hypothesis in terms of the molecular mechanism of AD.
6.2.2 Specialties of AlzExpress
6.2.2.1 NoSQL database
The selection of NoSQL database as data storage and retrieval model has granted large
scalability to the platform. Among the NoSQL family databases, MongoDB is selected as
the central database underneath, because it owns good quality like being open-source,
document-oriented and schema-free. The indexing and load balancing capability of
MongoDB enables the platform to run fast and efficiently, meanwhile allowing ad hoc
queries makes the development and structure design easy and flexible. Different from
tabular relational databases, NoSQL databases utilize a weaker concurrency model than
most relational (SQL) database systems. The ability to dynamically add new attributes
to data records empower great flexibility to NoSQL database. In a practical sense, if a
new attribute, for example education, is to be added in some of the samples in a dataset,
the update will be a simple operation which otherwise will cause huge change of schemas
in relational SQL. This characteristic makes AlzExpress very adaptive to future changes
such as attribute addition of samples, new linkage between datasets, etc.
6.2.2.2 Meta-analysis on expression profiles
To the best of our knowledge, previous databases relating to AD do not cover statistical
support of meta-analysis from the array profiling perspective. As described in the section
6.2, AlzGene specifies in revealing genetic association of AD via polymorphisms; AlzBase
addresses on the pathways and functional annotations, meanwhile including differential
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expression analysis but no meta-analysis is applied. AlzExpress include not only differ-
ential expression analysis but also meta-analytic results across all studies collected. The
process of meta-analysis is conducted with the intrinsic method of R package metaUnion
described in chapter 5. The inclusion of meta-analysis generalises the analysis output
from various studies and thus generating more unbiased and reliable conclusions.
6.2.2.3 Resilience in comparison selection and cross-talking
Another huge scalability of AlzExpress stems from the capacity to include DEM/meta-
analytic results from numerous comparisons. The meaning of diversity of comparisons
is multi-fold. First, though it is completely AD-focused at this stage, more datasets can
be easily imported into the database and ensuing analysis can be executed. Datasets of
diseases like Parkinson’s disease, other types of dementia or neurodegenerative diseases
are able to be enclosed. Second, different variables of samples like brain regions or
MMSE scores are included, so the comparisons can be made between different states
of these variables. These variances result in a diversified comparisons that AlzExpress
can provide. Given such an advantage, cross-talking of DEMs identified by different
groups/diseases can be conducted and very meaningful results can be obtained, such as
the DEM overlapping analysis.
6.2.3 Application summary
AlzExpress provides the functionality of query on biomolecule, such as mRNA, protein,
and provides reference for researchers in this field to identify differentially expressed
molecules in different categories of samples, with high statistically significance. It also
provides meta-analysis for separate results across different studies, which help take vary-
ing statistical power from different studies into consideration. Meta-analysis serves to
generalize and improve statistical reliability for each queried feature. AlzExpress adopts R
package metaUnion (https://github.com/chingtoe365/metaUnion) which was de-
veloped in 2015 to conduct meta-analysis. This package has been imployed to identify
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several major pathways and upstream regulators in AD [265].
6.3 System implementation
6.3.1 Data structure
The database side of AlzExpress is structured in a NoSQL convention and programmed
in MongoDB. It is composed of four database for different use – sample database,
annotation database, individual group test statistics database and meta-analysis statistics
database. The detailed design of the database cluster is demonstrated in Figure 6.1
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Figure 6.1: Data structure of AlzExpress. AlzExpress comprises four main databases
depending of functionality: sample, annotation, separate test statistics and meta-analysis
statistics.
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The sample database consists of a number of collections with each representing a
dataset for a single study. Each dataset then consists of a number of documents, each
created for a sample with sample information such as age, gender, disease state, etc.
The annotation database consists of two collections which are separately for mRNA
and protein. The mRNA collection is composed of thousands of documents with each
representing an mRNA with unique Entrez Gene ID. Every document contains the official
gene symbols and probe IDs which the particular mRNA corresponds to across different
platforms. The protein collection is composed in a similar way except Uniprot ID is
adopted as the identifier of each protein.
The individual group test statistics database and meta-analysis statistics database
locates the group comparison statistics for each probe between different disease states.
It includes fold change, hypothesis test z-score and p-value from either individual or
multiple studies, adjusted p-value, and regulation status across different studies (for
meta-analysis database). To facilitate the mediated data processing, two documents are
specially designed to be the parameter check-book for each collection in test statistics
database. One is designed for easy acquisition of sample count, and the other is designed
for easy acquisition of disease state of each sample (see Figure 6.1).
6.3.2 Data processing and analytical methods
Figure 6.2 shows the detailed data processing and analysis pipeline. All of the sample data
are stored in the sample database and are downloaded from GEO by GEOquery package
in R [312], except a study with GEO series GSE15222 which are downloaded from the
website of the experiment organisation – Myer’s lab. Meta-data of each sample including
age, gender, disease state (case or control), brain region where the sample locates (only
for samples collected from brain) are extracted. We follow pre-designed prototype (see
Table 6.1) to abbreviate the brain regions. Assay data are also extracted to an array of
expression value for a specific sample, the order of which corresponds to another array
for probe IDs.
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Figure 6.2: Data preprocessing and analysis pipeline of AlzExpress. The procedure
can be summarized as a) raw sample and annotation data preprocessed and imported
in JSON format b) separate tests are conducted for different datasets, with annotation
assigning UIDs (entrez gene ID) across datasets c) conduct meta-analysis based on UIDs
for specific groups
We adopted the expression data that the previous researchers had processed with
certain kinds of pre-processing methods, but we made sure that the expression values
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across all studies are logarithm transformed by two. For example, the values of GSE36980
are RMA normalized, wherein a logarithm transformation by two is performed, therefore
we adopted the original data and import into our database. The values of GSE44772 are
logarithm transformed by 10, so we transform it by exponentiation based by 10, after
which a logarithm transformation by two is then performed, details in Table 6.1.
Individual group DEG tests are conducted across different categorical groups for each
study. In each study, only samples from a particular category (eg. In region PFC) are
selected. Then both limma moderated t-test and student t-test are conducted to identify
DEMs. Their respective z-scores and p-values are recorded in the individual group test
statistics database. Meta-analysis is conducted across various categorical groups. In each
group (eg. region PFC), R package metaUnion is employed to perform meta-analysis by
combining p-values for each feature from different studies. And p-values are adjusted by
both BH and Bonforroni correction, with both common and union features numbers.
6.3.3 User interface
6.3.3.1 Functionality summary
Query function for specific genes are offered by AlzExpress, and individual test statistics
and meta-analysis results for those genes of interest are displayed. Genes are annotated
by NCBI and linked with STRING database. AlzExpress also provides investigation of
common differentially expressed biomoleculars across different categories. Also AlzEx-
press provides various visualization plots for researchers, such as volcano plots, heatmap
and bar-charts. All tables can be downloaded as CSV files.
6.3.3.2 Sample information overview
The summary section (shown in figure 6.3) provides an overview of meta data of datasets
collected in the database. A summary of datasets offers information for users to decide
what comparisons are able to be carried out from the platform. At this stage, the data
types of datasets include RNA, protein and RNAseq, and the tissues from which the
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Table 6.1: Summary of loaded datasets in AlzExpress




GSE33000 brain RNA Frontal cortex to ”PFC”; 10
to expression value and then
log two transformed
GSE48350 brain RNA Postcentral gyrus to
”POCG”; 10 to expres-
sion value and then log two
transformed
GSE15222 brain RNA parietal lobe to ”Postcentral
gyrus”; both expression and
covariate data from myers lab
GSE13214 brain RNA pathologic & defenitive
Alzheimer are both classed as
AD; use replicate 2, remove
probes with all null values
(234 probes)
GSE84890 brain RNA
GSE29378 brain RNA GPL6947 used but GPL10558
is the latest version so use lat-
ter
GSE63063 blood RNA GPL6947 used but GPL10558
is the latest version so use lat-
ter
GSE39087 blood protein NCBI reference sequence are
used as unique identifiers in
protein studies
GSE53697 brain RNAseq No probe ids so use symbols
directly; use log 2 rpkm value
as expression value; filter du-
plicate feature with largest
foldchange
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data is extracted include brain and blood.
6.3.3.3 Dataset meta information and analysis summary
The entire section is to provide information as per dataset basis.
Meta information
This section presents meta information breakdown for each dataset. In this section, pie
charts are plotted to provide these information (see figure 6.4). Moreover, a volcano
plot is also provided for a quick overview of the DEM analysis result for a particular
group that the user is interested in. It helps identify molecules with high likelihood to
be DEMs. If more than one regions exist in a dataset, a region input is required to
bootstrap the volcano plot.
Volcano plot and DEM analysis result collection
A volcano plot binds the view of distribution of p-values and fold change together into
one graph, such that those molecules that are likely to be DEMs can be identified easily.
Figure 6.5 is an example of this section, red points in the plot represent those molecules
with,
 Absolute fold change larger than 1.5
 limma p-value less than 0.05
From this statistic point of view, these molecules are assumed to be highly associated
with the onset of the disease, since the fact is supported by both fold change and limma
p-value.
At the bottom, a csv file download handler is also provided for the user to download
the statistics into a csv file format for all the molecules. This is for the purpose of further
analysis carried out based on the statistics calculated.
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6.3.3.4 Molecule based and sample filtered query
In this section, Alzexpress provides querying functions for the users on the molecule they
are interested in (shown in Figure 6.6).
The sample filter is very important before conducting queries to answer questions or
various hypothesis proposed by the users. The purpose of the filter is to control variables
so that only samples complying the required criteria remains. After applying the filter,
only the value of two variables - disease status and molecules - varies across all selected
samples. Therefore, the relationship between the expression of molecules and the disease
status can be revealed by unbias results obtained from Alzexpress database.
There are four main variables that are needed to be constrained
 Data type where there are three options at this stage - RNA, protein and RNAseq.
RNA stands for the expression profiling array data of transcripts, protein stands
for protein profiling by protein array, RNAseq stands for expression profiling of
transcripts by high throughput sequencing. This field is extendable and more data
type is to be included such as DNA methylation, microRNA, etc.
 Tissue from which the data is extracted is required specified. There are two
options at this stage - brain and blood.
 The third variable defines more detailed filters for the samples, where this filter can
further refine the samples by only selecting those meeting the category. At this
stage, only region as a category type is available and it will only be active with
”brain” as ”tissue” being selected, because samples extracted from blood will not
have region as a property obviously. And for the region category type, there are
11 values available - PFC, HIP, etc. (listed in Table 6.2). This field is extendable
and more category will be included such as MMSE score, ethnicity, etc.
 Comparison is the last variable required to be specified. At this stage, only the
comparison of AD versus Control is available. This field is extendable and more
disease status comparisons can be included in the future.
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Table 6.2: Required fields for the query form and their available options. Check Chapter
for abbreviations
Fields Options
Data Type RNA, protein, RNAseq
Tissue Brain, blood
Category Region
Category Value of region PFC, HIP, EC, CE,,SFG, PC, VI, TE,
MTG, PVC, TC, ALL
Comparison AD-vs-Control
Duplicate removal method Largest fold change
Table 6.2 shows detailed options for each field.
After required fields are filled, query can be submitted and an example result is shown
in figure 6.7. The tabs above the table display all the datasets where there are at least
one queried molecule found. In the example, there are four datasets found. For each
dataset, a table is appended, displaying the analysis results for each molecule. Useful
statistics including fold change, z-score and p-value calculated with normal student t-test
or limma moderated t-test respectively.
Additional annotation for each molecule is also provided, with the entries to external
sources of databases such as NCBI and STRING. It also provides an entry to the meta-
analysis result section which will be discussed in the next section.
6.3.3.5 Meta-analysis in AlzExpress
The meta-analysis result is calculated by combining the results from previous section.
The table on the top (see Figure 6.8) lists the following statistics
 meta z-score the z-score re-calculated by meta-analysis
 meta p-value the p-value re-calculated by meta-analysis
 BH adjusted p-values for union molecules
 BH adjusted p-values for commonly shared molecules respectively
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 Bonferroni adjusted p-values for union molecules
 Bonferroni adjusted p-values for commonly shared molecules
 Significance describes whether the particular molecule is significantly differen-
tially expressed across all the datasets, with ”!”, ”#” and ”?” representing being
significant, not significant and missing
 Effect indicate the direction of molecule regulation, with ”+”, ”-” and ”?” rep-
resenting up-regulated, down-regulated and missing
A table displaying the top 10 molecules with least meta p-values is also generated.
Two tables are specially separated to address the different dimensional contexts in which
the p-values were adjusted. One table is displaying the statistics calculated in the context
of union molecules, where molecules appearing at least in one dataset will be included
in the p-value adjustment process. In compared to this, another table is in the context
of overlapping molecules, where molecules appearing in all datasets will be included in
the p-value adjustment process.
The bottom table describes meta information for that particular meta-analysis. Sam-
ple count, AD sample count, control sample count and feature for each dataset are all in
list. Union feature countis the number of molecules appearing at least in one dataset,
whereas Intersect feature count is the number of molecules appearing in all datasets.
6.3.3.6 Common DEMs study
Alzexpress also provide a section for users to identify overlapping DEMs identified from
different sample groups/categories. In this section, users are able to choose whatever
sample groups they are interested in.
Suppose both ”Protein-blood” and ”RNA-PFC” are selected (see figure 6.9), the
result will be the overlapping DEMs identified by the two groups. The statistics displayed
in the table can have two sources. If the sample group selected only contains one dataset,
the statistics display for that group is limma p-value calculated with that single dataset.
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Otherwise, if the sample group contains more than one dataset, it is the Bonferroni
corrected meta p-value. Molecules are identified as DEMs if this value is less than 0.05.
In addition, there are cases when the selected groups do not share the same data
type, for example, one is in type ”protein” and the other two are in type ”RNA”. In
those situations, gene name will always act as the bridge between two different types. For
example, protein ”Apolipoprotein E” will be interchangeable to RNA with gene symbol
”APOE”, so that the overlapping calculation can proceed.
The graph at the bottom indicates the accountability of DEM identified and the
unique molecules in each sample group.
6.4 Limitation
AlzExpress is designed as a reference warehouse for AD reserchers, focusing on converting
past experiment results into conclusive statistics. There are a couple of limitations:
 Some visualization targets were not achieved, such as the idea of a heatmap
indicating the full range of probes involved in a particular study, due to the built-
in limitation of hardware performance from the perspective of users. An over-
complicated figure should overload most of the browers on normal computers.
 A feasible prototype for data pre-processing has not yet been developed for all the
other data types apart from microarray data, the data type which has been majorly
accommodated by the platform. Therefore, the automation of pre-processing is
still in very low level and the population of datasets needs to be supervised.
6.5 Summary
The invention of AlzExpress provides researchers with a powerful tool to obtain statistical
support to test and verify hypothesis in interest. The result of DEM analysis and meta-
analysis from different categorical groups for molecules in interest can be acquired easily
via AlzExpress. It also provides useful graphs such as volcano plots and pie charts for
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visualization of meta data, as well as convenient export of results via CSV files. Apart
from the microarray data being focused on at current stage, the scalability enables more
different types of measurements such as DNA methylation and sequencing data to be
imported, processed and analysed in the future. AlzExpress is an ideal warehouse for
high-throughput biostatistics in dementia research.
The future plans include importing and analysing samples with additional conditions
such as mild cognitive impairment and Parkinson’s disease in the future, and also aim
to analyse micro-RNA and DNA methylation microarray data to reveal a more complete




























































































































































































































The main contributions can be summarized in the following list
1. We discovered that the inclusion of age and APOE genotyping into the predic-
tion model can improve classifiers performance. A panel of 26 RNA transcripts
was discovered that has promising classification ability between AD patients and
healthy controls.
2. Three models (ECH1+NHLRC2, ECH1+HOXB7, ERBB2+FN1+SLC6A13) were
discovered in blood which were identified to have good diagnostic ability. A surpris-
ing and novel statistical pattern was recognised which shed light on the existence
of new pQTL for AD. Two novel SVM-based feature selection methods were pro-
posed to select significant serum proteins with or without the constraint of feature
pool. The result of the study was published in 2016 [240]
3. We developed an R package metaUnion, an advanced meta-analytic approach ap-
plicable for microarray data. This package is designed to overcome the defects
appear in other similar meta-analytic packages, such as the neglection of missing
data, the inflexibility of feature dimension, and the lack of functions to support
post-analysis summary. metaUnion has been applied in a study to identify differ-
entially expressed genes as part of the integrated genomic approaches. Genes like
NEUROD6, ZCCHC17, PPEF1 and MANBAL were identified to be potentially
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implicated in LOAD. The result of the study was published in 2015 [265].
4. A database to provide neuro-degenerative disease association references for molecules
- AlzExpress - was developed. AlzExpress offers the functionality of query on
biomolecule, such as RNA, protein, and provides reference for researchers to iden-
tify differentially expressed molecules (DEM) in different categories of samples,
with high statistically significance. It also provides meta-analysis to combine
statistics from separate studies in order to generalize the conclusions made the
and improve the reliability. It is the first system with a web-based interface to
integrate DEM analysis and meta-analysis, in additional to some dataset meta-
information and overlapping DEMs between different categories of studies. By
virtue of the fashionable NoSQL technology for data management, the system
shows high scalability and compatibility to include various types of molecular data
and different experiment designs.
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Chapter 8
Conclusions and future work
8.1 Summary
The possibility to accurately and convincingly diagnose Alzheimer’s disease (AD) in its
earliest stages has gained public health attention and priority resulting from the growing
prevalence of AD. The ability to diagnose early stage of AD is instantly important. Over
the past decade, many machine learning and pattern classification methods have been
used for early diagnosis of AD and MCI based on different modalities of biomarkers.
With the advent of high throughput biomolecule detection technologies, such as next
generation sequencing and microarray, and neuroimaging technique like MRI and PET,
diverse means of diagnosis have been provided for the potential biomarker discovery.
My investigation of AD biomarkers started with looking into transcriptomic biomarker
in brain and also studying the impacts of covariates, such as age, to the performances
of AD classifiers. The result shows that the inclusion of age and APOE genotyping
into the prediction model could enhance the performance of classifiers by around 8% in
both training and testing. I have also discovered a panel of 26 RNA transcripts that
has promising classification ability between AD patients and healthy controls, with the
performance of over 90% training accuracy and over 85% testing accuracy. A random
forest backward elimination is adopted as the major feature selection method, with the
assist of a recursive cross validation process and weighted accuracy of training and
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testing. The panel of transcripts turns out to be enriched in SNP, underpinned by
more risky p-values compared to SNPs around randomly selected genes. Though brain
biomarker may not have great potential in clinic diagnostic pratice, it offers great clues
for understanding AD pathology, which if well exploited, can also be a good starting
point for the discovery of new biomarkers in other tissue, such as blood.
The aim to discover non-invasive biomarker drove my interest into the blood-based
AD biomarkers. A comprehensive literature review is carried out to gain existing bio-
logical knowledge of potential AD biomarkers with which a knowledge feature pool is
constructed. A feature pool comprising of numerous AD related biomarkers was es-
tablished which we used to select several panels of biomarkers. Two novel SVM-based
feature selection methods were designed and deployed to select panels of serum features.
With the selected panels of serum, several classifiers were trained by SVM from training
dataset and then their performances were evaluated. After validation, we found that
a panel of only two or three proteins gave us good diagnostic ability, with two of the
three models estimated to have over 90% sensitivity and specificity. Beside, a novel
statistical pattern was also recognised, separating case and normal with upper and lower
boundaries. However, the reproducibility of these findings needs to be further validated
in larger cohorts.
With the advent of novel high throughput technology and chronic accumulation
of microarray based biological studies, meta-analysis is becoming more important in
biomarker discovery. Nonetheless, after assessing the current meta-analytic R packages,
many defects are discovered when being used in practice. First, current R packages
cannot handle data from different studies with different dimensions which reduces the
power of meta-analysis because of reduced sample size. Second, the presence of null
values in the input data is ignored by directly omitting cases with missing values in these
packages, which bias the true result of meta-analysis. Third, a lack of functions for
users to conduct post-calculation analysis were commonly found in previous packages.
To improve the usability and practicability of meta-analysis for bioinformatics research,
a new meta-analysis package metaUnion was developed to fix the existing deficiencies
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of current packages. It is able, first, to handle data from different studies with different
dimensions; second, to rectify the number according to the number of missing value in the
input; last, to provide the result of p-values, z-scores and effect sign for each gene. The
validation of metaUnion reveals that it is a powerful R package with notable advantages.
metaUnion can retain a maximum number of genes to be included in the analysis, thus
a large proportion of DEGs that do not commonly probed across all the studies are not
neglected - more than 70% in the validation test. metaUnion provides useful functions
for downstream analysis once the major meta-analysis process is completed. It provides
the functions to sort the result table by specific measurement and to plot Q-Q plot. In
conclusion, metaUnion has advanced features compared to other existing meta-analytic
R packages and is likely to gain popularity in conducting meta-analysis in microarray
studies in the future.
As the project proceed further, a growing need of managing and integrating exper-
iment data arises. Warehousing the data to make an efficient and fluent translation of
data into solid results become increasingly a big concern. With the outstanding urge of
this, the idea of developing a database to provide neuro-degenerative disease association
references for molecules emerged. And AlzExpress, a NoSQL backed web-based platform
is the answer. AlzExpress allows users to make queries on a biomolecule level, such as
RNA, protein, and delivers reference with high statistically confidence for researchers to
identify DEM in different categories of samples. Meta-analysis is embedded to combine
statistics from separate studies so that the conclusions can be generalised. As the first
system with a web-based interface to integrate DEM analysis and meta-analysis, it is
also equipped with some dataset meta-information and functionalities like overlapping
DEMs checking between different categories of studies. In support from the popular
NoSQL database MongoDB, the system shows high scalability and excellent capability
to extend its usage in the future.
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8.2 Limitations
In general, the limitations of our studies includes the following,
 The investigation and search of biomarkers did not cnsider the cellular heterogene-
ity in AD. Therefore, the possibility that the different cellular types are contributing
to the classifying performances of all models proposed cannot be eliminated.
 Only AD samples are included throughout all studies, but samples of other types of
dementia are not included, such as MCI or Parkinson’s disease (PD) samples. Since
some individuals can have mixed dementia, so the complexity has not been excluded
and properly explained. Also, this will obviously prevent the study from progressing
further onto investigations on other types of dementia, and the potential of cross
referencing between biomarkers from different types of disease in dementia will be
wasted.
 In general, the model assessment logic in every study weighs more on evaluating
the classifying ability of features themselves, while less on evaluating that of the
predictive models. So the performances metrics reported are actually indicators of
how good the selected features are on average, which in return will mislead the
system to choose a good model but not the best one.
 Different datasets are used in different studies, so there is a lack of continuity and
adherence for the results across studies.
8.3 Future work
Correlation based feature selection algorithms Although there are various kinds
of feature selection methods that show promising performance in specific microarray
datasets, almost all of the previous methods used in my past work have only considered
the classifying or separating ability for a single feature, which leads to the fact that these
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feature selection methods would only select features that are performing well on its own.
However, human being is an entity in which genes or proteins are cooperating to maintain
the biological function. Different types of relationships between genes, such as co-
expression, regulation (either positive or negative), antagonism. . . , can indicate different
physical condition an organism is in and thus can imply certain disease status. Therefore,
the information from specific feature combination should be taken into account as an
important signal during the process of feature selection. Unfortunately, most of the
current feature selection methods did not include this aspect into their methodology. As
a result, a feature selection method that can identify the feature set in combination with
best classifying ability will be of great interest to researchers in biomarker discovery from
a statistical learning perspective. Instead of identifying only those features that perform
well separately, these algorithms will be comparatively more robust and more generalized
findings that can be explained in a biological sense.
DNA methylation biomarkers Recently, the link between methylomic variation and
AD has been studied. A number of genes were identified as potentially associated with
LOAD [313], and some methylated regions in particular genes, such as ANK1 [314], also
manifest association with neuropathology. In the light of exploring more biological truth
in this aspect, we plan to investigate the probability of DNA methylomic variation as
potential biomarkers for AD diagnosis. We are going to employ robust and effective
feature selection and machine learning methods to current DNA methylation datasets,
in the hope of discovering some loci which are meaningful with classifying ability and
can be further used as diagnostic biomarker for AD.
Extension of AlzExpress AlzExpress provides a scalable web-based platform for the
integrative gene-specific analysis for the investigation of dementia biomarkers from an
expression level perspective. However, the potential of this platform is not yet fully
exploited. For the next stage of work, Scaling up the database with more experiment
data of more diseases from various sources will be of great research value. The high
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scalability and schema-free nature of NoSQL database empower the platform with the
potential to include other studies with different objectives diseases, such as Parkinson’s
disease or other types of dementia. Moreover, additional measurements or data type from
a variety of scientific instruments can be encompassed into the platform, such as data
of RNA sequencing, DNA methylation, microRNA expression, etc. The participation of
these subjects will not only enrich the diversity of database, but also envision a good
future of cross referencing and comparison of findings between different diseases and
different types of biomolecules.
Graphene biosensors for AD diagnosis From the perspective of developing practical
AD diagnostic instruments, new material will come on stage with the aim of bringing
excitement. Graphene biosensors exploit the promising physical, chemical and electronic
properties of the atomic-thick 2-dimentional material to develop a new generation of
label-free biosensors and sensor arrays with unprecedented sensitivities [315], which can
be used for the detection of the abnormal proteins/biomolecules of AD noninvasively
and at lower levels of concentrations than existing methods such as ELISA. In the past
several years, numerous improvement and breakthrough were made in graphene biosen-
sors research, and the engineering group from project BBDiag (Blood Biomarker-based
Diagnostic Tools for Early-stage Alzheimer’s Disease) in Plymouth University has been
largely contributing to the remarks. Outstanding breakthrough was made in progressing
graphene label-free biosensors from this group [316–318]. In the light of these biosen-
sors with high sensitivity, an AD diagnostic system combining this sensor with multiple
significant biomarkers from transcript array, protein array and methylation array data is
pragmatically more possible. The application of the potential multi-biomarkers to design
biosensor matrix integrating with other diagnostic methods such as MRI image and EEG
signal of objects, will further accelerate the realization of AD prognosis and diagnosis.
Academic institutions, the pharmaceutical industry and regulatory organizations all
agree that biomarkers have an important role in the drug development process. Through-
out my PhD the discovery of AD biomarkers by specifically statistical learning approaches
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has been the main focus. Biomarkers have several potential uses in clinical trials. These
include their use as diagnostic aids to enrich the patient sample with cases of AD; as
tools to identify and monitor the biochemical effect of the drug candidate; and as safety
markers to detect potential side effects of the drug. We followed strictly two directions
during the course of the entire research - biomarker driven studies and software driven
studies. Therefore, on one hand, novel findings were discovered in both RNA and blood
as tissue. On the other hand, fashionable software packages and platform were developed
to suit the need of future researchers in this field. We believe by the collaborative work
from different generations, the mystery of AD will finally be unveiled and a practical
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C. Berr, F. Pasquier, N. Fiévet, P. Barberger-Gateau, S. Engelborghs, P. D.
Deyn, I. Mateo, A. Franck, S. Helisalmi, E. Porcellini, O. Hanon, M. M.
de Pancorbo, C. Lendon, C. Dufouil, C. Jaillard, T. Leveillard, V. Alvarez,
P. Bosco, M. Mancuso, F. Panza, B. Nacmias, P. Bossù, P. Piccardi,
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[259] Å. Sandelius, H. Zetterberg, K. Blennow, R. Adiutori, A. Malaspina, M. Laura,
M. M. Reilly, and A. M. Rossor, “Plasma neurofilament light chain concentration
in the inherited peripheral neuropathies,” Neurology, vol. 90, no. 6, pp. e518–e524,
2018.
[260] N. Mattsson, H. Zetterberg, S. Janelidze, P. S. Insel, U. Andreasson, E. Stomrud,
S. Palmqvist, D. Baker, C. A. T. Hehir, A. Jeromin et al., “Plasma tau in alzheimer
disease,” Neurology, vol. 87, no. 17, pp. 1827–1835, 2016.
[261] E. Nagele, M. Han, C. DeMarshall, B. Belinka, and R. Nagele, “Diagnosis of
alzheimer’s disease based on disease-specific autoantibody profiles in human sera,”
PloS one, vol. 6, no. 8, p. e23112, 2011.
[262] E. P. Nagele, M. Han, N. K. Acharya, C. DeMarshall, M. C. Kosciuk, and R. G.
Nagele, “Natural igg autoantibodies are abundant and ubiquitous in human sera,
and their number is influenced by age, gender, and disease,” PLoS One, vol. 8,
no. 4, p. e60726, 2013.
[263] W. S. Liang, E. M. Reiman, J. Valla, T. Dunckley, T. G. Beach, A. Grover, T. L.
Niedzielko, L. E. Schneider, D. Mastroeni, R. Caselli et al., “Alzheimer’s disease
is associated with reduced expression of energy metabolism genes in posterior
cingulate neurons,” Proceedings of the National Academy of Sciences, vol. 105,
no. 11, pp. 4441–4446, 2008.
[264] W. N. Venables and B. D. Ripley, Modern Applied Statistics with S,
4th ed. New York: Springer, 2002, iSBN 0-387-95457-0. [Online]. Available:
http://www.stats.ox.ac.uk/pub/MASS4
234
[265] X. Li, J. Long, T. He, R. Belshaw, and J. Scott, “Integrated genomic approaches
identify major pathways and upstream regulators in late onset alzheimer’s disease,”
Scientific reports, vol. 5, 2015.
[266] D. Meyer, E. Dimitriadou, K. Hornik, A. Weingessel, and F. Leisch, e1071:
Misc Functions of the Department of Statistics, Probability Theory Group
(Formerly: E1071), TU Wien, 2017, r package version 1.6-8. [Online]. Available:
https://CRAN.R-project.org/package=e1071
[267] R. H. Fletcher, S. W. Fletcher, and G. S. Fletcher, Clinical epidemiology: the
essentials. Lippincott Williams & Wilkins, 2012.
[268] X. Robin, N. Turck, A. Hainard, N. Tiberti, F. Lisacek, J.-C. Sanchez, and
M. Müller, “proc: an open-source package for r and s+ to analyze and compare
roc curves,” BMC Bioinformatics, vol. 12, p. 77, 2011.
[269] T. F. S. Inc, ProtoArray Prospector v5.2.3, 2015.
[270] U. A. Khan, L. Liu, F. A. Provenzano, D. E. Berman, C. P. Profaci, R. Sloan,
R. Mayeux, K. E. Duff, and S. A. Small, “Molecular drivers and cortical spread
of lateral entorhinal cortex dysfunction in preclinical alzheimer’s disease,” Nature
neuroscience, vol. 17, no. 2, p. 304, 2014.
[271] M. Gleichmann, Y. Zhang, W. H. Wood, K. G. Becker, M. R. Mughal, M. J.
Pazin, H. van Praag, T. Kobilo, A. B. Zonderman, J. C. Troncoso et al., “Molec-
ular changes in brain aging and alzheimer’s disease are mirrored in experimentally
silenced cortical neuron networks,” Neurobiology of aging, vol. 33, no. 1, pp.
205–e1, 2012.
[272] W. Wagner, S. Bork, P. Horn, D. Krunic, T. Walenda, A. Diehlmann, V. Benes,
J. Blake, F. Huber, V. Eckstein, P. Boukamp, and D. Ho, “Aging and replicative
senescence have related effects on human stem and progenitor cells,” PLoS ONE,
vol. 4, no. 6, 2009.
235
[273] Y. Yarden and M. Sliwkowski, “Untangling the erbb signalling network,” Nat Rev
Mol Cell Biol, vol. 2, pp. 127–137, 2001.
[274] D. Falls, “Neuregulins: functions, forms, and signaling strategies,” Exp Cell Res,
vol. 284, pp. 14–30, 2003.
[275] A. Buonanno and G. Fischbach, “Neuregulin and erbb receptor signaling pathways
in the nervous system,” Curr Opin Neurobiol, vol. 11, pp. 287–296, 2001.
[276] G. Corfas, K. Roy, and J. Buxbaum, “Neuregulin 1-erbb signaling and the molec-
ular/cellular basis of schizophrenia,” Nat Neurosci, vol. 7, pp. 575–580, 2004.
[277] E. Anton, M. Marchionni, K. Lee, and P. Rakic, “Role of ggf/neuregulin signaling
in interactions between migrating neurons and radial glia in the developing cerebral
cortex,” Development, vol. 124, pp. 3501–3510, 1997.
[278] C. Rio, H. Rieff, P. Qi, T. Khurana, and G. Corfas, “Neuregulin and erbb receptors
play a critical role in neuronal migration,” Neuron, vol. 19, pp. 39–50, 1997.
[279] P. Fernandez, D. Tang, L. Cheng, A. Prochiantz, A. Mudge, and M. Raff, “Evi-
dence that axon-derived neuregulin promotes oligodendrocyte survival in the de-
veloping rat optic nerve,” Neuron, vol. 28, pp. 81–90, 2000.
[280] V. Calaora, B. Rogister, K. Bismuth, K. Murray, H. Brandt, P. Leprince, M. Mar-
chionni, and M. Dubois-Dalcq, “Neuregulin signaling regulates neural precursor
growth and the generation of oligodendrocytes in vitro.” J Neurosci, vol. 21, pp.
4740–4751, 2001.
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[295] G. Marot, F. Jaffrézic, and A. Rau, “metarnaseq: Differential meta-analysis of
rna-seq data,” dim (param), vol. 1, no. 26408, p. 3.
[296] I. Ihnatova, “Mama: an r package for meta-analysis of microarray,” R package
version, vol. 2, no. 1, 2013.
[297] L. Lusa, R. Gentleman, and M. Ruschhaupt, “Genemeta: metaanalysis for high
throughput experiments,” R package version, vol. 1, no. 1, 2013.
[298] J. K. Choi, U. Yu, S. Kim, and O. J. Yoo, “Combining multiple microarray studies
and modeling interstudy variation,” Bioinformatics, vol. 19, no. suppl 1, pp. i84–
i90, 2003.
[299] E. M. Conlon, J. J. Song, and A. Liu, “Bayesian meta-analysis models for mi-
croarray data: a comparative study,” BMC bioinformatics, vol. 8, no. 1, p. 80,
2007.
[300] R. B. Scharpf, H. Tjelmeland, G. Parmigiani, and A. B. Nobel, “A bayesian
model for cross-study differential gene expression,” Journal of the American
238
Statistical Association, vol. 104, no. 488, pp. 1295–1310, dec 2009. [Online].
Available: https://doi.org/10.1198/jasa.2009.ap07611
[301] P. Baldi and A. D. Long, “A bayesian framework for the analysis of microarray
expression data: regularized t-test and statistical inferences of gene changes,”
Bioinformatics, vol. 17, no. 6, pp. 509–519, 2001.
[302] G. K. Smyth, “Linear models and empirical bayes methods for assessing differen-
tial expression in microarray experiments,” Statistical applications in genetics and
molecular biology, vol. 3, no. 1, pp. 1–25, 2004.
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